0001808665-24-000023.txt : 20240506 0001808665-24-000023.hdr.sgml : 20240506 20240506165622 ACCESSION NUMBER: 0001808665-24-000023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 99 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240506 DATE AS OF CHANGE: 20240506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Assertio Holdings, Inc. CENTRAL INDEX KEY: 0001808665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 850598378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39294 FILM NUMBER: 24918383 BUSINESS ADDRESS: STREET 1: 100 S. SAUNDERS ROAD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: (224) 419-7106 MAIL ADDRESS: STREET 1: 100 S. SAUNDERS ROAD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 10-Q 1 asrt-20240331.htm 10-Q asrt-20240331
0001808665FALSE--12-312024Q10.2442003http://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#CostsAndExpenseshttp://fasb.org/us-gaap/2023#CostsAndExpenses00018086652024-01-012024-03-3100018086652024-05-01xbrli:shares00018086652024-03-31iso4217:USD00018086652023-12-31iso4217:USDxbrli:shares0001808665us-gaap:ProductMember2024-01-012024-03-310001808665us-gaap:ProductMember2023-01-012023-03-310001808665asrt:RoyaltiesAndMilestonesMember2024-01-012024-03-310001808665asrt:RoyaltiesAndMilestonesMember2023-01-012023-03-3100018086652023-01-012023-03-310001808665us-gaap:CommonStockMember2023-12-310001808665us-gaap:AdditionalPaidInCapitalMember2023-12-310001808665us-gaap:RetainedEarningsMember2023-12-310001808665us-gaap:CommonStockMember2024-01-012024-03-310001808665us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001808665us-gaap:RetainedEarningsMember2024-01-012024-03-310001808665us-gaap:CommonStockMember2024-03-310001808665us-gaap:AdditionalPaidInCapitalMember2024-03-310001808665us-gaap:RetainedEarningsMember2024-03-310001808665us-gaap:CommonStockMember2022-12-310001808665us-gaap:AdditionalPaidInCapitalMember2022-12-310001808665us-gaap:RetainedEarningsMember2022-12-3100018086652022-12-310001808665us-gaap:CommonStockMember2023-01-012023-03-310001808665us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001808665us-gaap:RetainedEarningsMember2023-01-012023-03-310001808665us-gaap:CommonStockMember2023-03-310001808665us-gaap:AdditionalPaidInCapitalMember2023-03-310001808665us-gaap:RetainedEarningsMember2023-03-3100018086652023-03-310001808665asrt:SpectrumPharmaceuticalsIncMember2023-07-31xbrli:pure0001808665srt:ScenarioForecastMemberasrt:SpectrumPharmaceuticalsIncMemberasrt:RolvedonMember2024-12-310001808665srt:ScenarioForecastMemberasrt:SpectrumPharmaceuticalsIncMemberasrt:RolvedonMember2025-12-310001808665asrt:SpectrumPharmaceuticalsIncMember2023-07-312023-07-310001808665asrt:SpectrumPharmaceuticalsIncMemberasrt:RolvedonMember2023-07-310001808665asrt:SpectrumPharmaceuticalsIncMember2023-12-310001808665asrt:SpectrumPharmaceuticalsIncMember2023-08-012023-12-310001808665asrt:SpectrumPharmaceuticalsIncMember2024-01-012024-03-310001808665asrt:SpectrumPharmaceuticalsIncMember2023-01-012023-03-310001808665asrt:RolvedonMember2024-01-012024-03-310001808665asrt:RolvedonMember2023-01-012023-03-310001808665asrt:INDOCINProductsMember2024-01-012024-03-310001808665asrt:INDOCINProductsMember2023-01-012023-03-310001808665asrt:SympazanMember2024-01-012024-03-310001808665asrt:SympazanMember2023-01-012023-03-310001808665asrt:OtrexupMember2024-01-012024-03-310001808665asrt:OtrexupMember2023-01-012023-03-310001808665asrt:SPRIXNasalSprayMember2024-01-012024-03-310001808665asrt:SPRIXNasalSprayMember2023-01-012023-03-310001808665asrt:CAMBIAMember2024-01-012024-03-310001808665asrt:CAMBIAMember2023-01-012023-03-310001808665asrt:ProductOtherMember2024-01-012024-03-310001808665asrt:ProductOtherMember2023-01-012023-03-310001808665asrt:CAMBIAMembercountry:CA2024-01-012024-03-310001808665asrt:CAMBIAMembercountry:CA2023-01-012023-03-310001808665asrt:FurnitureAndOfficeEquipmentMember2024-03-310001808665asrt:FurnitureAndOfficeEquipmentMember2023-12-310001808665us-gaap:EquipmentMember2024-03-310001808665us-gaap:EquipmentMember2023-12-310001808665us-gaap:LeaseholdImprovementsMember2024-03-310001808665us-gaap:LeaseholdImprovementsMember2023-12-310001808665us-gaap:ConstructionInProgressMember2024-03-310001808665us-gaap:ConstructionInProgressMember2023-12-310001808665asrt:ProductRightsMemberasrt:RolvedonMember2024-03-310001808665asrt:ProductRightsMemberasrt:RolvedonMember2023-12-310001808665asrt:INDOCINProductsMemberasrt:ProductRightsMember2024-03-310001808665asrt:INDOCINProductsMemberasrt:ProductRightsMember2023-12-310001808665asrt:SympazanMemberasrt:ProductRightsMember2024-03-310001808665asrt:SympazanMemberasrt:ProductRightsMember2023-12-310001808665asrt:OtrexupAcquisitionMemberasrt:ProductRightsMember2024-03-310001808665asrt:OtrexupAcquisitionMemberasrt:ProductRightsMember2023-12-310001808665asrt:ProductRightsMemberasrt:SPRIXNasalSprayMember2024-03-310001808665asrt:ProductRightsMemberasrt:SPRIXNasalSprayMember2023-12-310001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:ConvertibleDebtMember2024-03-310001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:ConvertibleDebtMember2023-12-310001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:ConvertibleDebtMember2022-08-220001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:ConvertibleDebtMember2022-08-222022-08-220001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:ConvertibleDebtMember2023-02-270001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:ConvertibleDebtMember2023-02-272023-02-27utr:Rate0001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:ConvertibleDebtMember2024-01-012024-03-310001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:ConvertibleDebtMember2023-01-012023-03-310001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:SeniorNotesMember2024-01-012024-03-310001808665asrt:ConvertibleSeniorNotes65Memberus-gaap:SeniorNotesMember2023-01-012023-03-310001808665us-gaap:SeniorNotesMember2024-01-012024-03-310001808665us-gaap:SeniorNotesMember2023-01-012023-03-310001808665us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001808665us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001808665us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001808665us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001808665us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001808665us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001808665us-gaap:SupplyCommitmentMember2024-03-310001808665us-gaap:SupplyCommitmentMemberasrt:JubilantHollisterStierLLCMember2024-03-310001808665us-gaap:SupplyCommitmentMemberasrt:AntaresMember2024-03-310001808665us-gaap:SupplyCommitmentMemberasrt:HanmiMember2024-03-310001808665us-gaap:SupplyCommitmentMemberasrt:HanmiMember2024-01-012024-03-310001808665asrt:GlumetzaAntitrustLitigationMember2021-09-142021-09-140001808665asrt:GlumetzaAntitrustLitigationMember2022-02-032022-02-0300018086652021-01-012021-03-3100018086652022-04-012022-06-300001808665us-gaap:ConvertibleDebtMember2023-03-310001808665us-gaap:ConvertibleDebtMember2024-01-012024-03-310001808665us-gaap:ConvertibleDebtMember2023-01-012023-03-310001808665us-gaap:StockCompensationPlanMember2024-01-012024-03-310001808665us-gaap:StockCompensationPlanMember2023-01-012023-03-310001808665us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001808665us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001808665us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001808665us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001808665us-gaap:FairValueMeasurementsRecurringMember2024-03-310001808665us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001808665us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001808665us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001808665us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001808665us-gaap:FairValueMeasurementsRecurringMember2023-12-310001808665asrt:SpectrumPharmaceuticalsIncMember2024-03-310001808665asrt:INDOCINProductsMember2023-12-310001808665asrt:INDOCINProductsMember2024-03-310001808665us-gaap:MeasurementInputPriceVolatilityMember2024-03-310001808665us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMember2024-03-310001808665us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputCreditSpreadMember2024-03-310001808665asrt:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2023-12-310001808665asrt:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001808665asrt:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2024-01-012024-03-310001808665asrt:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-03-310001808665asrt:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2024-03-310001808665asrt:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2023-03-310001808665us-gaap:MeasurementInputCreditSpreadMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-03-310001808665us-gaap:FairValueInputsLevel2Member2024-03-310001808665us-gaap:FairValueInputsLevel2Member2023-12-310001808665us-gaap:EmployeeSeveranceMemberasrt:SpectrumReorganizationPlanMember2024-03-310001808665us-gaap:FacilityClosingMemberasrt:SpectrumReorganizationPlanMember2023-01-012023-12-310001808665us-gaap:FacilityClosingMemberasrt:SpectrumReorganizationPlanMember2023-12-310001808665us-gaap:EmployeeSeveranceMembersrt:ChiefExecutiveOfficerMember2023-01-012023-12-310001808665us-gaap:EmployeeSeveranceMember2023-12-310001808665us-gaap:EmployeeSeveranceMember2024-01-012024-03-310001808665us-gaap:EmployeeSeveranceMember2024-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 FORM 10-Q
 ☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024
 OR
 ☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE TRANSITION PERIOD FROM TO      
 COMMISSION FILE NUMBER 001-39294

 ASSERTIO HOLDINGS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware85-0598378
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)		(I.R.S. EMPLOYER IDENTIFICATION NUMBER)
 100 South Saunders Road, Suite 300
Lake Forest, Illinois 60045
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES; ZIP CODE)
 (224) 419-7106
(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:    Trading Symbol(s):Name of each exchange on which registered:
Common Stock, $0.0001 par value
 ASRTThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
Large accelerated filer
☐
Accelerated filer☒
 Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒
 
The number of issued and outstanding shares of the registrant’s Common Stock, $0.0001 par value, as of May 1, 2024, was 95,124,605.


ASSERTIO HOLDINGS, INC.
FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2024
TABLE OF CONTENTS
Item 1. 
Condensed Consolidated Balance Sheets at March 31, 2024 and December 31, 2023
Item 2. 
Item 3. 
Item 4. 
Item 1. 
Item 1A. 
Item 2.
Item 6. 
2


PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS
ASSERTIO HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
(Unaudited)
 March 31, 2024December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents$80,743 $73,441 
Accounts receivable, net42,610 47,663 
Inventories, net38,602 37,686 
Prepaid and other current assets10,519 12,272 
Total current assets172,474 171,062 
Property and equipment, net704 770 
Intangible assets, net105,701 111,332 
Other long-term assets3,086 3,255 
Total assets$281,965 $286,419 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable$15,650 $13,439 
Accrued rebates, returns and discounts57,870 58,137 
Accrued liabilities15,401 18,213 
Contingent consideration, current portion2,700 2,700 
Other current liabilities823 954 
Total current liabilities92,444 93,443 
Long-term debt38,621 38,514 
Other long-term liabilities16,406 16,459 
Total liabilities147,471 148,416 
Commitments and contingencies (Note 15)
Shareholders’ equity:
Common stock, $0.0001 par value, 200,000,000 shares authorized; 95,115,452
 and 94,668,523 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.
9 9 
Additional paid-in capital790,538 789,537 
Accumulated deficit(656,053)(651,543)
Total shareholders’ equity134,494 138,003 
Total liabilities and shareholders' equity$281,965 $286,419 
        
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3

ASSERTIO HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands, except per share data)
(Unaudited)
 
Three Months Ended March 31,
20242023
Revenues:
Product sales, net$31,862 $41,769 
Royalties and milestones586 697 
Total revenues32,448 42,466 
Costs and expenses:
Cost of sales11,177 5,467 
Research and development expenses733 — 
Selling, general and administrative expenses18,524 16,904 
Change in fair value of contingent consideration— 9,167 
Amortization of intangible assets5,631 6,284 
Restructuring charges720 — 
Total costs and expenses36,785 37,822 
(Loss) income from operations(4,337)4,644 
Other (expense) income:
Debt-related expenses— (9,918)
Interest expense(757)(1,122)
Other gain 716 802 
Total other expense(41)(10,238)
Net loss before income taxes(4,378)(5,594)
Income tax (expense) benefit(132)2,110 
Net loss and comprehensive loss$(4,510)$(3,484)
Basic and diluted net loss per share$(0.05)$(0.07)
Shares used in computing basic and diluted net loss per share94,980 51,005 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

ASSERTIO HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(in thousands)
(Unaudited)

Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Shareholders’
Equity
SharesAmount
Balances at December 31, 202394,669 $9 $789,537 $(651,543)$138,003 
Common stock issuance and other impacts of the vesting and settlement of equity awards446 — (206)— (206)
Stock-based compensation— — 1,207 — 1,207 
Net loss and comprehensive loss— — — (4,510)(4,510)
Balances at March 31, 202495,115 $9 $790,538 $(656,053)$134,494 


Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Shareholders’
Equity
SharesAmount
Balances at December 31, 202248,320 $5 $545,321 $(319,601)$225,725 
Induced exchange of convertible notes (See Note 16)
6,990 — 26,699 — 26,699 
Common stock issuance and other impacts of the vesting and settlement of equity awards352 — (722)— (722)
Stock-based compensation— — 2,446 — 2,446 
Net loss and comprehensive loss— — — (3,484)(3,484)
Balances at March 31, 202355,662 $5 $573,744 $(323,085)$250,664 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

ASSERTIO HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
 Three Months Ended March 31,
 20242023
Operating Activities  
Net loss$(4,510)$(3,484)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization5,696 6,484 
Amortization of debt issuance costs and Royalty Rights107 147 
Recurring fair value measurements of assets and liabilities— 9,167 
Debt-related expenses— 9,918 
Provisions for inventory and other assets1,428 1,072 
Stock-based compensation1,207 2,446 
Deferred income taxes— (1,367)
Changes in assets and liabilities:
Accounts receivable5,054 (1,109)
Inventories(2,344)(3,602)
Prepaid and other assets1,921 1,824 
Accounts payable and other accrued liabilities(134)(290)
Accrued rebates, returns and discounts(267)2,887 
Interest payable(650)(1,376)
Net cash provided by operating activities7,508 22,717 
Investing Activities
Purchase of Sympazan— (105)
Net cash used in investing activities— (105)
Financing Activities
Payments in connection with 2027 Convertible Notes— (10,500)
Payment of direct transaction costs related to convertible debt inducement— (1,119)
Payment of contingent consideration— (6,609)
Payments related to the vesting and settlement of equity awards, net(206)(722)
Net cash used in financing activities(206)(18,950)
Net increase in cash and cash equivalents7,302 3,662 
Cash and cash equivalents at beginning of year73,441 64,941 
Cash and cash equivalents at end of period$80,743 $68,603 
Supplemental Disclosure of Cash Flow Information
Net cash paid for income taxes$11 $29 
Cash paid for interest$1,300 $2,351 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

ASSERTIO HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited) 
NOTE 1.  ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Organization

Assertio Holdings, Inc., or the Company, is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients. The Company has built its product portfolio through the acquisition or licensing of approved products. The Company’s commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (elflapegrastim-xnst) injection for subcutaneous use, INDOCIN® (indomethacin) Suppositories, INDOCIN® (indomethacin) Oral Suspension, Sympazan® (clobazam) oral film, Otrexup® (methotrexate) injection for subcutaneous use, SPRIX® (ketorolac tromethamine) Nasal Spray, CAMBIA® (diclofenac potassium for oral solution), and Zipsor® (diclofenac potassium) Liquid filled capsules. To date, substantially all of the Company’s revenues are related to product sales in the U.S.

Unless otherwise noted or required by context, use of “Assertio,” “Company,” “we,” “our” and “us” refer to Assertio Holdings and/or its applicable subsidiary or subsidiaries.

Basis of Presentation

The unaudited condensed consolidated financial statements of the Company and its subsidiaries and the related footnote information of the Company have been prepared pursuant to the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information that are normally required by United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of the Company’s management, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of the information for the periods presented. The results for the three months ended March 31, 2024, are not necessarily indicative of results to be expected for the entire year ending December 31, 2024 or future operating periods.

The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2023, included in Assertio Holdings, Inc.’s Annual Report on Form 10-K filed with the SEC on March 11, 2024 (the “2023 Form 10-K”). The Condensed Consolidated Balance Sheet as of December 31, 2023, has been derived from the audited financial statements at that date, as filed in the Company’s 2023 Form 10-K.
NOTE 2. ACQUISITIONS
Spectrum Pharmaceuticals

On July 31, 2023, (the “Effective Date”), the Company completed the acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”), a commercial stage biopharmaceutical company focused on novel and targeted oncology products (the “Spectrum Merger”). The Spectrum Merger was completed pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 24, 2023, through a merger of a wholly-owned subsidiary of the Company with and into Spectrum, with Spectrum surviving the Merger as a wholly-owned subsidiary of the Company. The Company accounted for the Spectrum Merger using the acquisition method of accounting under Accounting Standards Codification (“ASC”) 805 and is considered the accounting acquirer.

Pursuant to the Merger Agreement, each issued and outstanding share of Spectrum common stock as of the Effective Date was converted into the right to receive (i) 0.1783 shares of the Company’s common stock and (ii) one contingent value right (“CVR”) representing a contractual right to receive future conditional payments worth up to an aggregate maximum amount of $0.20, settleable in cash, additional shares of Assertio common stock or a combination of cash and additional shares of Assertio common stock at the Company’s sole discretion, upon the achievement of certain sales milestones related to Spectrum’s product ROLVEDON. Subject to adjustments, each CVR represents the right to receive up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175 million during the calendar year ending December 31, 2024, and up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $225 million during the calendar year
7

ending December 31, 2025. In addition, upon consummation of the Spectrum Merger, Spectrum’s outstanding employee stock awards and other warrants that were outstanding immediately as of the Effective Date automatically vested (if unvested) and/or cancelled, as applicable, which generally resulted in the issuance of shares of the Company’s common stock and/or CVRs to the holders of such stock awards or other warrants, in each case as dictated by the terms of the Merger Agreement. These shares and CVRs issued are considered part of the consideration transferred, and no compensation expense was recognized because the settlement was a condition of the Merger Agreement and other existing individual agreements, no future performance is required by the holders, and the fair value of the shares and CVRs is equivalent to the fair value of the existing employee stock awards and other warrants.

The following table reflects the components of the consideration transferred in the Spectrum Merger (in thousands, except exchange ratio and per share data):

Assertio shares issued38,013 
Assertio closing price per share as of the Effective Date$5.69 
Fair value of Assertio shares issued$216,294 
Repayment of Spectrum's long-term debt (1)
32,647 
CVRs (2)
3,932 
Total fair value of consideration transferred$252,873 

(1)Represents settlement of Spectrum’s existing long-term debt in connection with the close of the transaction. The Company concluded it did not assume the debt, therefore the amount paid to settle the debt has been accounted for and disclosed as part of the consideration transferred.
(2)Represents the Effective Date fair value of 223,397 CVRs at $0.0176 per CVR issued to holders of Spectrum common stock, employee stock awards and warrants.

The CVRs represent a contingent consideration obligation measured at fair value and classified as liabilities on the Company’s Condensed Consolidated Balance Sheets. The fair value of the CVR contingent consideration is determined using a Monte Carlo simulation model under the income approach and is based on Level 3 inputs. Refer to Note 18, Fair Value, for additional information. Fair value is based on the probability of achievement of 2024 and 2025 annual ROLVEDON net sales milestones. Significant assumptions include the discount rate and the probability assigned to the achievement of the net sales milestones. Achievement of both the 2024 and 2025 annual ROLVEDON net sales milestones would obligate the Company to transfer a maximum of approximately $44.7 million of additional consideration. No additional consideration would be paid by the Company if neither the 2024 nor 2025 annual ROLVEDON net sales milestones are achieved.

8

The following table reflects the fair values of the assets acquired and liabilities assumed at the Effective Date (in thousands). The fair values were based on management’s estimates and assumptions. There were no changes for the three months ended March 31, 2024, to the estimated preliminary fair values of the assets acquired and liabilities assumed. The final determination was completed as of March 31, 2024.

Initial Preliminary Purchase Price Allocation to Fair Value
Adjustments to Purchase Price Allocation to Fair Value (2)
Final Purchase Price Allocation to Fair Value
Assets:
Cash and cash equivalents$34,600 $— $34,600 
Marketable securities2,194 — 2,194 
Accounts receivable50,975 — 50,975 
Inventories22,244 61 22,305 
Prepaid and other current assets1,287 698 1,985 
Property and equipment100 — 100 
Intangible assets234,000 (13,500)220,500 
Other long-term assets1,396 — 1,396 
Total$346,796 $(12,741)$334,055 
Liabilities:
Accounts payable$10,108 $— $10,108 
Accrued rebates, returns and discounts21,025 — 21,025 
Accrued liabilities36,509 (2,343)34,166 
Other current liabilities784 — 784 
Deferred taxes34,250 (30,254)3,996 
Other long-term liabilities11,103 — 11,103 
Total$113,779 $(32,597)$81,182 
Total Spectrum net assets acquired (1)
$233,017 $19,856 $252,873 
Goodwill$19,856 $(19,856)$— 

(1)Application of the acquisition method required the Company to adjust Spectrum assets and liabilities as of the Effective Date, including certain liabilities for variable consideration associated with ROLVEDON, to reflect conformity of Spectrum’s accounting policies to those of Assertio. Liabilities assumed include certain bonuses owed to former Spectrum executives under the terms of existing employment agreements triggered by the consummation of the Spectrum Merger.
(2)Adjustments made to the preliminary purchase price allocation to fair value primarily reflect completion of studies and other analysis necessary to determine the income tax effects of the net identifiable assets acquired and further refinement of the assumptions used in the valuation supporting the ROLVEDON product rights. These adjustments did not materially impact the Consolidated Statement of Comprehensive (Loss) Income.

The income approach was primarily used to value the acquired intangible assets, representing rights to Spectrum’s product ROLVEDON. Significant assumptions include the amount and timing of projected future cash flows; the discount rate selected to measure the inherent risk of future cash flows; and the assessment of the product’s life cycle and the competitive trends impacting the product. The ROLVEDON product rights will be amortized on a straight-line basis over its estimated useful life of 10 years.

There were no acquisition costs related to the Spectrum Merger recognized for the three months ended March 31, 2024.

9

The following unaudited pro forma information represents the Company’s results of operations as if the Spectrum Merger had been completed as of January 1, 2023, (in thousands) and includes nonrecurring adjustments for additional costs of sales from the fair value step-up of inventories and transaction costs. The disclosure of pro forma net sales and net loss does not purport to indicate the results that would actually have been obtained had the Spectrum Merger been completed on the assumed date for the periods presented, or which may be realized in the future. The unaudited pro forma information does not reflect any operating efficiencies or cost savings that may be realized from the integration of the acquisition.

Three Months Ended
March 31, 2023
Total revenues$58,081 
Net loss(13,944)

NOTE 3. REVENUE
 
Disaggregated Revenue
 
The following table reflects total revenue, net for the three months ended March 31, 2024 and 2023 (in thousands): 
Three Months Ended March 31,
20242023
Product sales, net:
ROLVEDON$14,478 $— 
INDOCIN products8,682 30,346 
Sympazan2,617 2,502 
Otrexup2,882 2,822 
SPRIX1,437 1,889 
CAMBIA1,256 2,264 
Other products510 1,946 
Total product sales, net31,862 41,769 
Royalties and milestone revenue586 697 
Total revenues$32,448 $42,466 
Product Sales, net

As a result of the Spectrum Merger, the Company began recognizing ROLVEDON sales in August 2023.

Other net product sales for the three months ended March 31, 2023 include product sales for OXAYDO and Zipsor. The Company ceased OXAYDO product sales beginning in September 2023.
Royalties and Milestone Revenue

In November 2010, the Company entered into a license agreement granting Miravo the rights to commercially market CAMBIA in Canada. Miravo independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. The Company recognized royalties revenue related to the CAMBIA licensing agreement of $0.6 million and $0.5 million for the three months ended March 31, 2024 and 2023, respectively.

The Company recognized no milestone revenue associated with the completion of certain service milestones for the three months ended March 31, 2024, and $0.2 million for the three months ended March 31, 2023.
NOTE 4. ACCOUNTS RECEIVABLES, NET
 
As of March 31, 2024 and December 31, 2023, accounts receivable, net, consisted entirely of receivables related to product sales, net of allowances for cash discounts for prompt payment of $0.4 million and $0.9 million, respectively.
10

NOTE 5.  INVENTORIES, NET
 
The following table reflects the components of inventory, net as of March 31, 2024 and December 31, 2023 (in thousands): 
 March 31, 2024December 31, 2023
Raw materials$18,872 $10,537 
Work-in-process2,452 2,239 
Finished goods17,278 24,910 
Total inventories, net$38,602 $37,686 
The Company writes down the value of inventory for potential excess or obsolete inventories based on an analysis of inventory on hand and projected demand. As of March 31, 2024 and December 31, 2023, inventory reserves were $7.3 million and $6.8 million, respectively.

NOTE 6. PREPAID AND OTHER CURRENT ASSETS

The following table reflects prepaid and other current as of March 31, 2024 and December 31, 2023 (in thousands): 

March 31, 2024December 31, 2023
Prepaid assets and deposits$10,222 $11,973 
Other current assets297 299 
Total prepaid and other current assets$10,519 $12,272 

In August 2018, the Company entered into a Convertible Secured Note Purchase Agreement (the “Note Agreement”) with NES Therapeutic, Inc. (“NES”), pursuant to which it purchased a Convertible Secured Promissory Note (the “NES Note”). The Company’s investment in the NES Note, which is included in other current assets, is accounted for as a loan receivable and is valued at amortized cost. As of both March 31, 2024 and December 31, 2023, the Company has assessed an estimated $3.5 million expected credit loss reserve on its investment based on its evaluation of probability of default that exists. The expected credit loss reserve recognized in each period represents the entire aggregate principal amount and outstanding interest incurred on the NES Note as of both March 31, 2024 and December 31, 2023.


NOTE 7. PROPERTY AND EQUIPMENT, NET
 
The following table reflects property and equipment, net as of March 31, 2024 and December 31, 2023 (in thousands): 

March 31, 2024December 31, 2023
Furniture and office equipment$1,908 $1,908 
Laboratory equipment20 20 
Leasehold improvements3,473 2,945 
Construction in progress— 528 
5,401 5,401 
Less: Accumulated depreciation(4,697)(4,631)
Property and equipment, net$704 $770 
 
Depreciation expense was $0.1 million and $0.2 million for the three months ended March 31, 2024 and 2023, respectively. Depreciation expense is recognized in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss.

11

NOTE 8.  INTANGIBLE ASSETS

The following table reflects the gross carrying amounts and net book values of intangible assets as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands): 

 March 31, 2024December 31, 2023
Products rights:Remaining Useful Life
 (In years)		Gross Carrying AmountAccumulated AmortizationNet Book ValueGross Carrying AmountAccumulated AmortizationImpairmentNet Book Value
ROLVEDON9.3$63,405 $(6,787)$56,618 $220,500 $(5,270)$(157,095)$58,135 
INDOCIN1.865,606 (47,413)18,193 154,100 (44,814)(88,494)20,792 
Sympazan10.614,550 (1,718)12,832 14,550 (1,415)— 13,135 
Otrexup5.716,364 (10,364)6,000 44,086 (10,103)(27,723)6,260 
SPRIX3.132,673 (20,615)12,058 39,000 (19,663)(6,327)13,010 
Total intangible Assets $192,598 $(86,897)$105,701 $472,236 $(81,265)$(279,639)$111,332 

Amortization expense was $5.6 million and $6.3 million for the three months ended March 31, 2024 and 2023, respectively.

The following table reflects future amortization expense the Company expects for its intangible assets (in thousands): 

Year Ending December 31,Estimated
Amortization Expense
2024 (remainder)16,894 
202522,526 
202612,130 
20279,909 
20288,322 
Thereafter35,920 
Total$105,701 

During the three months ended March 31, 2024, the Company’s market capitalization declined to below the book value of the Company’s equity, which management determined represented an indicator of impairment with respect to its long-lived assets. Applying the relevant accounting guidance, the Company first assessed the recoverability of its long-lived assets. Similar to its previous assessment in the fourth quarter of 2023, as described in the Company’s 2023 Form 10-K, management concluded it was appropriate to group its assets at the product level. After grouping the long-lived assets at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other assets and liabilities, the Company estimated the future net undiscounted cash flows expected to be generated from the use of the long-lived asset groups and their eventual disposition. The Company then compared the estimated undiscounted cash flows to the carrying amounts of the long-lived asset groups. Based on this test, the Company determined that the estimated undiscounted cash flows were in excess of the carrying amounts for all of the long-lived asset groups and, accordingly, that the long-lived asset groups are fully recoverable and no adjustment to their carrying values was required.
NOTE 9.  OTHER LONG-TERM ASSETS
 
The following table reflects other long-term assets as of March 31, 2024 and December 31, 2023 (in thousands): 

 March 31, 2024December 31, 2023
Operating lease right-of-use assets$1,234 $1,269 
Prepaid asset and deposits1,155 1,289 
Other 697 697 
Total other long-term assets$3,086 $3,255 

12

NOTE 10.  ACCRUED LIABILITIES
 
The following table reflects accrued liabilities as of March 31, 2024 and December 31, 2023 (in thousands): 

 March 31, 2024December 31, 2023
Accrued compensation$1,452 $2,438 
Accrued restructuring costs (See Note 20)
3,368 4,378 
Other accrued liabilities9,123 9,492 
Interest payable217 867 
Accrued royalties1,241 1,038 
Total accrued liabilities$15,401 $18,213 

NOTE 11.  DEBT
 
The following table reflects the Company’s debt as of March 31, 2024 and December 31, 2023 (in thousands):

March 31, 2024December 31, 2023
6.5% Convertible Senior Secured Notes due 2027 principal amount
$40,000$40,000
Plus: derivative liability for embedded conversion feature308308
Less: unamortized debt issuance costs(1,687)(1,794)
Carrying value38,62138,514
Less: current portion of long-term debt——
Long-term debt, net$38,621$38,514


6.5% Convertible Senior Notes due 2027

On August 22, 2022, Assertio entered into a purchase agreement (the “Purchase Agreement”), with U.S. Bank Trust Company as the trustee (the “2027 Convertible Note Trustee”) of the initial purchasers (the “Initial Purchasers”) to issue $60.0 million in aggregate principal amount of 6.5% Convertible Senior Notes due 2027 (the “2027 Convertible Notes”). Under the Purchase Agreement, the Initial Purchasers were also granted an overallotment option to purchase up to an additional $10.0 million aggregate principal amount of the 2027 Convertible Notes solely to cover overallotment (the “Overallotment Option”) within a 13-day period from the date the initial 2027 Convertible Notes were issued. On August 24, 2022, the Initial Purchasers exercised the Overallotment Option in full for the $10.0 million aggregate principal of additional 2027 Convertible Notes. The 2027 Convertible Notes are senior unsecured obligations of the Company.

On February 27, 2023, the Company completed a privately negotiated exchange of $30.0 million principal amount of the 2027 Convertible Notes (the “Convertible Note Exchange”). As a result of the Convertible Note Exchange in the first quarter of 2023, the Company recorded an induced conversion expense of approximately $8.8 million and direct transaction costs of approximately $1.1 million, the total of which is reported in Debt-related expenses in the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2023. The induced conversion expense represents the fair value of the consideration transferred in the Convertible Note Exchange in excess of the fair value of common stock issuable under the original terms of the 2027 Convertible Notes.

The terms of the 2027 Convertible Notes are governed by an indenture dated August 25, 2022 (the “2027 Convertible Note Indenture”). The terms of the 2027 Convertible Notes allow for conversion into the Company’s common stock, cash, or a combination of cash and common stock, at the Company’s election only, at an initial conversion rate of 244.2003 shares of the Company’s common stock per $1,000 principal amount (equal to an initial conversion price of approximately $4.09 per share), subject to adjustments specified in the 2027 Convertible Note Indenture (the “Conversion Rate”). The 2027 Convertible Notes will mature on September 1, 2027, unless earlier repurchased or converted.

The 2027 Convertible Notes bear interest from August 25, 2022, at a rate of 6.5% per annum payable semiannually in arrears on March 1 and September 1 of each year, beginning on March 1, 2023.

13

Pursuant to the terms of the Indenture, the Company and its restricted subsidiaries must comply with certain covenants, including mergers, consolidations, and divestitures; guarantees of debt by subsidiaries; issuance of preferred and/or disqualified stock; and liens on the Company’s properties or assets. The Company was in compliance with its covenants with respect to the 2027 Convertible Notes as of March 31, 2024.

The following table reflects the carrying balance of the 2027 Convertible Notes as of March 31, 2024 and December 31, 2023 (in thousands):

March 31, 2024December 31, 2023
Principal balance$40,000 $40,000 
Derivative liability for embedded conversion feature308 308 
Unamortized debt issuance costs(1,687)(1,794)
Carrying balance$38,621 $38,514 

The debt issuance costs incurred related to the 2027 Convertible Notes are recognized as a debt discount and are being amortized as interest expense over the term of the 2027 Convertible Notes using the effective interest method, with an effective interest rate determined to be 7.8%. During each of the three months ended March 31, 2024 and 2023, the Company amortized $0.1 million of the debt discount on the 2027 Convertible Notes.

The Company determined that an embedded conversion feature included in the 2027 Convertible Notes required bifurcation from the host contract and to be recognized as a separate derivative liability carried at fair value. See Note 18, Fair Value, for further details around the estimated fair value of the derivative liability. All of the other embedded features of the 2027 Convertible Notes were clearly and closely related to the debt host and did not require bifurcation as a derivative liability, or the fair value of the bifurcated features was immaterial to the Company’s financial statements.
    
Interest Expense

The following table reflects debt-related interest included in Interest expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2024 and 2023 (in thousands):

Three Months Ended March 31,
20242023
Interest on 2027 Convertible Notes$650$975
Amortization of debt issuance costs107147
Total interest expense$757$1,122

NOTE 12.  OTHER LONG-TERM LIABILITIES

The following table reflects other long-term liabilities as of March 31, 2024 and December 31, 2023 (in thousands):
 March 31, 2024December 31, 2023
ROLVEDON product royalties$9,224 $9,224 
Noncurrent operating lease liabilities1,350 1,470 
Liability for uncertain tax provisions4,620 4,553 
Deferred employee retention credits1,212 1,212 
Total other long-term liabilities$16,406 $16,459 

14

NOTE 13.  STOCK-BASED COMPENSATION
    
The Company’s stock-based compensation generally includes time-based restricted stock units (“RSU”) and options, as well as performance-based RSUs and options.

For the three months ended March 31, 2024 and 2023, stock-based compensation of $1.2 million and $2.4 million, respectively, was recognized in Selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive Loss.

During the three months ended March 31, 2024, the Company granted 0.9 million RSUs at a weighted-average fair market value of $0.80 per share, and 3.0 million options at a weighted-average fair market value of $0.77 per share. During the three months ended March 31, 2023, the Company granted 0.5 million RSUs at a weighted-average fair market value of $5.15 per share, and 0.6 million options at a weighted-average fair market value of $4.39 per share.


NOTE 14.  LEASES

As of March 31, 2024, the Company has a non-cancelable operating lease for its corporate office, which is located in Lake Forest, Illinois (the “Lake Forest Lease”). On May 1, 2023, the Company amended the Lake Forest Lease to reduce the size of leased premises and extend the term of the lease through December 31, 2030. Additionally, in connection with the Spectrum Merger, the Company assumed leases for two facilities and certain office equipment which Spectrum had previously been the lessee.

The following table reflects lease expense and income for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
Financial Statement Classification20242023
Operating lease costSelling, general and administrative expenses$66 $39 
The following table reflects supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Cash paid for amounts included in measurement of liabilities:
Operating cash flows from operating leases$282 $104 
The following table reflects supplemental balance sheet information related to leases as of March 31, 2024 and December 31, 2023 (in thousands):
Financial Statement ClassificationMarch 31, 2024December 31, 2023
Assets
Operating lease right-of-use assetsOther long-term assets$1,234 $1,269 
Liabilities
Current operating lease liabilitiesOther current liabilities$797 $928 
Noncurrent operating lease liabilitiesOther long-term liabilities1,350 1,470 
Total lease liabilities$2,147 $2,398 


15

NOTE 15.  COMMITMENTS AND CONTINGENCIES

Jubilant HollisterStier Manufacturing and Supply Agreement

In connection with the Company’s merger with Zyla Life Sciences (“Zyla”) in May 2020 (the “Zyla Merger”), the Company assumed a Manufacturing and Supply Agreement (the “Jubilant HollisterStier Agreement”) with Jubilant HollisterStier LLC (“JHS”) pursuant to which the Company engaged JHS to provide certain services related to the manufacture and supply of SPRIX for the Company’s commercial use. Under the Jubilant HollisterStier Agreement, JHS is responsible for supplying a minimum of 75% of the Company’s annual requirements of SPRIX. The Company agreed to purchase a minimum number of batches of SPRIX per calendar year from JHS over the term of the Jubilant HollisterStier Agreement. Total annual commitments to JHS are approximately $1.5 million.

Antares Supply Agreement

In connection with the Otrexup acquisition, the Company entered into a supply agreement with Antares pursuant to which Antares will manufacture and supply the finished Otrexup products (the “Antares Supply Agreement”). Under the Antares Supply Agreement, the Company has agreed to annual minimum purchase obligations from Antares, which approximate $2.0 million annually. The Antares Supply Agreement has an initial term through December 2031 with renewal terms beyond.

Hanmi Supply Agreement

In connection with the Spectrum Merger, the Company assumed a Manufacturing and Supply Agreement (the “Hanmi Agreement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) pursuant to which the Company engaged Hanmi to provide certain services related to the manufacture and supply of ROLVEDON for the Company’s commercial use. The Company has agreed to purchase a minimum number of batches totaling approximately $19.1 million in 2024 and $3.8 million in 2025. The Company has purchased $8.4 million of inventory from Hanmi during the three months ended March 31, 2024.

General
The Company is currently involved in various lawsuits, claims, investigations and other legal proceedings that arise in the ordinary course of business. The Company recognizes a loss contingency provision in its financial statements when it concludes that a contingent liability is probable, and the amount thereof is estimable. Costs associated with the Company’s involvement in legal proceedings are expensed as incurred. Amounts accrued for legal contingencies are based on management’s best estimate of a loss based upon the status of the cases described below, assessments of the likelihood of damages, and the advice of counsel and often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. As of both March 31, 2024 and December 31, 2023, the Company had a legal contingency accrual of approximately $3.2 million. The Company continues to monitor each matter and adjust accruals as warranted based on new information and further developments in accordance with ASC 450-20-25. For matters discussed below for which a loss is not probable, or a probable loss cannot be reasonably estimated, no liability has been recorded. Provisions for loss contingencies are recorded in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss and the related accruals are recorded in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets.

Other than matters disclosed below, the Company may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of its business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims and other matters. The Company may also become party to further litigation in federal and state courts relating to opioid drugs. Although actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, other than the matters set forth below, the Company is not currently involved in any matters that the Company believes may have a material adverse effect on its business, results of operations, cash flows or financial condition. However, regardless of the outcome, litigation can have an adverse impact on the Company because of associated cost and diversion of management time.

16

Glumetza Antitrust Litigation
Antitrust class actions and related direct antitrust actions were filed in the U.S. District Court for the Northern District of California against the Company and several other defendants relating to its former drug Glumetza®. The plaintiffs sought to represent a putative class of direct purchasers of Glumetza. In addition, several retailers, including CVS Pharmacy, Inc., Rite Aid Corporation, Walgreen Co., the Kroger Co., the Albertsons Companies, Inc., H-E-B, L.P., and Hy-Vee, Inc. (the “Retailer Plaintiffs”), filed substantially similar direct purchaser antitrust claims in the same District Court.

On July 30, 2020, Humana Inc. (“Humana”) also filed a complaint against the Company and several other defendants in the U.S. District Court for the Northern District of California alleging similar claims related to Glumetza. The claims asserted by Humana in its federal case were ultimately withdrawn, and analogous claims were instead asserted by Humana in an action it filed in the Superior Court of the State of California for the County of Alameda on February 8, 2021, and subsequently amended in September 2021. Additionally, on April 5, 2022, Health Care Service Corporation (“HCSC”) filed a complaint against the Company and the same other defendants in the California Superior Court of Alameda alleging similar claims related to Glumetza.

These antitrust cases arise out of a Settlement and License Agreement (the “Settlement”) that the Company, Santarus, Inc. (“Santarus”) and Lupin Limited (“Lupin”) entered into in February 2012 that resolved patent infringement litigation filed by the Company against Lupin regarding Lupin’s Abbreviated New Drug Application for generic 500 mg and 1000 mg tablets of Glumetza. The antitrust plaintiffs allege, among other things, that the Settlement violated the antitrust laws because it allegedly included a “reverse payment” that caused Lupin to delay its entry in the market with a generic version of Glumetza. The alleged “reverse payment” is an alleged commitment on the part of the settling parties not to launch an authorized generic version of Glumetza for a certain period. The antitrust plaintiffs allege that the Company and its co-defendants, which include Lupin as well as Bausch Health (the alleged successor in interest to Santarus), are liable for damages under the antitrust laws for overcharges that the antitrust plaintiffs allege they paid when they purchased the branded version of Glumetza due to delayed generic entry. Plaintiffs seek treble damages for alleged past harm, attorneys’ fees and costs.

On September 14, 2021, the Retailer Plaintiffs voluntarily dismissed all claims against the Company pursuant to a settlement agreement with the Company in return for $3.15 million. On February 3, 2022, the District Court issued its final order approving a settlement of the direct purchaser class plaintiffs’ claims against the Company in return for $3.85 million.

With respect to the California state court lawsuits, on November 24, 2021, the state court granted in part and denied in part a demurrer by the defendants in the Humana action. That case was consolidated in November 2022 with the HCSC action for pre-trial and trial purposes. On July 5, 2023, the state court denied a motion for judgment on the pleadings filed by the defendants in the Humana action. These California state cases are now in the midst of discovery, and trial is scheduled for December 2024.

The Company intends to defend itself vigorously in the consolidated California state court lawsuits. A liability for this matter has been recorded in the financial statements.

Opioid-Related Request and Subpoenas

As a result of the greater public awareness of the public health issue of opioid abuse, there has been increased scrutiny of, and investigation into, the commercial practices of opioid manufacturers generally by federal, state, and local regulatory and governmental agencies. In March 2017, Assertio Therapeutics received a letter from then-Sen. Claire McCaskill (D-MO), the then-Ranking Member on the U.S. Senate Committee on Homeland Security and Governmental Affairs, requesting certain information regarding Assertio Therapeutics’ historical commercialization of opioid products. Assertio Therapeutics voluntarily furnished information responsive to Sen. McCaskill’s request. Since 2017, Assertio Therapeutics has received and responded to subpoenas from the U.S. Department of Justice (“DOJ”) seeking documents and information regarding its historical sales and marketing of opioid products. Assertio Therapeutics has also received and responded to subpoenas or civil investigative demands focused on its historical promotion and sales of Lazanda, NUCYNTA, and NUCYNTA ER from various state attorneys general seeking documents and information regarding Assertio Therapeutics’ historical sales and marketing of opioid products. In addition, Assertio Therapeutics received and responded to a subpoena from the State of California Department of Insurance (“CDI”) seeking information relating to its historical sales and marketing of Lazanda. The CDI subpoena also sought information on Gralise, a non-opioid product formerly in Assertio Therapeutics’ portfolio. In addition, Assertio Therapeutics received and responded to a subpoena from the New York Department of Financial Services seeking information relating to its historical sales and marketing of opioid products. The Company has also received a subpoena from the New York Attorney General in May 2023, pursuant to which the New York Attorney General is seeking information concerning the sales and marketing of opioid products (Lazanda, NUCYNTA, NUCYNTA ER, and OXAYDO) by Assertio Therapeutics and Zyla. The
17

Company also from time to time receives and responds to subpoenas from governmental authorities related to investigations primarily focused on third parties, including healthcare practitioners. The Company is cooperating with the foregoing governmental investigations and inquiries.

In July 2022, the Company became aware that the DOJ issued a press release stating that it had settled claims against a physician whom the DOJ alleged had received payments for paid speaking and consulting work from two pharmaceutical companies, including Depomed, Inc. (“Depomed,” now known as Assertio Therapeutics), in exchange for prescribing certain of the companies’ respective products. As part of the settlement, the physician did not admit liability for such claims and the press release stated that there has been no determination of any liability for such claims. The Company denies any wrongdoing and disputes the DOJ’s characterization of the payments from Depomed.

Multidistrict and Other Federal Opioid Litigation
A number of pharmaceutical manufacturers, distributors and other industry participants have been named in numerous lawsuits around the country brought by various groups of plaintiffs, including city and county governments, hospitals, individuals and others. In general, the lawsuits assert claims arising from defendants’ manufacturing, distributing, marketing and promoting of FDA-approved opioid drugs. The specific legal theories asserted vary from case to case, but the lawsuits generally include federal and/or state statutory claims, as well as claims arising under state common law. Plaintiffs seek various forms of damages, injunctive and other relief and attorneys’ fees and costs.
For such cases filed in or removed to federal court, the Judicial Panel on Multi-District Litigation issued an order in December 2017, establishing a Multi-District Litigation court (“MDL Court”) in the Northern District of Ohio (In re National Prescription Opiate Litigation, Case No. 1:17-MD-2804). Since that time, more than 2,000 such cases that were originally filed in U.S. District Courts, or removed to federal court from state court, have been filed in or transferred to the MDL Court. Assertio Therapeutics is currently involved in a subset of the lawsuits that have been filed in or transferred to the MDL Court. Assertio Holdings has also been named in six such cases. In April 2022, the Judicial Panel on Multi-District Litigation issued an order stating that it would no longer transfer new opioid cases to the MDL Court. Since that time, Assertio Therapeutics has been named in lawsuits pending in federal courts outside of the MDL Court (in Georgia and New York). Plaintiffs may file additional lawsuits in which the Company may be named, and plaintiffs may also seek leave to add the Company to lawsuits already on file in the MDL Court. Plaintiffs in the pending federal cases involving Assertio Therapeutics or Assertio Holdings include individuals; county, municipal and other governmental entities; employee benefit plans, health insurance providers and other payors; hospitals, health clinics and other health care providers; Native American tribes; and non-profit organizations who assert, for themselves and in some cases for a putative class, federal and state statutory claims and state common law claims, such as conspiracy, nuisance, fraud, negligence, gross negligence, negligent and intentional infliction of emotional distress, deceptive trade practices, and products liability claims (defective design/failure to warn). In these cases, plaintiffs seek a variety of forms of relief, including actual damages to compensate for alleged personal injuries and for alleged past and future costs such as to provide care and services to persons with opioid-related addiction or related conditions, injunctive relief, including to prohibit alleged deceptive marketing practices and abate an alleged nuisance, establishment of a compensation fund, establishment of medical monitoring programs, disgorgement of profits, punitive and statutory treble damages, and attorneys’ fees and costs. No trial date has been set for any of these lawsuits, which are at an early stage of proceedings. Assertio Therapeutics and Assertio Holdings intend to defend themselves vigorously in these matters.
State Opioid Litigation

Related to the federal cases noted above, there have been hundreds of similar lawsuits filed in state courts around the country, in which various groups of plaintiffs assert opioid-drug related claims against similar groups of defendants. Assertio Therapeutics is currently named in a subset of those cases, including cases in Delaware, Missouri, Pennsylvania, Texas and Utah. Assertio Holdings is named as a defendant in one of these cases in Pennsylvania. Plaintiffs may file additional lawsuits in which the Company may be named. In the pending cases involving Assertio Therapeutics or Assertio Holdings, plaintiffs are asserting state common law and statutory claims against the defendants, and the majority of those cases are similar in nature to the claims asserted in the MDL cases. Plaintiffs are seeking actual damages, disgorgement of profits, injunctive relief, punitive and statutory treble damages, and attorneys’ fees and costs. The state lawsuits in which Assertio Therapeutics or Assertio Holdings has been served are generally each at an early stage of proceedings. Assertio Therapeutics and Assertio Holdings intend to defend themselves vigorously in these matters.

Insurance Litigation

On January 15, 2019, Assertio Therapeutics was named as a defendant in a declaratory judgment action filed by Navigators Specialty Insurance Company (“Navigators”) in the U.S. District Court for the Northern District of California (Case No. 3:19-cv-255). Navigators was Assertio Therapeutics’ primary product liability insurer. Navigators was seeking declaratory
18

judgment that opioid litigation claims noticed by Assertio Therapeutics (as further described above under “Multidistrict and Other Federal Opioid Litigation” and “State Opioid Litigation”) are not covered by Assertio Therapeutics’ life sciences liability policies with Navigators. On February 3, 2021, Assertio Therapeutics entered into a Confidential Settlement Agreement and Mutual Release with Navigators to resolve the declaratory judgment action and Assertio Therapeutics’ counterclaims. Pursuant to the Settlement Agreement, the parties settled and the coverage action was dismissed without prejudice.

During the first quarter of 2021, Assertio Therapeutics received $5.0 million in insurance reimbursement for previous opioid-related spend, which was recognized within Selling, general and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the year ended December 31, 2021.

On July 16, 2021, Assertio Therapeutics filed a complaint for declaratory relief against one of its excess products liability insurers, Lloyd’s of London Newline Syndicate 1218 and related entities (“Newline”), in the Superior Court of the State of California for the County of Alameda. Newline removed the case to the U.S. District Court for the Northern District of California (Case No. 3:21-cv-06642). Assertio Therapeutics was seeking a declaratory judgment that Newline has a duty to defend Assertio Therapeutics or, alternatively, to reimburse Assertio Therapeutics’ attorneys’ fees and other defense costs for opioid litigation claims noticed by Assertio Therapeutics. On May 18, 2022, Assertio Therapeutics entered into a Confidential Settlement Agreement and Mutual Release with Newline to resolve Assertio Therapeutics’ declaratory judgment action. Pursuant to the Settlement Agreement, the parties settled and the coverage action was dismissed with prejudice.

During the second quarter of 2022, Assertio Therapeutics received $2.0 million in insurance reimbursement for previous opioid-related spend, which was recognized within Selling, general and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive (Loss) Income for the year ended December 31, 2022.

On April 1, 2022, Assertio Therapeutics filed a complaint against its former insurance broker, Woodruff-Sawyer & Co. (“Woodruff”), in the Superior Court of the State of California for the County of Alameda (Case No. 22CV009380). Assertio Therapeutics alleged claims for negligence and breach of fiduciary duty in connection with Woodruff’s negotiation and procurement of products liability insurance coverage for Assertio Therapeutics. On April 26, 2024, Assertio Therapeutics and Woodruff executed a binding settlement term sheet to resolve Assertio Therapeutics’ claims.

Stockholder Actions

Shapiro v. Assertio Holdings, Inc., et al., U.S. District Court, Northern District of Illinois, Case No. 1:24-cv-00169. On January 5, 2024, this putative securities class action lawsuit was filed by a purported shareholder, alleging that Assertio and certain of its current and former executive officers made false or misleading statements and failed to disclose material facts regarding the likely impact of INDOCIN sales and the Spectrum Merger on Assertio’s profitability in violation of Sections 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act of 1934, as amended (the “Exchange Act”). On April 11, 2024, the court appointed Continental General Insurance Company as the lead plaintiff. The Company intends to vigorously defend itself in this matter.

Edwards v. Assertio Holdings, Inc., et al., Court of Chancery of the State of Delaware, Case No. 2024-0151. On February 19, 2024, this putative securities class action lawsuit was filed by a purported shareholder, alleging that certain former officers and directors of Spectrum breached their fiduciary duties in connection the Spectrum Merger, and that Guggenheim Securities LLC and Assertio aided and abetted such fiduciary duty breaches. The Company intends to vigorously defend itself in this matter.

Jung v. Peisert, et al., U.S. District Court, Delaware, Case No. 1:24-cv-00383-UNA. On March 26, 2024, this putative stockholder derivative action was filed against the Company (as a nominal defendant) and certain of its current and former executive offers and directors. The stockholder derivative complaint alleges, inter alia, that certain of the Company’s current and former executive officers and directors are liable to the Company, pursuant to Section 10(b) and 21(d) of the Exchange Act for contribution and indemnification, relating to allegedly false or misleading statements and alleged failure to disclose material facts regarding the likely impact of INDOCIN sales and the Spectrum Merger on the Company’s profitability. The complaint further alleges that certain of the Company’s current and former officers and directors breached their fiduciary duties, and that certain of the Company’s directors negligently violated Section 14(a) of the Exchange Act, by allegedly causing such false or misleading statements to be issued and/or failing to disclose material facts about such matters. The allegations state that as a result of the violations, certain of the Company’s current and former executive officers and directors committed acts of gross mismanagement, abuse of control, or were unjustly enriched. The plaintiffs generally seek corporate reforms, damages, interest, costs, attorneys’ fees, and other unspecified equitable relief.

19

Luo v. Spectrum Pharmaceuticals, Inc., et al., U.S. District Court, District of Nevada, Case No. 2:21-cv-01612. On August 31, 2021, this putative securities class action lawsuit was filed by a purported shareholder, alleging that Spectrum and certain of its former executive officers and directors made false or misleading statements and failed to disclose material facts about Spectrum’s business and the prospects of approval for its Biologic License Application (“BLA”) to the FDA for eflapegrastim (ROLVEDON) in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act. On November 1, 2021, four individuals and one entity filed competing motions to be appointed lead plaintiff and for approval of counsel. On July 28, 2022, the Court appointed a lead plaintiff and counsel for the putative class. On September 26, 2022, an amended complaint was filed alleging, inter alia, false and misleading statements with respect to ROLVEDON manufacturing operations and controls and adding allegations that defendants misled investors about the efficacy of, clinical trial data and market need for poziotinib during a Class Period of March 7, 2018 to August 5, 2021. The amended complaint seeks damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the Court. On November 30, 2022, the defendants filed a motion to dismiss the amended complaint, which was fully briefed as of February 27, 2023. On February 6, 2024, the Court held a hearing on the motion to dismiss and issued an order dismissing the lawsuit without prejudice to the lead plaintiff’s ability to replead their claims. The lead plaintiff filed a further amended complaint on March 29, 2024. The Company intends to vigorously defend itself in this matter.

Christiansen v. Spectrum Pharmaceuticals, Inc. et al., Case No. 1:22-cv-10292 (filed December 5, 2022 in the U.S. District Court for the Southern District of New York) (the “New York Action”). Three additional related putative securities class action lawsuits were subsequently filed by Spectrum shareholders against Spectrum and certain of its former executive officers in the U.S. District Court for the Southern District of New York: Osorio-Franco v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10292 (filed December 5, 2022); Cummings v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10677 (filed December 19, 2022); and Carneiro v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:23-cv-00767 (filed January 30, 2023). These three New York lawsuits allege that Spectrum and certain of its former executive officers made false or misleading statements about, inter alia, the safety and efficacy of and clinical trial data for poziotinib in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act, and seek remedies including damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the Court. On February 15, 2023, the Court consolidated the three New York lawsuits. On March 21, 2023, the Court entered an order designating Steven Christiansen as the lead plaintiff. Lead plaintiff Christiansen filed an amended consolidated complaint in the New York Action under the caption Christiansen v. Spectrum Pharmaceuticals, Inc, et al., on May 30, 2023, alleging a Class Period between March 17, 2022 and September 2022. The defendants filed a motion to dismiss the consolidated New York Action on July 25, 2023, which was fully briefed as of October 19, 2023. On January 23, 2024, the Court granted the motion to dismiss in part as to five of the challenged statements but denied the motion to dismiss as to two specific statements. The Company filed its answer to the complaint on March 8, 2024. The Company intends to vigorously defend itself in this matter.

Csaba v. Turgeon, et. al (filed December 15, 2021 in the U.S. District Court District of Nevada); Shumacher v. Turgeon, et. al (filed March 15, 2022 in the U.S. District Court District of Nevada); Johnson v. Turgeon, et. al (filed March 29, 2022 in the U.S. District Court District of Nevada); Raul v. Turgeon, et. al (filed April 28, 2022 in the U.S. District Court District of Delaware); and Albayrak v. Turgeon, et. al (filed June 9, 2022 in the U.S. District Court District of Nevada). These putative stockholder derivative actions were filed against Spectrum (as a nominal defendant) and certain of Spectrum’s former executive officers and directors. The stockholder derivative complaints allege, inter alia, that certain of Spectrum’s former executive officers are liable to Spectrum, pursuant to Section 10(b) and 21(d) of the Exchange Act for contribution and indemnification, if they are deemed (in the Luo class action), to have made false or misleading statements and failed to disclose material facts about Spectrum’s business and the prospects of approval for its BLA to the FDA for eflapegrastim. The complaints generally but not uniformly further allege that certain of Spectrum’s former officers and directors breached their fiduciary duties, and certain of Spectrum’s former directors negligently violated Section 14(a) of the Exchange Act, by allegedly causing such false or misleading statements to be issued and/or failing to disclose material facts about Spectrum’s business and the prospects of approval for its BLA to the FDA for eflapegrastim. The allegations state that as a result of the violations, certain of Spectrum’s former executive officers and directors committed acts of gross mismanagement, abuse of control, or were unjustly enriched. The plaintiffs generally seek corporate reforms, damages, interest, costs, attorneys’ fees, and other unspecified equitable relief. The parties have agreed to stay these derivative actions until there is a decision in the Luo Nevada securities class action either denying a motion to dismiss in whole or in part, or dismissing that securities class action with prejudice.

20

NOTE 16. SHAREHOLDERS EQUITY

Issuance of Common Stock in the Spectrum Merger

Pursuant to the Merger Agreement, shares of Spectrum common stock issued and outstanding immediately prior to the Effective Date, as well as Spectrum restricted stock units, certain stock appreciation rights, certain options to purchase Spectrum common stock, and warrants to purchase Spectrum common stock, which, in each case, were outstanding immediately prior to the Effective Date and were either vested or became vested as a result of the Spectrum Merger on the Effective Date, were converted into the right to receive fully paid and non-assessable shares of the Company’s common stock based on the exchange ratio as set forth in the Merger Agreement (see Note 2, Acquisitions) and the CVRs. Accordingly, on the Effective Date the Company issued approximately 38.0 million shares of its common stock to the previous holders of Spectrum common stock, net of a fractional share settlement.

Exchanged Convertible Notes

In connection with the Convertible Note Exchange (See Note 11, Debt) in the first quarter of 2023, the Company paid an aggregate of $10.5 million in cash and issued an aggregate of approximately 7.0 million shares of its common stock in partial settlement of the 2027 Convertible Notes (the “Exchanged Notes”). The Company did not receive any cash proceeds from the issuance of the shares of its common stock but recognized additional paid-in capital of $28.3 million during the three months ended March 31, 2023, related to the common stock share issuance, net of approximately $1.6 million of unamortized issuance costs related to the Exchanged Notes.

NOTE 17.  NET LOSS PER SHARE

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period.

Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, plus potentially dilutive common shares, consisting of stock-based awards and equivalents, and convertible debt. For the purposes of this calculation, stock-based awards and convertible debt are considered to be potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive. The Company uses the treasury-stock method to compute diluted earnings per share with respect to its stock-based awards and equivalents. The Company uses the if-converted method to compute diluted earnings per share with respect to its convertible debt. Under the if-converted method, the Company assumes any convertible debt outstanding was converted at the beginning of each period presented when the effect is dilutive. As a result, interest expense, net of tax, and any other income statement impact associated with the 2027 Convertible Notes, net of tax, is added back to net loss used in the diluted earnings per share calculation. Additionally, the diluted shares used in the diluted earnings per share calculation includes the potential dilution effect of the convertible debt if converted into the Company’s common stock. As the Company was in a loss position for the three months ended March 31, 2024 and March 31, 2023, the Company’s potentially dilutive stock-based awards and convertible debt were not included in the computation of diluted net loss per share, because to do so would be anti-dilutive.

The following table reflects the calculation of basic and diluted loss per common share for the three months ended March 31, 2024 and 2023 (in thousands, except for per share amounts):

 Three Months Ended March 31,
20242023
Basic and diluted net loss per share
Net loss$(4,510)$(3,484)
Weighted-average common shares outstanding94,980 51,005 
Basic and diluted net loss per share$(0.05)$(0.07)
 
21

The following table reflects outstanding potentially dilutive common shares that are not included in the computation of diluted net loss per share, because to do so would be anti-dilutive, for the three months ended March 31, 2024 and 2023 (in thousands):
 Three Months Ended March 31,
20242023
Convertible notes9,768 14,489 
Stock-based awards and equivalents8,422 8,271 
Total potentially dilutive common shares18,190 22,760 

NOTE 18.  FAIR VALUE

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
 
•Level 1: Quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
22

The following table reflects the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):

March 31, 2024Financial Statement ClassificationLevel 1Level 2Level 3Total
Assets:
U.S. TreasuriesCash and cash equivalents$— $36,518 $— $36,518 
U.S. Government agenciesCash and cash equivalents— 2,750 — 2,750 
Money market fundsCash and cash equivalents40,168 — — 40,168 
Total$40,168 $39,268 $— $79,436 
Liabilities:
Short-term contingent considerationContingent consideration, current portion$— $— $2,700 $2,700 
Derivative liabilityLong-term debt— — 308 308 
Total$— $— $3,008 $3,008 

December 31, 2023Financial Statement ClassificationLevel 1Level 2Level 3Total
Assets:
U.S. TreasuriesCash and cash equivalents$— $35,458 $— $35,458 
U.S. Government agenciesCash and cash equivalents— 3,294 — 3,294 
Money market fundsCash and cash equivalents32,534 — — 32,534 
Total$32,534 $38,752 $— $71,286 
Liabilities:
Short-term contingent considerationContingent consideration, current portion$— $— $2,700 $2,700 
Derivative liabilityLong-term debt— — 308 308 
Total$— $— $3,008 $3,008 
    
Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity date of purchase of three months or less to be cash equivalents. The Company invests its cash in money market funds and marketable securities including U.S. Treasury and government agency securities, commercial paper, and higher quality debt securities of financial and commercial institutions. The Company classified money market funds as Level 1, due to their short-term maturity, and measured the fair value based on quoted prices in active markets for identical assets. The Company classified commercial paper, U.S. Treasury and government agency securities as Level 2, as the inputs used to value these instruments are directly observable or can be corroborated by observable market data for substantially the full term of the assets.

Contingent Consideration Obligations

Spectrum Merger Contingent Variable Rights

In connection with the Spectrum Merger, the Company issued CVRs (See Note 2, Acquisitions) that represent a contingent consideration obligation which is measured at fair value.

As of both March 31, 2024 and December 31, 2023, the fair value of the Company’s CVR liability related to the Spectrum Merger was determined by the Company to be zero. Accordingly, the Company recognized no expense or benefit for the change in fair value of the CVR contingent consideration during the three months ended March 31, 2024. The fair value of the CVR contingent consideration is determined using a Monte Carlo simulation model under the income approach based on the probability of achievement of ROLVEDON net sales milestones using projections of 2024 and 2025 net sales and discounted to present value. The significant assumptions used in the calculation of the fair value as of March 31, 2024 included updated projections of future ROLVEDON product net sales, which resulted in no probability of achievement under the Monte Carlo simulation.

23

Zyla Merger Contingent Consideration Obligation

In connection with the Zyla Merger, the Company assumed a contingent consideration obligation which is measured at fair value. The Company has obligations to make contingent consideration payments for future royalties to an affiliate of CR Group L.P. based upon annual INDOCIN product net sales over $20.0 million at a 20% royalty through January 2029. The Company classified the acquisition-related contingent consideration liabilities to be settled in cash as Level 3, due to the lack of relevant observable inputs and market activity. As of both March 31, 2024 and December 31, 2023, the fair value of the INDOCIN product contingent consideration was determined to be $2.7 million and has been classified as current contingent consideration in the Company’s Condensed Consolidated Balance Sheets.

During the three months ended March 31, 2024 and 2023, the Company recognized an expense of zero and $9.2 million, respectively, for the change in fair value of contingent consideration, which was recognized in Change in fair value of contingent consideration in the Company’s Condensed Consolidated Statements of Comprehensive Loss. The fair value of the contingent consideration incurred in the Zyla Merger is determined using an option pricing model under the income approach based on estimated INDOCIN product revenues through January 2029 and discounted to present value. The significant assumptions used in the calculation of the fair value as of March 31, 2024 included revenue volatility of 15%, discount rate of 5.5%, credit spread of 9.2% and projections of future INDOCIN product revenues.

The following table summarizes changes in fair value of the Company’s contingent consideration obligations that are measured on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2024 and 2023 (in thousands):

 Three Months Ended March 31,
20242023
Fair value, beginning of the period$2,700 $48,500 
Change in fair value of contingent consideration recorded within costs and expenses— 9,167 
Cash payment related to contingent consideration— (6,609)
Fair value, end of the period$2,700 $51,058 

Derivative Liability
The Company determined that an embedded conversion feature included in the 2027 Convertible Notes required bifurcation from the host contract and to be recognized as a separate derivative liability carried at fair value. The estimated fair value of the derivative liability, which represents a Level 3 valuation, was $0.3 million as of both March 31, 2024 and December 31, 2023, and was determined using a binomial lattice model using certain assumptions and consideration of an increased conversion ratio on the underlying convertible notes that could result from the occurrence of certain events. The significant assumption used in the binomial lattice model is a credit spread of 8.8%.

There was no change in the fair value of the derivative liability for the three months ended March 31, 2024 or 2023.

Financial Instruments Not Required to be Remeasured at Fair Value

The Company’s other financial assets and liabilities are not remeasured to fair value, as the carrying cost of each approximates its fair value. As of March 31, 2024, the estimated fair value of the 2027 Convertible Notes, excluding the bifurcated embedded conversion option, was approximately $33.8 million, compared to a par value of $40.0 million. As of December 31, 2023, the estimated fair value of the 2027 Convertible Notes, excluding the bifurcated embedded conversion option, was approximately $35.7 million, compared to a par value of $40.0 million. The Company estimated the fair value of its 2027 Convertible Notes as of March 31, 2024 and December 31, 2023 based on a market approach which represents a Level 2 valuation.

24

NOTE 19.  INCOME TAXES

As of March 31, 2024, the Company has concluded that it is not more likely than not that it will realize the net deferred tax asset recorded as of March 31, 2024. As a result, the Company has recorded a full valuation allowance against the net deferred tax asset recorded as of March 31, 2024. The valuation allowance is determined in accordance with the provisions of ASC 740, Income Taxes, which require an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company primarily relied on its reversing taxable temporary differences to assess its valuation allowance, which resulted in recording a full valuation allowance against our net deferred tax assets during the quarter. If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made.

For the three months ended March 31, 2024, the Company recorded an income tax expense of $0.1 million. The difference between the income tax expense and the tax at the federal statutory rate of 21.0% on current year operations is principally due to the impact of the valuation allowance and state income taxes.

NOTE 20.  RESTRUCTURING CHARGES

In August 2023, the Company implemented a reorganization plan of its workforce and other resources primarily designed to realize the synergies of the Spectrum Merger (the “Spectrum Reorganization Plan”). The Spectrum Reorganization Plan was primarily focused on the reduction of staff at the Company’s headquarters office and the exit of certain leased facilities and office equipment. The Company expects the recognition of any additional costs and all cash payments under the Spectrum Reorganization Plan to be completed by the end of 2024.

The staff reductions under the Spectrum Reorganization Plan were the result of a distinct severance plan approved by the Company’s Board of Directors and were not executed as part of established Company policies or plans. Total employee compensation costs recognized under the Spectrum Reorganization Plan through March 31, 2024, were approximately $3.3 million. In addition, the leased facilities and office equipment referenced above are not expected to be used for any business purpose, and the Company will not sublease the facilities and office equipment due to the short remaining lease terms. The facility exit costs represent the acceleration of the underlying right-of-use asset amortization to align with the cease use date for the abandoned facilities and office equipment. Total facility exit costs recognized under the Spectrum Reorganization Plan through March 31, 2024, were approximately $1.3 million. There were no remaining facility exit costs expected to be recognized by the Company under the Spectrum Reorganization Plan as of March 31, 2024.

Effective as of January 2, 2024, the Company separated from the service of its former President and Chief Executive Officer. Pursuant to his then existing Management Continuity Agreement with the Company, the former President and Chief Executive Officer was entitled to severance compensation and benefits of approximately $1.5 million, which was recognized as Restructuring charges within the Condensed Consolidated Statement of Comprehensive (Loss) Income for year ended December 31, 2023, the period in which the separation and related severance benefit was determined to be probable. The Company does not expect to recognize any additional restructuring charges related to the separation from the former President and Chief Executive Officer.

The Company recognized restructuring charges of $0.7 million for the three months ended March 31, 2024, all of which related to employee compensation costs. The Company recognized no restructuring charges for the three months ended March 31, 2023.

The following table summarizes the changes in the Company’s accrued restructuring liability for employee compensation costs, which is classified within Accrued liabilities in the Condensed Consolidated Balance Sheets (in thousands):
 Employee compensation costs
Balance as of December 31, 2023$4,378 
Restructuring charges720 
Cash paid(1,730)
Balance as of March 31, 2024$3,368 

25

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING INFORMATION

Statements made in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as “anticipate,” “approximate”, “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “opportunity,” “plan,” “potential,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “will” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Examples of forward-looking statements include, but are not necessarily limited to, those relating to:
 
•our ability to grow sales of ROLVEDON and the commercial success and market acceptance of ROLVEDON and our other products, including the coverage of our products by payors and pharmacy benefit managers;

•our ability to successfully develop and execute our sales, marketing and promotion strategies using our sales force and non-personal promotion model capabilities, including developing and maintaining relationships with customers, physicians, payors and other constituencies;

•the entry and sales of generics of our products and/or other products competitive with any of our products (including indomethacin suppositories compounded by hospitals and other institutions including a 503B compounder which we believe is violating certain provisions of the Food, Drug and Cosmetic Act);

•the timing and impact of additional generic approvals and uncertainty around the recent approvals and launches of generic INDOCIN products (which are not patent protected and now face generic competition as a result of the August 2023 approval and launch of generic indomethacin suppositories and January 2024 approval and subsequent launch of a generic indomethacin oral suspension product) on our future results of operations, financial condition, and cash flows;

•our ability to successfully execute our business strategy, business development, strategic partnerships, and investment opportunities to build and grow for the future, including through product acquisitions, commercialization agreements, licensing or technology agreements, equity investments, and business combinations;

•our ability to achieve the expected financial performance from products we acquire, as well as delays, challenges and expenses, and unexpected liabilities and costs associated with integrating and operating newly-acquired products, including our expectations around the sales and growth prospect of ROLVEDON;

•our expectations regarding industry trends, including pricing pressures and managed healthcare practices;

•our ability to execute on and realize anticipated benefits from our reorganization plan in connection with the Spectrum Merger;

•our ability to attract and retain executive leadership and key employees, including in connection with our ongoing search for a permanent Chief Executive Officer (“CEO”);

•the ability of our third-party manufacturers to manufacture adequate quantities of commercially salable inventory and active pharmaceutical ingredients for each of our products on commercially reasonable terms and in compliance with their contractual obligations to us, and our ability to maintain our supply chain which relies on single-source suppliers;

•the outcome of, and our intentions with respect to, any litigation or government investigations, including pending and potential future shareholder litigation relating to the Spectrum Merger and/or the approval and launch of generic indomethacin suppositories in the second half of 2023, antitrust litigation, opioid-related government investigations and opioid-related litigation, as well as Spectrum’s legacy shareholder and other litigation, and other disputes and litigation, and the costs and expenses associated therewith;

26

•the timing, cost and results of our clinical studies and other research and development efforts, including the extent to which data from the ROLVEDON same-day dosing trial, if and when completed, may support our ongoing commercialization efforts;

•our compliance or non-compliance with, or being subject to, legal and regulatory requirements related to the development or promotion of pharmaceutical products in the United States (“U.S.”);

•the potential impacts of future outbreaks of epidemics, pandemics or other diseases on our liquidity, capital resources, operations and business and those of the third parties on which we rely, including suppliers and distributors;

•our ability to obtain and maintain intellectual property protection for our products and operate our business without infringing the intellectual property rights of others;

•our ability to generate sufficient cash flow from our business to fund operations and to make payments on our indebtedness, our ability to restructure or refinance our indebtedness, if necessary, and our compliance with the terms and conditions of the agreements governing our indebtedness;

•our ability to raise additional capital or refinance our debt, if necessary;

•our intentions or expectations regarding the use of available funds and any future earnings or the use of net proceeds from securities offerings;

•our commitments and estimates regarding future obligations, contingent consideration obligations and other expenses, future revenues, capital requirements and needs for additional financing;

•our counterparties’ compliance or non-compliance with their obligations under our agreements;

•variations in revenues obtained from commercialization agreements, including contingent milestone payments, royalties, license fees and other contract revenues, including non-recurring revenues, and the accounting treatment with respect thereto;

•the estimation, projection or availability of net operating losses or credit carryforwards;

•the potential impacts of adverse business and economic conditions including inflationary pressures, economic slowdown or recession, relatively high interest rates, changes in monetary policy, potential U.S. federal government shutdowns, geopolitical conflicts and financial institution instability; and
•our common stock maintaining compliance with The Nasdaq Capital Market’s minimum closing bid requirement of at least $1.00 per share, particularly in light of our stock trading below or only slight above $1.00 per share recently.

Factors that could cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described and incorporated by reference in the “RISK FACTORS” section and elsewhere in this Quarterly Report on Form 10-Q, and in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 11, 2024 (the “2023 Form 10-K”). Except as required by law, we assume no obligation to update any forward-looking statement publicly, or to revise any forward-looking statement to reflect events or developments occurring after the date of this Quarterly Report on Form 10-Q, even if new information becomes available in the future.

27


COMPANY OVERVIEW

We are a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients. We have built our product portfolio through the acquisition or licensing of approved products. Our commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. Our primary marketed products are:

ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use
A long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation that is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
INDOCIN® (indomethacin) Suppositories
A suppository and oral solution of indomethacin used both in hospitals and out-patient settings. Both products are nonsteroidal anti-inflammatory drug (NSAID), indicated for:
• Moderate to severe rheumatoid arthritis including acute flares of chronic disease
• Moderate to severe ankylosing spondylitis
INDOCIN® (indomethacin) Oral Suspension
• Moderate to severe osteoarthritis
• Acute painful shoulder (bursitis and/or tendinitis)
• Acute gouty arthritis
Sympazan® (clobazam) oral filmA benzodiazepine indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients aged two years of age or older. Sympazan is the only product to offer clobazam in a convenient film with PharmFilm® technology. Sympazan is taken without water or liquid, adheres to the tongue, and dissolves to deliver clobazam.
Otrexup® (methotrexate)
injection for subcutaneous use
A once weekly single-dose auto-injector containing a prescription medicine, methotrexate. Otrexup is a folate analog metabolic inhibitor indicated for the:
• Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy.
• Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.
SPRIX® (ketorolac tromethamine) Nasal Spray
A prescription NSAID indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at an opioid level. SPRIX is a non-narcotic nasal spray that provides patients with moderate to moderately severe short-term pain relief in a form of ketorolac that is absorbed rapidly but does not require an injection administered by a healthcare provider.
CAMBIA® (diclofenac potassium for oral solution)
A prescription NSAID indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older. CAMBIA can help patients with migraine pain, nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound). CAMBIA is not a pill; it is a powder, and combining CAMBIA with water activates the medicine in a unique way.
    

On July 31, 2023 (the “Effective Date”), pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 24, 2023, we completed the acquisition of Spectrum Pharmaceutical, Inc. (“Spectrum”), a commercial stage biopharmaceutical company focused on novel and targeted oncology products (the “Spectrum Merger”), through a merger of a wholly-owned subsidiary of the Company with and into Spectrum, with Spectrum surviving the merger as a wholly-owned subsidiary of the Company. We accounted for the Spectrum Merger using the acquisition method of accounting under Accounting Standards Codification (“ASC”) 805 and are considered the accounting acquirer. The results of operations of Spectrum are included in our condensed consolidated financial statements as of the Effective Date.

Pursuant to the Merger Agreement, each issued and outstanding share of Spectrum common stock as of the Effective Date was converted into the right to receive (i) 0.1783 shares of our common stock and (ii) one contingent value right (“CVR”) representing a contractual right to receive future conditional payments worth up to an aggregate maximum amount of $0.20, settleable in cash, additional shares of Assertio common stock or a combination of cash and additional shares of Assertio
28

common stock at our sole discretion, upon the achievement of certain sales milestones related to Spectrum’s product ROLVEDON. Subject to adjustments, each CVR represents the right to receive up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175 million during the calendar year ending December 31, 2024, and up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $225 million during the calendar year ending December 31, 2025. In addition, upon consummation of the Spectrum Merger, Spectrum’s outstanding employee stock awards and other warrants that were outstanding immediately as of the Effective Date automatically vested (if unvested) and/or cancelled, as applicable, which generally resulted in the issuance of shares of Assertio common stock and/or CVRs to the holders of such stock awards or other warrants, in each case as dictated by the terms of the Merger Agreement. These shares and CVRs issued are considered part of the consideration transferred, and no compensation expense was recognized because the settlement was a condition of the Merger Agreement and other existing individual agreements, no future performance is required by the holders, and the fair value of the shares and CVRs is equivalent to the fair value of the existing employee stock awards and other warrants.

Segment Information

We manage our business within one reportable segment. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions, and assesses operating performance. To date, substantially all of our revenues are related to product sales in the U.S.


RESULTS OF OPERATIONS
Revenues
The following table reflects total revenues, net for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended
March 31, 2024December 31, 2023March 31, 2023
Product sales, net:
ROLVEDON$14,478 $11,043 $— 
INDOCIN products8,682 10,848 30,346 
Sympazan2,617 2,706 2,502 
Otrexup2,882 2,804 2,822 
SPRIX1,437 2,343 1,889 
CAMBIA1,256 2,008 2,264 
Other products510 710 1,946 
Total product sales, net31,862 32,462 41,769 
Royalties and milestone revenue586 523 697 
Total revenues$32,448 $32,985 $42,466 
Product sales, net
ROLVEDON net product sales were $14.5 million for the three months ended March 31, 2024 compared to $11.0 million for the three months ended December 31, 2023, which was the first full quarter of ROLVEDON net product sales since the acquisition of Spectrum on July 31, 2023. The quarter-over-quarter increase of $3.5 million was primarily due to volume growth.
INDOCIN net product sales for the three months ended March 31, 2024 were $8.7 million, a decrease of $21.6 million from net product sales of $30.3 million for the three months ended March 31, 2023, and a decrease of $2.2 million from net product sales of $10.8 million for the three months ended December 31, 2023. The decrease for the three months ended March 31, 2024 compared to both prior periods is primarily due to lower volume and pricing as a result of the August 2023 approval and launch of generic indomethacin suppositories. In the remainder of 2024, we expect INDOCIN net product sales to continue to be impacted unfavorably by increasing competition as a result of existing generic entrants, expected future generic entrants and other competitive products.
Sympazan net product sales increased $0.1 million from $2.5 million for the three months ended March 31, 2023 to $2.6 million for the three months ended March 31, 2024, primarily due to favorable payor mix, partially offset by lower
29

volume. Sympazan net product sales for the three months ended March 31, 2024 decreased $0.1 million from $2.7 million for the three months ended December 31, 2023, primarily due to unfavorable payor mix, partially offset by higher volume.
Otrexup net product sales were $2.9 million for the three months ended March 31, 2024, an increase of $0.1 million from net product sales of $2.8 million for each of the three months ended March 31, 2023 and December 31, 2023, primarily due to favorable payor mix, partially offset by a decline in volume.
SPRIX net product sales were $1.4 million for the three months ended March 31, 2024, a decrease of $0.5 million from net product sales of $1.9 million for the three months ended March 31, 2023, and a decrease of $0.9 million from net product sales of $2.3 million for the three months ended December 31, 2023, primarily due to lower volume.
CAMBIA net product sales were $1.3 million for the three months ended March 31, 2024, a decrease of $1.0 million from net product sales of $2.3 million for the three months ended March 31, 2023, and a decrease of $0.7 million from net product sales of $2.0 million for the three months ended December 31, 2023, primarily due to lower volume caused by generic entrants in 2023.
Other net product sales for the three months ended March 31, 2023 include net product sales for OXAYDO of $0.8 million and net product sales of Zipsor of $1.2 million. As we ceased OXAYDO product sales beginning in September 2023, other net product sales for the three months ended March 31, 2024 of $0.5 million and the three months ended December 31, 2023 of $0.7 million represent only net product sales of Zipsor.
The decrease in total product sales, net, for the three months ended March 31, 2024 as compared to December 31, 2023 and March 31, 2023, also reflects a year-over-year increase in the amounts charged as a reduction to revenue for sales and return allowances, discounts, chargebacks, and rebates, which is primarily attributed to a shift in product mix with the addition of ROLVEDON and the decrease in product sales of INDOCIN and CAMBIA.
    
Royalties & Milestone revenue

In November 2010, we entered into a license agreement granting Miravo the rights to commercially market CAMBIA in Canada. The counterparty to the license agreement independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. We recognized royalties revenue related to the CAMBIA license agreement of $0.6 million for the three months ended March 31, 2024, and $0.5 million for each of the three months ended March 31, 2023 and December 31, 2023.

We recognized no milestone revenue associated with the completion of certain service milestones for each of the three months ended March 31, 2024 and December 31, 2023, and milestone revenue associated with the completion of certain service milestones of $0.2 million for the three months ended March 31, 2023.

Cost of Sales
Cost of sales consists of costs of the active pharmaceutical ingredient, contract manufacturing and packaging costs, royalties payable to third parties, inventory write downs or scrap costs, product quality testing, internal employee costs related to the manufacturing process, distribution costs, and shipping costs related to our product sales. Cost of sales excludes the amortization of intangible assets. Fair value of inventories acquired through business combinations or asset acquisitions include an inventory step-up within the value of inventories. The inventory step-up value is amortized as the related inventory is sold and is included in cost of sales.

Cost of sales for the three months ended March 31, 2024 increased $5.7 million from $5.5 million for the three months ended March 31, 2023 to $11.2 million for the three months ended March 31, 2024, primarily due to $4.1 million of ROLVEDON inventory step-up amortization and $1.1 million of ROLVEDON inventory write downs, which the Company acquired as part of the Spectrum Merger, and the impact of product mix, which increased cost of sales by $1.3 million. The increase in cost of sales was partially offset by $0.8 million of lower non-ROLVEDON inventory write downs.

Cost of sales for the three months ended March 31, 2024 increased $1.5 million from $9.7 million for the three months ended December 31, 2023 to $11.2 million for the three months ended March 31, 2024, primarily due to an increase in ROLVEDON specific cost of sales, including quarter-over-quarter increases in inventory step-up amortization of $1.1 million, inventory write downs of $0.9 million, and $0.4 million of cost of sales directly attributable to ROLVEDON product sales. The increase in cost of sales due to ROLVEDON was partially offset by $0.9 million of lower non-ROLVEDON inventory write downs and the impact of product mix, which decreased cost of sales by $0.2 million.

30

Cost of sales are impacted by both product volume and mix, changes in which will have an impact on Cost of sales recognized by us in future periods. In the remainder of 2024, we expect Cost of sales, as a percentage of sales, to be higher due to changes in product volume and mix.

Research and Development Expenses
Research and development expenses include salaries, costs for planned clinical trials, consultant fees, supplies, and allocations of corporate costs. It is difficult to predict the scope and magnitude of future research and development expenses for our product candidates in research and development, as it is difficult to determine the nature, timing and extent of planned clinical trials and studies and the U.S. Food and Drug Administration’s (“FDA”) requirements for a particular drug. As potential products proceed through the development process, each step is typically more extensive, and therefore more expensive, than the previous step. Therefore, success in development generally results in increasing expenditures until actual product approval.

Research and development expenses were $0.7 million for the three months ended March 31, 2024, representing primarily costs directly associated with ongoing clinical trial activity for ROLVEDON. We did not recognize any research and development expenses for the three months ended March 31, 2023.

Research and development expenses decreased $0.3 million from $1.0 million for the three months ended December 31, 2023 to $0.7 million for the three months ended March 31, 2024, primarily due to lower costs associated with ongoing clinical activity for ROLVEDON for the three months ended March 31, 2024.

Selling, General and Administrative Expenses

Selling, general and administrative expenses primarily consist of personnel, contract personnel, marketing and promotion expenses associated with our commercial products, personnel expenses to support our administrative and operating activities, facility costs, and professional expenses, such as legal and accounting fees.

Selling, general, and administrative expenses increased $1.6 million from $16.9 million for the three months ended March 31, 2023 to $18.5 million for the three months ended March 31, 2024, primarily due to: (i) $6.7 million of higher operating expenses incurred following the Spectrum Merger, partially offset by; (ii) $2.4 million of lower transaction-related expenses, primarily legal and professional fees, associated with the Spectrum Merger, (iii) $2.3 million of lower marketing and promotion expenses, and (iv) a net decrease of $0.4 million in other general operating expenses.

Selling, general and administrative expenses decreased $5.5 million from $24.0 million for the three months ended December 31, 2023 to $18.5 million for the three months ended March 31, 2024, primarily due to: (i) $2.8 million of lower ROLVEDON direct expenses, (ii) a decrease of $1.4 million in stock-based compensation expense, (iii) $1.0 million of lower marketing and promotion expenses, and (iv) $0.4 million of lower transaction-related expenses associated with the Spectrum Merger. The decrease was partially offset by a net increase of $0.2 million in other general operating expenses.

Change in Fair Value of Contingent Consideration

In connection with the Spectrum Merger, we issued CVRs that represent a contingent consideration obligation which is measured at fair value. See Company Overview for further information. Pursuant to our merger with Zyla Life Sciences (“Zyla”) in May 2020 (the “Zyla Merger”), we assumed a contingent consideration obligation for future royalties on annual INDOCIN product net sales which is measured at fair value. The fair values of both contingent consideration obligations are remeasured each reporting period, with changes in the fair value of each of the contingent consideration obligations resulting from changes in the respective underlying inputs being recognized in operating expenses until both the contingent consideration obligation arrangements are settled.

For the three months ended March 31, 2024 and 2023, we recognized an expense of zero and $9.2 million, respectively, for the change in fair value of contingent consideration.

The fair value of the CVR contingent consideration is determined using a Monte Carlo simulation model under the income approach based on the probability of achievement of ROLVEDON net sales milestones using projections of 2024 and 2025 net sales and discounted to present value. As of March 31, 2024 and December 31, 2023, the fair value of the CVR liability was determined to be zero. The significant assumptions used in the calculation of the fair value as of March 31, 2024, included updated projections of future ROLVEDON product net sales, which resulted in no probability of achievement under the Monte Carlo simulation.
31


The fair value of the contingent consideration obligation incurred in the Zyla Merger is determined using an option pricing model under the income approach based on estimated INDOCIN product revenues through January 2029, and discounted to present value. As of both March 31, 2024 and December 31, 2023, the fair value of the INDOCIN product contingent consideration was determined to be $2.7 million. The significant assumptions used in the calculation of the fair value as of March 31, 2024, included revenue volatility of 15%, discount rate of 5.5%, credit spread of 9.2% and updated projections of future INDOCIN product revenues.

Amortization of Intangible Assets

The following table reflects amortization of intangible assets for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Amortization of intangible assets—ROLVEDON$1,517 $— 
Amortization of intangible assets—INDOCIN2,598 3,210 
Amortization of intangible assets—Sympazan303 303 
Amortization of intangible assets—Otrexup261 1,377 
Amortization of intangible assets—SPRIX952 1,394 
Total $5,631 $6,284 
 
Amortization expense decreased $0.7 million from $6.3 million for the three months ended March 31, 2023 to $5.6 million for the three months ended March 31, 2024, primarily due to a lower carrying value of intangible assets due to impairment charges recognized in the third and fourth quarters of 2023, offset by the additional amortization of the ROLVEDON product rights, acquired in July 2023.

Restructuring Charges

Restructuring charges were $0.7 million for the three months ended March 31, 2024 compared to zero for the three months ended March 31, 2023. In August 2023, we implemented a reorganization plan of our workforce and other resources primarily designed to realize the synergies of the Spectrum Merger (the “Spectrum Reorganization Plan”). The Spectrum Reorganization Plan was primarily focused on the reduction of staff at our headquarters office and the exit of certain leased facilities. We expect the recognition of any additional costs and all cash payments under the Spectrum Reorganization Plan to be completed by the end of 2024.

We regularly evaluate our operations to identify opportunities to streamline operations and optimize operating efficiencies as an anticipation to changes in the business environment.

Other (Expense) Income

The following table reflects other expense (income) for the three months ended March 31, 2024 and 2023 (in thousands):
 Three Months Ended March 31,
20242023
Debt-related expenses$— $(9,918)
Interest expense(757)(1,122)
Other gain 716 802 
Total other expense$(41)$(10,238)

Other expense decreased by $10.2 million for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, primarily due to debt-related expenses incurred in the prior year and lower interest expense. Debt-related expenses for the three months ended March 31, 2023, consisted of an induced conversion expense of approximately $8.8 million and direct transaction costs of approximately $1.1 million incurred as a result of the $30.0 million
32

Convertible Note Exchange in the first quarter of 2023, as further described under the heading “Liquidity and Capital Resources” below. There were no similar debt-related expenses in the three months ended March 31, 2024.

The following table reflects interest expense for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Interest payable on 2027 Convertible Notes$650 $975 
Amortization of debt issuance costs107 147 
Total interest expense$757 $1,122 

For the three months ended March 31, 2024, total interest expense decreased $0.3 million from $1.1 million for the three months ended March 31, 2023 to $0.8 million for the three months ended March 31, 2024, primarily due to a lower principal balance of 2027 Convertible Notes outstanding.

Income Tax Provision

For the three months ended March 31, 2024, we recorded an income tax expense of $0.1 million. The difference between the income tax expense and the tax at the federal statutory rate of 21.0% on current year operations is primarily due to the impact of the valuation allowance and state income taxes. As of March 31, 2024, we concluded that it is not more likely than not that we will realize the net deferred tax asset recorded as of March 31, 2024. As a result, we have recorded a full valuation allowance against the net deferred tax asset as of March 31, 2024.

LIQUIDITY AND CAPITAL RESOURCES

We have and continue to finance our operations and business development efforts primarily from product sales, private and public sales of equity securities, including convertible debt securities, the proceeds of secured borrowings, the sale of rights to future royalties and milestones, upfront license, milestone and fees from collaborative and license partners.

On August 22, 2022, we issued $70.0 million aggregate principal amount of convertible senior notes which mature on September 1, 2027, and bear interest at the rate of 6.5% per annum, payable semi-annually in arrears on March 1 and September 1 of each year beginning March 1, 2023 (the “2027 Convertible Notes”). On February 27, 2023, we completed a privately negotiated exchange of $30.0 million principal amount of the 2027 Convertible Notes (the “Convertible Note Exchange”). Pursuant to the Convertible Note Exchange, 6,990,000 shares of the Company’s common stock, plus an additional $10.5 million in cash, were issued in a partial settlement of the 2027 Convertible Notes.

The terms of the 2027 Convertible Notes are governed by an indenture dated August 25, 2022 (the “2027 Convertible Note Indenture”). Pursuant to the terms of the 2027 Convertible Note Indenture, we and our restricted subsidiaries must comply with certain covenants, including mergers, consolidations, and divestitures; guarantees of debt by subsidiaries; issuance of preferred and/or disqualified stock; and liens on our properties or assets. We were in compliance with our covenants with respect to the 2027 Convertible Notes as of March 31, 2024.

We believe that our existing cash will be sufficient to fund our operations and make the required payments under our debt agreements due for the next twelve months from the date of this filing. We base this expectation on our current operating plan, which may change as a result of many factors.
 
Our cash needs may vary materially from our current expectations because of differences between the actual cash impacts and our expected impacts related to numerous factors, including:

•acquisitions or licenses of complementary businesses, products, technologies or companies;
•declines in sales of our marketed products, including those resulting from the entry and sales of generics and/or other products competitive with any of our products;
•expenditures related to our commercialization of our products, including our efforts to manage supply costs and enhance the long-term prospects of ROLVEDON product sales;
•milestone and royalty revenue we receive under our collaborative development arrangements;
•interest and principal payments on our current and future indebtedness;
•financial terms of definitive license agreements or other commercial agreements we may enter into;
•changes in the focus and direction of our business strategy and/or research and development programs;
33

•potential expenses relating to any litigation matters, including relating to Assertio Therapeutics’ prior opioid product franchise for which we have not accrued any reserves due to an inability to estimate the magnitude and/or probability of such expenses, and former drug Glumetza;
•potential expenses relating to the Spectrum Reorganization Plan and/or termination expenses if a decision is made to cease development of Spectrum’s de-prioritized development asset poziotinib; and
•expenditures related to future clinical trial costs.

The inability to raise any additional capital that may be required to fund our future operations, payments due under our debt agreements, or product acquisitions and strategic transactions that we may pursue could have a material adverse effect on the Company.

The following table reflects summarized cash flow activities for the three months ended March 31, 2024 and 2023 (in thousands):
 Three Months Ended March 31,
20242023
Net cash provided by operating activities$7,508 $22,717 
Net cash used in investing activities— (105)
Net cash used in financing activities(206)(18,950)
Net increase in cash and cash equivalents$7,302 $3,662 

Cash Flows from Operating Activities

Cash provided by operating activities was $7.5 million for the three months ended March 31, 2024 compared to $22.7 million for the three months ended March 31, 2023, primarily due to lower net income including non-cash items, partially offset by favorable working capital cash flows compared to last year.

For the three months ended March 31, 2024, net loss was $4.5 million compared to $3.5 million for the three months ended March 31, 2023. For the three months ended March 31, 2024, adjustments for non-cash items contributed approximately $19.4 million less to operating cash flows compared to the same period in 2023, primarily due to debt-related expenses of $9.9 million and an expense of $9.2 million for the change in fair value of contingent consideration, both of which did not recur in the current year period. For the three months ended March 31, 2024, net working capital cash generated by operations of approximately $3.6 million was $5.3 million higher than net working capital cash used in operations of approximately $1.7 million in the same period in 2023, primarily due to increased cash from accounts receivable payments and decreased cash used for inventory due to the timing of purchases and receipts, partially offset by increased cash used in the settlement of accrued rebates, returns and discounts due to impact of sales product mix as well as timing of settlement.

Cash flows from operating activities are impacted by, among other things, product revenue, operating profit and changes in working capital. Fluctuations in any of these will impact our cash flows from operating activities recognized in future periods, and cash flows from operating activities in future periods may vary significantly from those in prior periods as a result of these factors.

Cash Flows from Investing Activities

There was no cash provided by or used in investing activities for the three months ended March 31, 2024. Cash used in investing activities for the three months ended March 31, 2023, was $0.1 million, which consisted entirely of cash paid for the transaction costs incurred with the acquisition of Otrexup.

Cash Flows from Financing Activities

Cash used in financing activities for the three months ended March 31, 2024, was $0.2 million, which consisted entirely of cash used for employees’ withholding tax liability upon the vesting of employee stock awards. Cash used in financing activities for the three months ended March 31, 2023, was $19.0 million, which primarily consisted of (i) $10.5 million in cash payments and $1.1 million of direct transaction cost payments made in connection with the Convertible Note Exchange, (ii) a $6.6 million payment for contingent consideration, and (iii) cash used for employees’ withholding tax liability on stock award releases.

34

Contractual Obligations

Our principal material cash requirements consist of obligations related to our debt, our contingent consideration obligation, payments for rebates, returns and discounts, non-cancelable contractual obligations for our purchase commitments, and non-cancelable leases for our office space. There were no material changes to our material cash requirements from contractual or other obligations outside the ordinary course of business or due to other factors since our Annual Report on Form 10-K for the year ended December 31, 2023. For a description of our material contractual or other obligations, see “Note 15. Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT ESTIMATES

Critical accounting policies are those that require significant judgment and/or estimates by management at the time that the financial statements are prepared such that materially different results might have been reported if other assumptions had been made. We consider certain accounting policies related to revenue recognition, acquisitions, impairment of long-lived assets, contingent consideration obligations, and income taxes to be critical policies. These estimates form the basis for making judgments about the carrying value of assets and liabilities. We believe there have been no significant changes in our critical accounting policies and significant judgements and estimates since we filed our 2023 Form 10-K. See ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS — Critical Accounting Policies and Significant Estimates in our 2023 Form 10-K for further information.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk represents the risk of changes in the value of market risk-sensitive instruments caused by fluctuations in interest rates, foreign exchange rates and commodity prices. Changes in these factors could cause fluctuations in our results of operations and cash flows.

Our exposure to interest rate risk relates primarily to our cash equivalents that are from time to time invested in highly liquid money market funds and marketable securities, including U.S. treasury and government agency securities with a maturity date at the time of purchase of three months or less. The primary objective of our investment activities is to preserve our capital to fund operations. We also seek to maximize income from our investments without assuming significant risk. We do not use derivative financial instruments in our investment portfolio. Our cash and investments policy emphasizes liquidity and preservation of principal over other portfolio considerations. We estimate a 100 basis point decrease or increase in interest rates during the reporting periods presented would not have a material impact on our results of operations and cash flows as of March 31, 2024.

We do not have material exposures to foreign exchange rates and commodity prices as of March 31, 2024.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective as of March 31, 2024.

We review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis to improve our controls and procedures over time and to correct any deficiencies that we may discover in the future. Our goal is to ensure that our senior management has timely access to all material financial and non-financial information concerning our business. While we believe the present design of our disclosure controls and procedures is effective to achieve our goal, future events affecting our business may cause us to significantly modify our disclosure controls and procedures.

35

Changes in Internal Controls over Financial Reporting

During the three months ended March 31, 2024, we finalized the process of integrating our acquisition of Spectrum’s operations into our internal control environment.

There were no other changes in our internal controls over financial reporting during the three months ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For a description of our material pending legal proceedings, see “Note 15. Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

ITEM 1A.    RISK FACTORS

We are subject to various risks and uncertainties that could have a material impact on our business, results of operations and financial condition, including those hereby incorporated by reference from Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023. Except as set forth below, there have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2023. In addition to other information in this report, the following risk factor, together with the risks and uncertainties referenced above, should be considered carefully in evaluating an investment in our securities. If any of these risks or uncertainties actually occurs, our business, results of operations or financial condition would be materially and adversely affected. The risks and uncertainties referenced above are not the only ones facing us. Additional risks and uncertainties of which we are unaware or that we currently deem immaterial may also become important factors that may harm our business, results of operations and financial condition.

We face risks relating to product liability losses and other litigation liability for which we may be unable to maintain or obtain adequate protection.

We are or may be involved in various legal proceedings, lawsuits and certain government inquiries and investigations, including with respect to, but not limited to, patent infringement, product liability, personal injury, antitrust matters, securities class action lawsuits, breach of contract, Medicare and Medicaid reimbursement claims, opioid-related matters, promotional practices and compliance with laws relating to the manufacture and sale of controlled substances. For example, we, along with other opioid manufacturers and, often, distributors, have been named in lawsuits related to the manufacturing, distribution, marketing and promotion of opioids. In addition, we have also received various subpoenas and requests for information related to the distribution, marketing and sale of our former opioid products. Moreover, we have settled coverage litigation with our primary product liability insurer and first excess carrier regarding whether opioid litigation claims noticed by us are covered by our policies with such insurers. We have also signed a confidential settlement term sheet with our former insurance broker to resolve Assertio Therapeutics’ claims against the broker for negligence and breach of fiduciary duty in connection with the broker’s negotiation and procurement of products liability insurance coverage for Assertio Therapeutics. Insurance coverage for pending and future claims relating to our historical commercialization of opioids under our remaining insurance policies is doubtful and such policies may provide no protection at all for such claims. Further, we are subject to pending antitrust litigation and pending and potential future shareholder litigation relating to the Spectrum Merger and/or the approval and launch of generic indomethacin suppositories in the second half of 2023, and Spectrum is named in several securities class action and shareholder derivative lawsuits filed by former Spectrum stockholders. Such litigation and related matters are described in “Item 8. Financial Statements and Supplementary Data – Note 15. Commitments and Contingencies.” If any of these legal proceedings, inquiries or investigations were to result in an adverse outcome, the impact could have an adverse effect on our competitive position, business, financial condition, results of operations and cash flows.

We have obtained product liability insurance for sales of our products and any future clinical trials currently underway, but:

•we may be unable to maintain product liability insurance on acceptable terms;
•we may be unable to obtain product liability insurance for future trials;
•we may be unable to obtain product liability insurance for future products; or
36
•our insurance may not provide adequate protection against potential liabilities or may provide no protection at all.

Our inability to obtain or maintain adequate insurance coverage at an acceptable cost could prevent or inhibit the commercialization of our products. Defending a lawsuit could be costly and significantly divert management’s attention from conducting our business. If third parties were to bring a successful product liability or other claims, or series of claims, against us for uninsured liabilities, or in excess of our insured liability limits, our business, results of operations and financial condition could be adversely affected.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
We did not repurchase any shares of the Company’s common stock during the period covered by this Quarterly Report, except for shares surrendered to us, as reflected in the following table, to satisfy tax withholding obligations in connection with the vesting of equity awards.
                                 
(a) Total Number of Shares (or Units) Purchased (1)

(b) Average Price Paid per Share
(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs
(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
January 1, 2024 - January 31, 202471,396$1.12N/AN/A
February 1, 2024 - February 29, 2024152,541$0.80N/AN/A
March 1, 2024- March 31, 20242,890$0.88N/AN/A
Total226,827$0.90

(1) Consists of shares withheld to pay employees’ tax liability in connection with the vesting of restricted stock units granted under our stock-based compensation plans. These shares may be deemed to be “issuer purchases” of shares.

37
ITEM 6. EXHIBITS
31.1
31.2
32.1**
32.2**
101.INS
Inline XBRL Instance Document
101.SCH
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104
Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101)
_______________________________________________________
**    Furnished Herewith

38
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Date: May 6, 2024ASSERTIO HOLDINGS, INC.
  
 
/s/ Heather L. Mason
 Heather L. Mason
 Interim Chief Executive Officer
/s/ Ajay Patel
Ajay Patel
Senior Vice President and Chief Financial Officer
39
 EX-31.1 2 exhibit311-q12024.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
 
I, Heather L. Mason, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Assertio Holdings, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 6, 2024By:/s/ Heather L. Mason
  Heather L. Mason
  Interim Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 exhibit312-q12024.htm EX-31.2 Document

Exhibit 31.2
 
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
 
I, Ajay Patel, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Assertio Holdings, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 6, 2024By:/s/ Ajay Patel
  Ajay Patel
  Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 4 exhibit321-q12024.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Assertio Holdings, Inc. (the “Company”) for the quarterly period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Heather L. Mason, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
 
(1)    The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: May 6, 2024 /s/ Heather L. Mason
 Heather L. Mason
  Interim Chief Executive Officer
(Principal Executive Officer)

 EX-32.2 5 exhibit322-q12024.htm EX-32.2 Document

Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Assertio Holdings, Inc. (the “Company”) for the quarterly period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ajay Patel, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
 
(1)    The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: May 6, 2024 /s/ Ajay Patel
  Ajay Patel
  Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-101.SCH 6 asrt-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER PAGE link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - ACCOUNTS RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - PREPAID AND OTHER CURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - OTHER LONG-TERM ASSETS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - OTHER LONG-TERM LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - SHAREHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - RESTRUCTURING CHARGES link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - PREPAID AND OTHER CURRENT ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - OTHER LONG-TERM ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - OTHER LONG-TERM LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - RESTRUCTURING CHARGES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - ACQUISITIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - ACQUISITIONS - Acquisition Date Fair Value of Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - ACQUISITIONS - Fair Values of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - ACQUISITIONS - Unaudited Pro Forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - REVENUE - Schedule of Disaggregated Revenue from Contracts with Customers (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - REVENUE - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - ACCOUNTS RECEIVABLES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - INVENTORIES, NET - Schedule of Inventories, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - INVENTORIES, NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - PREPAID AND OTHER CURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - PREPAID AND OTHER CURRENT ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - INTANGIBLE ASSETS - Summary of Future Amortization Expense of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - OTHER LONG-TERM ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - DEBT - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - DEBT - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - DEBT - Schedule of Carrying Values Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - DEBT - Schedule of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - OTHER LONG-TERM LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - LEASES - Lease Cost Components (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - LEASES - Supplemental Cash Flow and Other Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supply Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - COMMITMENTS AND CONTINGENCIES - Legal Matters (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - COMMITMENTS AND CONTINGENCIES - Glumetza Antitrust Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - COMMITMENTS AND CONTINGENCIES - Insurance Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - SHAREHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - NET LOSS PER SHARE - Schedule of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - NET LOSS PER SHARE - Schedule of Potentially Dilutive Common Shares (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - FAIR VALUE - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - FAIR VALUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - FAIR VALUE - Schedule of Changes in Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - RESTRUCTURING CHARGES - Schedule of Accrued Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 asrt-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 asrt-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 asrt-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Deferred taxes Business Combination Provisional Information Initial Accounting Incomplete Adjustment, Deferred Tax Liabilities Business Combination Provisional Information Initial Accounting Incomplete Adjustment, Deferred Tax Liabilities Deferred income taxes Deferred Income Taxes and Tax Credits Change in fair value of contingent consideration recorded within costs and expenses Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Inventory reserves Inventory Valuation Reserves Additional purchase capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development expenses Research and Development Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Schedule of Net Revenue Revenue from External Customers by Products and Services [Table Text Block] Award Type [Domain] Award Type [Domain] Supply Commitment Arrangement [Domain] Supply Commitment Arrangement [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Impairment Finite-Lived Intangible Assets, Accumulated Impairment Finite-Lived Intangible Assets, Accumulated Impairment Otrexup Otrexup [Member] Otrexup Accounts payable Accounts Payable, Current Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Credit Spread Measurement Input, Credit Spread [Member] Total other expense Nonoperating Income (Expense) Commitments and contingencies (Note 15) Commitments and Contingencies Revenue Volatility Measurement Input, Price Volatility [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Annual purchase obligation Purchase Obligation, Annual Obligation Purchase Obligation, Annual Obligation SHAREHOLDERS EQUITY Equity [Text Block] Proceeds from the issuance of common stock Proceeds from Issuance of Common Stock Geographical [Axis] Geographical [Axis] INCOME TAXES Income Tax Disclosure [Text Block] JHS Jubilant HollisterStier LLC [Member] Jubilant HollisterStier LLC Common stock issuance and other impacts of the vesting and settlement of equity awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Current liabilities: Liabilities, Current [Abstract] Purchase obligation, percentage Purchase Obligation, Percentage Purchase Obligation, Percentage Business Acquisition [Line Items] Business Acquisition [Line Items] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Inventory Inventory, Net [Abstract] Payment of direct transaction costs related to convertible debt inducement Payment for Contingent Consideration Liability, Financing Activities Diluted net loss per share (in dollars per share) Diluted net loss per share (in dollars per share) Earnings Per Share, Diluted Spectrum Pharmaceuticals, Inc. Spectrum Pharmaceuticals, Inc. [Member] Spectrum Pharmaceuticals, Inc. Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Supply Commitment [Axis] Supply Commitment [Axis] Accrued rebates, returns and discounts Customer Refund Liability, Current Assertio closing price per share as of the Effective Date (in dollars per share) Business Acquisition, Share Price Level 3 Fair Value, Inputs, Level 3 [Member] LEASES Lessor, Operating Leases [Text Block] Contingent Consideration Contingent Consideration [Member] Represents activity related to contingent consideration liabilities arising from business combinations. Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] U.S. Government agencies US Government Agencies Debt Securities [Member] Schedule of Prepaid and Other Current Assets Schedule of Other Current Assets [Table Text Block] Average market fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net loss and comprehensive loss Net (loss) income Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Business combination, contingent consideration liability, number of shares (in shares) Business Combination, Contingent Consideration Liability, Number of Shares Business Combination, Contingent Consideration Liability, Number of Shares LEASES Lessee, Operating Leases [Text Block] Interest payable Interest Payable, Current Supply Commitment [Line Items] Supply Commitment [Line Items] Other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity [Abstract] Intangible assets Finite-Lived Intangible Assets [Line Items] Payments in connection with 2027 Convertible Notes Repayments of Convertible Debt Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Shareholders’ equity: Equity, Attributable to Parent [Abstract] Other Other Assets, Miscellaneous, Noncurrent Schedule of Calculation of Basic and Diluted Earnings Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Acquired finite-lived intangible assets, useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Level 1 Fair Value, Inputs, Level 1 [Member] INDOCIN products INDOCIN INDOCIN Products [Member] INDOCIN Products Goodwill Goodwill Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Prepaid and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Entity Smaller Reporting Company Entity Small Business 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Forecast Forecast [Member] Selling, General and Administrative Expenses Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Cash payment related to contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Measurement Frequency [Axis] Measurement Frequency [Axis] Noncurrent operating lease liabilities Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Insurance reimbursement Increase (Decrease) in Insurance Settlements Receivable Restricted Stock Units Restricted Stock Units (RSUs) [Member] Number of days to cover over allotment (in days) Number Of Days To Cover Over Allotment Number Of Days To Cover Over Allotment Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation expense Depreciation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Supply Commitment [Table] Supply Commitment [Table] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-Term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Less: unamortized debt issuance costs Unamortized issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Option Pricing Model Valuation Technique, Option Pricing Model [Member] Accrued royalties Accrued Income Taxes, Current Schedule of Potentially Dilutive Common Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Product and Service [Domain] Product and Service [Domain] Debt-related expenses Debt-related expenses Direct transaction costs Interest Expense, Debt Principal balance Convertible Debt Schedule of Lease Expense Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Balance at beginning of period Balance at end of period Restructuring Reserve Acquisition costs related to the transaction Business Combination, Acquisition Related Costs Total potentially dilutive common shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Payment of contingent consideration Payment for Debt Extinguishment or Debt Prepayment Cost Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Property and equipment, gross Property, Plant and Equipment, Gross 2024 (remainder) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Contingent consideration, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Discount Rate Measurement Input, Discount Rate [Member] Current operating lease liabilities Operating Lease, Liability, Current 6.5% Convertible Senior Secured Notes due 2027 principal amount Interest on 2027 Convertible Notes Convertible Senior Notes, 6.5% [Member] Convertible Senior Notes, 6.5% [Member] Business acquisition, contingent consideration, per share, maximum (in dollars per share) Business Acquisition, Contingent Consideration, Per Share, Maximum Business Acquisition, Contingent Consideration, Per Share, Maximum Changes in fair value of all financial liabilities measured at fair value on a recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Amortization of intangible assets Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Total Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Induced conversion of convertible debt expense Induced Conversion of Convertible Debt Expense Counterparty Name [Domain] Counterparty Name [Domain] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and cash equivalents at beginning of year Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Operating lease cost Operating Lease, Cost Common stock, issued (in shares) Balances (in shares) Balances (in shares) Common Stock, Shares, Issued Schedule of Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Costs and expenses: Operating Costs and Expenses [Abstract] Total fair value of consideration transferred Business Combination, Consideration Transferred Recurring fair value measurements of assets and liabilities Fair Value Gain (Loss) Of Assets And Liabilities Fair Value Gain (Loss) Of Assets And Liabilities Security Exchange Name Security Exchange Name Total Assets, Fair Value Disclosure Carrying value Long-Term Debt Selling, general and administrative expenses Selling, General and Administrative Expense Options Employee Stock Option [Member] Total costs and expenses Costs and Expenses Cost incurred, cumulative Restructuring and Related Cost, Cost Incurred to Date Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Royalties and milestones Royalties and milestone revenue Royalties And Milestones [Member] Royalties And Milestones [Member] Schedule of Cash and Cash Equivalents and Marketable Securities [Table] Schedule of Cash and Cash Equivalents and Marketable Securities [Table] Schedule of cash and cash equivalent balances and investments in marketable securities. Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Cost of sales Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Chief Executive Officer Chief Executive Officer [Member] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets and Goodwill Schedule of Finite-Lived Intangible Assets [Table Text Block] Other current liabilities Other Liabilities, Current Accounts payable and other accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Intangible assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Raw materials Inventory, Raw Materials, Net of Reserves Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Schedule of Accrued Restructuring and Severance Costs Schedule of Restructuring Reserve by Type of Cost [Table Text Block] ACQUISITIONS Business Combination Disclosure [Text Block] Net loss Business Acquisition, Pro Forma Net Income (Loss) Change in fair value of contingent consideration recorded within costs and expenses [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Hanmi Hanmi [Member] Hanmi Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Adjustments to Purchase Price Allocation to Fair Value Business Combination, Provisional Information [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventories, net Total inventories, net Inventory, Net Interest payable on notes Interest Expense, Debt, Excluding Amortization Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total Spectrum net assets acquired Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred DEBT Long-Term Debt [Text Block] Other long-term assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Carrying balance Convertible Notes Payable Product sales, net Total product sales, net Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Glumetza Antitrust Litigation Glumetza Antitrust Litigation [Member] Glumetza Antitrust Litigation Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accrued rebates, returns and discounts Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Rebates, Returns And Discounts Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Rebates, Returns And Discounts Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Aggregate principal amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Carrying Values Convertible Notes Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Purchase obligation in 2024 Purchase Obligation, to be Paid, Year One 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Interest payable Increase (Decrease) in Interest Payable, Net Operating cash flows from operating leases Operating Lease, Payments Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Conversion ratio Debt Instrument, Convertible, Conversion Ratio Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Inventory, Net Schedule of Inventory, Current [Table Text Block] Business acquisition, contingent consideration, per share (in dollars per share) Business Acquisition, Contingent Consideration, Per Share Business Acquisition, Contingent Consideration, Per Share Debt Instrument [Axis] Debt Instrument [Axis] Antares Antares [Member] Antares Total lease liabilities Operating Lease, Liability Measurement Input Type [Domain] Measurement Input Type [Domain] Induced exchange of convertible notes (in shares) Conversion of Stock, Shares Converted Liability for uncertain tax provisions Liability for Uncertainty in Income Taxes, Noncurrent Total liabilities Liabilities Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepaid and other assets Increase (Decrease) in Prepaid Expense and Other Assets Measurement Frequency [Domain] Measurement Frequency [Domain] PROPERTY AND EQUIPMENT, NET Property, Plant and Equipment Disclosure [Text Block] Title of Individual [Axis] Title of Individual [Axis] ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Change in fair value of embedded derivative liability Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Debt Disclosure [Abstract] Furniture and office equipment Furniture And Office Equipment [Member] Represents information pertaining to equipment commonly used in offices and stores, which have no permanent connection to the structure of a building or utilities and tangible personal property used in an office setting. Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Canada CANADA Purchase of inventory Payments to Suppliers Earnings Per Share [Abstract] Earnings Per Share [Abstract] Common stock, $0.0001 par value, 200,000,000 shares authorized; 95,115,452 and 94,668,523 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. Common Stock, Value, Issued Allowance for cash discounts for prompt payment Accounts Receivable, Allowance For Cash Discount Accounts Receivable, Allowance For Cash Discount Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Induced exchange of convertible notes, gross Conversion Of Stock, Amount Converted, Gross Conversion Of Stock, Amount Converted, Gross Provisions for inventory and other assets Provision For Inventory And Other Assets Provision For Inventory And Other Assets Senior Notes Senior Notes [Member] Total current assets Assets, Current Total Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities CVRs Contingent consideration Business Combination, Contingent Consideration, Liability Product Sales and Royalties Revenue from Contract with Customer [Abstract] Supplemental Disclosure of Cash Flow Information Supplemental Cash Flow Information [Abstract] Sympazan Sympazan Sympazan [Member] Sympazan Cash paid for amounts included in measurement of liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Litigation Case [Domain] Litigation Case [Domain] Other gain Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Credit loss allowance Financing Receivable, Allowance for Credit Loss Restructuring Type [Axis] Restructuring Type [Axis] Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Prepaid and other current assets Business Combination Provisional Information Initial Accounting Incomplete Adjustment Current Assets, Prepaid Expense and Other Assets Business Combination Provisional Information Initial Accounting Incomplete Adjustment Current Assets, Prepaid Expense and Other Assets Fair value, beginning of the period Fair value, end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Marketable securities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Spectrum Reorganization Plan Spectrum Reorganization Plan [Member] Spectrum Reorganization Plan Average fair market value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Assets Assets, Lessee [Abstract] Assets, Lessee Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Schedule of the Future Amortization Expenses of Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Contingent consideration, current portion Short-term contingent consideration Business Combination, Contingent Consideration, Liability, Current Interest expense Total interest expense Interest Expense, Other Other accrued liabilities Other Accrued Liabilities, Current Depreciation and amortization Depreciation, Depletion and Amortization Settlement amount Litigation Settlement, Amount Awarded to Other Party Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] Total shareholders’ equity Balances Balances Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Total revenues Business Acquisition, Pro Forma Revenue Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue recognized Contract with Customer, Liability, Revenue Recognized Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Thereafter Finite-Lived Intangible Asset, Expected Amortization, After Year Four Finite-Lived Intangible Asset, Expected Amortization, After Year Four Convertible notes, par value Fair Value Of Convertible Notes, Par Value Fair Value Of Convertible Notes, Par Value Deferred taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Total Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities OTHER LONG-TERM ASSETS Other Assets Disclosure [Text Block] Induced exchange of convertible notes (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Supply Agreement Supply Commitment [Member] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] RESTRUCTURING CHARGES Restructuring, Impairment, and Other Activities Disclosure [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Remaining Useful Life (In years) Finite-Lived Intangible Asset, Useful Life Antidilutive Securities [Axis] Antidilutive Securities [Axis] Stock-based awards and equivalents Share-Based Payment Arrangement [Member] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Purchase of Sympazan Payments to Acquire Other Productive Assets Common Stock Common Stock [Member] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code NET LOSS PER SHARE Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Discounted Cash Flow Valuation Technique, Discounted Cash Flow [Member] Schedule of Changes in Fair Value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Receivables [Abstract] Receivables [Abstract] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Otrexup Otrexup Acquisition [Member] Otrexup Acquisition Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Business combination, contingent consideration arrangements, range of outcomes, value, high Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total Liabilities, Fair Value Disclosure Assets: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Payments related to the vesting and settlement of equity awards, net Payment, Tax Withholding, Share-Based Payment Arrangement Liabilities: Liabilities [Abstract] Financing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] U.S. Treasuries US Treasury Securities [Member] Net cash paid for income taxes Income Taxes Paid, Net Liabilities: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Embedded derivative liability, measurement input Embedded Derivative Liability, Measurement Input Accumulated Deficit Retained Earnings [Member] Less: current portion of long-term debt Long-Term Debt, Current Maturities Product Rights Product Rights [Member] Legal rights held to use a product. Total liabilities and shareholders' equity Liabilities and Equity Other (expense) income: Nonoperating Income (Expense) [Abstract] Other long-term assets Total other long-term assets Other Assets, Noncurrent Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Basic net loss per share (in dollars per share) Basic net loss per share (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Contingent consideration, royalty percentage Business Combination, Contingent Consideration, Royalty Percentage Business Combination, Contingent Consideration, Royalty Percentage Accounts Payable and Accrued Liabilities, Current [Abstract] Accounts Payable and Accrued Liabilities, Current [Abstract] Schedule of Other Long-Term Assets Schedule of Other Assets, Noncurrent [Table Text Block] Inventories Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Contingent payment consideration, future royalties covenant, product net sales (over) Fair Value Disclosure, Contingent Consideration, Liability, Future Royalties, Minimum Product Net Sales Fair Value Disclosure, Contingent Consideration, Liability, Future Royalties, Minimum Product Net Sales Entity Address, City or Town Entity Address, City or Town Purchase obligation in 2025 Purchase Obligation, to be Paid, Year Two Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Investing Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Restructuring charges Restructuring charges Restructuring Charges Schedule of Consideration Transferred Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Document Transition Report Document Transition Report Prepaid assets and deposits Prepaid Expense And Deposit Assets, Current Prepaid Expense And Deposit Assets, Current Goodwill Goodwill, Purchase Accounting Adjustments Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Debt conversion option value Convertible Debt, Fair Value Disclosures ROLVEDON product royalties Product Royalty Liability, Noncurrent Product Royalty Liability, Noncurrent Common stock, authorized (in shares) Common Stock, Shares Authorized Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] SPRIX SPRIX SPRIX Nasal Spray [Member] SPRIX Nasal Spray Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Other Liabilities Disclosure [Abstract] Prepaid asset and deposits Prepaid Expense And Deposit Assets, Noncurrent Prepaid Expense And Deposit Assets, Noncurrent Gross, long-term debt Long-Term Debt, Gross Adjustments to reconcile net loss to net cash from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Accrued restructuring and severance costs rollforward Restructuring Reserve [Roll Forward] Title of Individual [Domain] Title of Individual [Domain] Total Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Accrued liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities Liabilities Liabilities, Lessee [Abstract] Liabilities, Lessee [Abstract] Additional paid-in capital Additional Paid in Capital ROLVEDON ROLVEDON Rolvedon [Member] Rolvedon Restructuring Plan [Axis] Restructuring Plan [Axis] Repayment of Spectrum's long-term debt Business Combination, Consideration Transferred, Liabilities Incurred Accrued rebates, returns and discounts Increase (Decrease) in Accrued Rebates, Returns and Discounts The increase (decrease) during the reporting period related to rebates, returns and discounts incurred but not paid. Convertible Notes Convertible notes Convertible Debt [Member] Other products Product, Other [Member] Product, Other Prepaid and other current assets Total prepaid and other current assets Prepaid Expense and Other Assets, Current 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Assertio shares issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Accrued liabilities Business Combination Provisional Information Initial Accounting Incomplete Adjustment, Accrued Liabilities Business Combination Provisional Information Initial Accounting Incomplete Adjustment, Accrued Liabilities PREPAID AND OTHER CURRENT ASSETS Other Current Assets [Text Block] Accrued restructuring costs Restructuring Reserve, Current Entity Registrant Name Entity Registrant Name 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Issuance of common stock (in shares) Stock Issued During Period, Shares, Acquisitions Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Employee compensation costs Employee Severance [Member] Cash paid Payments for Restructuring Document Period End Date Document Period End Date Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Common stock issuance and other impacts of the vesting and settlement of equity awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Schedule of Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Pro Forma Financial Information Business Acquisition, Pro Forma Information [Table Text Block] Entity Central Index Key Entity Central Index Key Legal contingency accrual Loss Contingency Accrual Share-based compensation expense Share-Based Payment Arrangement, Expense Gross Carrying Amount Finite-Lived Intangible Assets, Gross Income tax (expense) benefit Income tax expense Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Accrued compensation Employee-related Liabilities, Current Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] FAIR VALUE Fair Value Disclosures [Text Block] Schedule of Debt Related Interest Schedule of Interest Expense [Table Text Block] Tabular disclosure of the amount of interest expense. Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] INVENTORIES, NET Inventory Disclosure [Text Block] Total Spectrum net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Restructuring and related cost, expected cost remaining Restructuring and Related Cost, Expected Cost Remaining Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Long-term debt Long-term debt, net Long-Term Debt, Excluding Current Maturities Leasehold improvements Leasehold Improvements [Member] Shares used in computing diluted net loss per share (in shares) Weighted-average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Schedule of Other Long-term Liabilities Other Noncurrent Liabilities [Table Text Block] REVENUE Revenue from Contract with Customer [Text Block] Additional Paid-In Capital Additional Paid-in Capital [Member] Amortization of debt issuance costs and Royalty Rights Amortization Of Royalty Rights Amortization Of Royalty Rights Total assets Assets Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Laboratory equipment Equipment [Member] ACCOUNTS RECEIVABLES, NET Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of Debt Issuance Costs Recurring Fair Value, Recurring [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] OTHER LONG-TERM LIABILITIES Other Liabilities Disclosure [Text Block] Plus: derivative liability for embedded conversion feature Derivative liability for embedded conversion feature Derivative liability Embedded Derivative, Fair Value of Embedded Derivative Liability Other long-term liabilities Other long-term liabilities Other Liabilities, Noncurrent Construction in progress Construction in Progress [Member] Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Equity Component [Domain] Equity Component [Domain] Work-in-process Inventory, Work in Process, Net of Reserves Fair value of Assertio shares issued Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Deferred employee retention credits Deferred Employee Retention Credits, Noncurrent Deferred Employee Retention Credits, Noncurrent Debt Instrument [Line Items] Debt Instrument [Line Items] Scenario [Axis] Scenario [Axis] Shares used in computing basic net loss per share (in shares) Weighted-average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Unamortized debt issuance costs Unamortized Debt Issuance Expense (Loss) income from operations Operating Income (Loss) Facility exit costs Facility Closing [Member] Revenues: Revenues [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Business acquisition, fixed exchange ratio Business Acquisition, Fixed Exchange Ratio Business Acquisition, Fixed Exchange Ratio Operating Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Induced exchange of convertible notes Stock Issued During Period, Value, Conversion of Convertible Securities Scenario [Domain] Scenario [Domain] Type of Restructuring [Domain] Type of Restructuring [Domain] CAMBIA CAMBIA [Member] Represents information pertaining to CAMBIA, a product of the entity. Total Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets EX-101.PRE 10 asrt-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COVER PAGE - shares
 3 Months Ended
Mar. 31, 2024
May 01, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-39294  
Entity Registrant Name ASSERTIO HOLDINGS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-0598378  
Entity Address, Address Line One 100 South Saunders Road  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town Lake Forest  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60045  
City Area Code 224  
Local Phone Number 419-7106  
Title of 12(b) Security Common Stock, $0.0001 par value  
Trading Symbol ASRT  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Smaller Reporting Company false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   95,124,605
Entity Central Index Key 0001808665  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 80,743 $ 73,441
Accounts receivable, net 42,610 47,663
Inventories, net 38,602 37,686
Prepaid and other current assets 10,519 12,272
Total current assets 172,474 171,062
Property and equipment, net 704 770
Intangible assets, net 105,701 111,332
Other long-term assets 3,086 3,255
Total assets 281,965 286,419
Current liabilities:    
Accounts payable 15,650 13,439
Accrued rebates, returns and discounts 57,870 58,137
Accrued liabilities 15,401 18,213
Contingent consideration, current portion 2,700 2,700
Other current liabilities 823 954
Total current liabilities 92,444 93,443
Long-term debt 38,621 38,514
Other long-term liabilities 16,406 16,459
Total liabilities 147,471 148,416
Commitments and contingencies (Note 15)
Shareholders’ equity:    
Common stock, $0.0001 par value, 200,000,000 shares authorized; 95,115,452 and 94,668,523 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. 9 9
Additional paid-in capital 790,538 789,537
Accumulated deficit (656,053) (651,543)
Total shareholders’ equity 134,494 138,003
Total liabilities and shareholders' equity $ 281,965 $ 286,419
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 200,000,000 200,000,000
Common stock, issued (in shares) 95,115,452 94,668,523
Common stock, outstanding (in shares) 95,115,452 94,668,523
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
Total revenues $ 32,448 $ 42,466
Costs and expenses:    
Cost of sales 11,177 5,467
Research and development expenses 733 0
Selling, general and administrative expenses 18,524 16,904
Change in fair value of contingent consideration 0 9,167
Amortization of intangible assets 5,631 6,284
Restructuring charges 720 0
Total costs and expenses 36,785 37,822
(Loss) income from operations (4,337) 4,644
Other (expense) income:    
Debt-related expenses 0 (9,918)
Interest expense (757) (1,122)
Other gain 716 802
Total other expense (41) (10,238)
Net loss before income taxes (4,378) (5,594)
Income tax (expense) benefit (132) 2,110
Net loss and comprehensive loss $ (4,510) $ (3,484)
Basic net loss per share (in dollars per share) $ (0.05) $ (0.07)
Diluted net loss per share (in dollars per share) $ (0.05) $ (0.07)
Shares used in computing basic net loss per share (in shares) 94,980 51,005
Shares used in computing diluted net loss per share (in shares) 94,980 51,005
Product sales, net    
Revenues:    
Total revenues $ 31,862 $ 41,769
Royalties and milestones    
Revenues:    
Total revenues $ 586 $ 697
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Balances (in shares) at Dec. 31, 2022   48,320,000    
Balances at Dec. 31, 2022 $ 225,725 $ 5 $ 545,321 $ (319,601)
Increase (Decrease) in Stockholders' Equity        
Induced exchange of convertible notes (in shares)   6,990,000    
Induced exchange of convertible notes 26,699   26,699  
Common stock issuance and other impacts of the vesting and settlement of equity awards (in shares)   352,000    
Common stock issuance and other impacts of the vesting and settlement of equity awards (722)   (722)  
Stock-based compensation 2,446   2,446  
Net (loss) income (3,484)     (3,484)
Comprehensive income (loss) (3,484)     (3,484)
Balances (in shares) at Mar. 31, 2023   55,662,000    
Balances at Mar. 31, 2023 $ 250,664 $ 5 573,744 (323,085)
Balances (in shares) at Dec. 31, 2023 94,668,523 94,669,000    
Balances at Dec. 31, 2023 $ 138,003 $ 9 789,537 (651,543)
Increase (Decrease) in Stockholders' Equity        
Common stock issuance and other impacts of the vesting and settlement of equity awards (in shares)   446,000    
Common stock issuance and other impacts of the vesting and settlement of equity awards (206)   (206)  
Stock-based compensation 1,207   1,207  
Net (loss) income (4,510)     (4,510)
Comprehensive income (loss) $ (4,510)     (4,510)
Balances (in shares) at Mar. 31, 2024 95,115,452 95,115,000    
Balances at Mar. 31, 2024 $ 134,494 $ 9 $ 790,538 $ (656,053)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating Activities    
Net loss $ (4,510) $ (3,484)
Adjustments to reconcile net loss to net cash from operating activities:    
Depreciation and amortization 5,696 6,484
Amortization of debt issuance costs and Royalty Rights 107 147
Recurring fair value measurements of assets and liabilities 0 9,167
Debt-related expenses 0 9,918
Provisions for inventory and other assets 1,428 1,072
Stock-based compensation 1,207 2,446
Deferred income taxes 0 (1,367)
Changes in assets and liabilities:    
Accounts receivable 5,054 (1,109)
Inventories (2,344) (3,602)
Prepaid and other assets 1,921 1,824
Accounts payable and other accrued liabilities (134) (290)
Accrued rebates, returns and discounts (267) 2,887
Interest payable (650) (1,376)
Net cash provided by operating activities 7,508 22,717
Investing Activities    
Purchase of Sympazan 0 (105)
Net cash used in investing activities 0 (105)
Financing Activities    
Payments in connection with 2027 Convertible Notes 0 (10,500)
Payment of direct transaction costs related to convertible debt inducement 0 (1,119)
Payment of contingent consideration 0 (6,609)
Payments related to the vesting and settlement of equity awards, net (206) (722)
Net cash used in financing activities (206) (18,950)
Net increase in cash and cash equivalents 7,302 3,662
Cash and cash equivalents at beginning of year 73,441 64,941
Cash and cash equivalents at end of period 80,743 68,603
Supplemental Disclosure of Cash Flow Information    
Net cash paid for income taxes 11 29
Cash paid for interest $ 1,300 $ 2,351
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Organization

Assertio Holdings, Inc., or the Company, is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients. The Company has built its product portfolio through the acquisition or licensing of approved products. The Company’s commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (elflapegrastim-xnst) injection for subcutaneous use, INDOCIN® (indomethacin) Suppositories, INDOCIN® (indomethacin) Oral Suspension, Sympazan® (clobazam) oral film, Otrexup® (methotrexate) injection for subcutaneous use, SPRIX® (ketorolac tromethamine) Nasal Spray, CAMBIA® (diclofenac potassium for oral solution), and Zipsor® (diclofenac potassium) Liquid filled capsules. To date, substantially all of the Company’s revenues are related to product sales in the U.S.

Unless otherwise noted or required by context, use of “Assertio,” “Company,” “we,” “our” and “us” refer to Assertio Holdings and/or its applicable subsidiary or subsidiaries.

Basis of Presentation

The unaudited condensed consolidated financial statements of the Company and its subsidiaries and the related footnote information of the Company have been prepared pursuant to the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information that are normally required by United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of the Company’s management, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of the information for the periods presented. The results for the three months ended March 31, 2024, are not necessarily indicative of results to be expected for the entire year ending December 31, 2024 or future operating periods.

The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2023, included in Assertio Holdings, Inc.’s Annual Report on Form 10-K filed with the SEC on March 11, 2024 (the “2023 Form 10-K”). The Condensed Consolidated Balance Sheet as of December 31, 2023, has been derived from the audited financial statements at that date, as filed in the Company’s 2023 Form 10-K.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACQUISITIONS
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
ACQUISITIONS ACQUISITIONS
Spectrum Pharmaceuticals

On July 31, 2023, (the “Effective Date”), the Company completed the acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”), a commercial stage biopharmaceutical company focused on novel and targeted oncology products (the “Spectrum Merger”). The Spectrum Merger was completed pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 24, 2023, through a merger of a wholly-owned subsidiary of the Company with and into Spectrum, with Spectrum surviving the Merger as a wholly-owned subsidiary of the Company. The Company accounted for the Spectrum Merger using the acquisition method of accounting under Accounting Standards Codification (“ASC”) 805 and is considered the accounting acquirer.

Pursuant to the Merger Agreement, each issued and outstanding share of Spectrum common stock as of the Effective Date was converted into the right to receive (i) 0.1783 shares of the Company’s common stock and (ii) one contingent value right (“CVR”) representing a contractual right to receive future conditional payments worth up to an aggregate maximum amount of $0.20, settleable in cash, additional shares of Assertio common stock or a combination of cash and additional shares of Assertio common stock at the Company’s sole discretion, upon the achievement of certain sales milestones related to Spectrum’s product ROLVEDON. Subject to adjustments, each CVR represents the right to receive up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175 million during the calendar year ending December 31, 2024, and up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $225 million during the calendar year
ending December 31, 2025. In addition, upon consummation of the Spectrum Merger, Spectrum’s outstanding employee stock awards and other warrants that were outstanding immediately as of the Effective Date automatically vested (if unvested) and/or cancelled, as applicable, which generally resulted in the issuance of shares of the Company’s common stock and/or CVRs to the holders of such stock awards or other warrants, in each case as dictated by the terms of the Merger Agreement. These shares and CVRs issued are considered part of the consideration transferred, and no compensation expense was recognized because the settlement was a condition of the Merger Agreement and other existing individual agreements, no future performance is required by the holders, and the fair value of the shares and CVRs is equivalent to the fair value of the existing employee stock awards and other warrants.

The following table reflects the components of the consideration transferred in the Spectrum Merger (in thousands, except exchange ratio and per share data):

Assertio shares issued38,013 
Assertio closing price per share as of the Effective Date$5.69 
Fair value of Assertio shares issued$216,294 
Repayment of Spectrum's long-term debt (1)
32,647 
CVRs (2)
3,932 
Total fair value of consideration transferred$252,873 

(1)Represents settlement of Spectrum’s existing long-term debt in connection with the close of the transaction. The Company concluded it did not assume the debt, therefore the amount paid to settle the debt has been accounted for and disclosed as part of the consideration transferred.
(2)Represents the Effective Date fair value of 223,397 CVRs at $0.0176 per CVR issued to holders of Spectrum common stock, employee stock awards and warrants.

The CVRs represent a contingent consideration obligation measured at fair value and classified as liabilities on the Company’s Condensed Consolidated Balance Sheets. The fair value of the CVR contingent consideration is determined using a Monte Carlo simulation model under the income approach and is based on Level 3 inputs. Refer to Note 18, Fair Value, for additional information. Fair value is based on the probability of achievement of 2024 and 2025 annual ROLVEDON net sales milestones. Significant assumptions include the discount rate and the probability assigned to the achievement of the net sales milestones. Achievement of both the 2024 and 2025 annual ROLVEDON net sales milestones would obligate the Company to transfer a maximum of approximately $44.7 million of additional consideration. No additional consideration would be paid by the Company if neither the 2024 nor 2025 annual ROLVEDON net sales milestones are achieved.
The following table reflects the fair values of the assets acquired and liabilities assumed at the Effective Date (in thousands). The fair values were based on management’s estimates and assumptions. There were no changes for the three months ended March 31, 2024, to the estimated preliminary fair values of the assets acquired and liabilities assumed. The final determination was completed as of March 31, 2024.

Initial Preliminary Purchase Price Allocation to Fair Value
Adjustments to Purchase Price Allocation to Fair Value (2)
Final Purchase Price Allocation to Fair Value
Assets:
Cash and cash equivalents$34,600 $— $34,600 
Marketable securities2,194 — 2,194 
Accounts receivable50,975 — 50,975 
Inventories22,244 61 22,305 
Prepaid and other current assets1,287 698 1,985 
Property and equipment100 — 100 
Intangible assets234,000 (13,500)220,500 
Other long-term assets1,396 — 1,396 
Total$346,796 $(12,741)$334,055 
Liabilities:
Accounts payable$10,108 $— $10,108 
Accrued rebates, returns and discounts21,025 — 21,025 
Accrued liabilities36,509 (2,343)34,166 
Other current liabilities784 — 784 
Deferred taxes34,250 (30,254)3,996 
Other long-term liabilities11,103 — 11,103 
Total$113,779 $(32,597)$81,182 
Total Spectrum net assets acquired (1)
$233,017 $19,856 $252,873 
Goodwill$19,856 $(19,856)$— 

(1)Application of the acquisition method required the Company to adjust Spectrum assets and liabilities as of the Effective Date, including certain liabilities for variable consideration associated with ROLVEDON, to reflect conformity of Spectrum’s accounting policies to those of Assertio. Liabilities assumed include certain bonuses owed to former Spectrum executives under the terms of existing employment agreements triggered by the consummation of the Spectrum Merger.
(2)Adjustments made to the preliminary purchase price allocation to fair value primarily reflect completion of studies and other analysis necessary to determine the income tax effects of the net identifiable assets acquired and further refinement of the assumptions used in the valuation supporting the ROLVEDON product rights. These adjustments did not materially impact the Consolidated Statement of Comprehensive (Loss) Income.

The income approach was primarily used to value the acquired intangible assets, representing rights to Spectrum’s product ROLVEDON. Significant assumptions include the amount and timing of projected future cash flows; the discount rate selected to measure the inherent risk of future cash flows; and the assessment of the product’s life cycle and the competitive trends impacting the product. The ROLVEDON product rights will be amortized on a straight-line basis over its estimated useful life of 10 years.

There were no acquisition costs related to the Spectrum Merger recognized for the three months ended March 31, 2024.
The following unaudited pro forma information represents the Company’s results of operations as if the Spectrum Merger had been completed as of January 1, 2023, (in thousands) and includes nonrecurring adjustments for additional costs of sales from the fair value step-up of inventories and transaction costs. The disclosure of pro forma net sales and net loss does not purport to indicate the results that would actually have been obtained had the Spectrum Merger been completed on the assumed date for the periods presented, or which may be realized in the future. The unaudited pro forma information does not reflect any operating efficiencies or cost savings that may be realized from the integration of the acquisition.

Three Months Ended
March 31, 2023
Total revenues$58,081 
Net loss(13,944)
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
 
Disaggregated Revenue
 
The following table reflects total revenue, net for the three months ended March 31, 2024 and 2023 (in thousands): 
Three Months Ended March 31,
20242023
Product sales, net:
ROLVEDON$14,478 $— 
INDOCIN products8,682 30,346 
Sympazan2,617 2,502 
Otrexup2,882 2,822 
SPRIX1,437 1,889 
CAMBIA1,256 2,264 
Other products510 1,946 
Total product sales, net31,862 41,769 
Royalties and milestone revenue586 697 
Total revenues$32,448 $42,466 
Product Sales, net

As a result of the Spectrum Merger, the Company began recognizing ROLVEDON sales in August 2023.

Other net product sales for the three months ended March 31, 2023 include product sales for OXAYDO and Zipsor. The Company ceased OXAYDO product sales beginning in September 2023.
Royalties and Milestone Revenue

In November 2010, the Company entered into a license agreement granting Miravo the rights to commercially market CAMBIA in Canada. Miravo independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. The Company recognized royalties revenue related to the CAMBIA licensing agreement of $0.6 million and $0.5 million for the three months ended March 31, 2024 and 2023, respectively.

The Company recognized no milestone revenue associated with the completion of certain service milestones for the three months ended March 31, 2024, and $0.2 million for the three months ended March 31, 2023.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCOUNTS RECEIVABLES, NET
 3 Months Ended
Mar. 31, 2024
Receivables [Abstract]  
ACCOUNTS RECEIVABLES, NET ACCOUNTS RECEIVABLES, NET
 
As of March 31, 2024 and December 31, 2023, accounts receivable, net, consisted entirely of receivables related to product sales, net of allowances for cash discounts for prompt payment of $0.4 million and $0.9 million, respectively.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES, NET
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
INVENTORIES, NET INVENTORIES, NET
 
The following table reflects the components of inventory, net as of March 31, 2024 and December 31, 2023 (in thousands): 
 March 31, 2024December 31, 2023
Raw materials$18,872 $10,537 
Work-in-process2,452 2,239 
Finished goods17,278 24,910 
Total inventories, net$38,602 $37,686 
The Company writes down the value of inventory for potential excess or obsolete inventories based on an analysis of inventory on hand and projected demand. As of March 31, 2024 and December 31, 2023, inventory reserves were $7.3 million and $6.8 million, respectively.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PREPAID AND OTHER CURRENT ASSETS
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
PREPAID AND OTHER CURRENT ASSETS PREPAID AND OTHER CURRENT ASSETS
The following table reflects prepaid and other current as of March 31, 2024 and December 31, 2023 (in thousands): 

March 31, 2024December 31, 2023
Prepaid assets and deposits$10,222 $11,973 
Other current assets297 299 
Total prepaid and other current assets$10,519 $12,272 

In August 2018, the Company entered into a Convertible Secured Note Purchase Agreement (the “Note Agreement”) with NES Therapeutic, Inc. (“NES”), pursuant to which it purchased a Convertible Secured Promissory Note (the “NES Note”). The Company’s investment in the NES Note, which is included in other current assets, is accounted for as a loan receivable and is valued at amortized cost. As of both March 31, 2024 and December 31, 2023, the Company has assessed an estimated $3.5 million expected credit loss reserve on its investment based on its evaluation of probability of default that exists. The expected credit loss reserve recognized in each period represents the entire aggregate principal amount and outstanding interest incurred on the NES Note as of both March 31, 2024 and December 31, 2023.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PROPERTY AND EQUIPMENT, NET
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET PROPERTY AND EQUIPMENT, NET
 
The following table reflects property and equipment, net as of March 31, 2024 and December 31, 2023 (in thousands): 

March 31, 2024December 31, 2023
Furniture and office equipment$1,908 $1,908 
Laboratory equipment20 20 
Leasehold improvements3,473 2,945 
Construction in progress— 528 
5,401 5,401 
Less: Accumulated depreciation(4,697)(4,631)
Property and equipment, net$704 $770 
 
Depreciation expense was $0.1 million and $0.2 million for the three months ended March 31, 2024 and 2023, respectively. Depreciation expense is recognized in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS INTANGIBLE ASSETS
The following table reflects the gross carrying amounts and net book values of intangible assets as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands): 

 March 31, 2024December 31, 2023
Products rights:Remaining Useful Life
 (In years)		Gross Carrying AmountAccumulated AmortizationNet Book ValueGross Carrying AmountAccumulated AmortizationImpairmentNet Book Value
ROLVEDON9.3$63,405 $(6,787)$56,618 $220,500 $(5,270)$(157,095)$58,135 
INDOCIN1.865,606 (47,413)18,193 154,100 (44,814)(88,494)20,792 
Sympazan10.614,550 (1,718)12,832 14,550 (1,415)— 13,135 
Otrexup5.716,364 (10,364)6,000 44,086 (10,103)(27,723)6,260 
SPRIX3.132,673 (20,615)12,058 39,000 (19,663)(6,327)13,010 
Total intangible Assets $192,598 $(86,897)$105,701 $472,236 $(81,265)$(279,639)$111,332 

Amortization expense was $5.6 million and $6.3 million for the three months ended March 31, 2024 and 2023, respectively.

The following table reflects future amortization expense the Company expects for its intangible assets (in thousands): 

Year Ending December 31,Estimated
Amortization Expense
2024 (remainder)16,894 
202522,526 
202612,130 
20279,909 
20288,322 
Thereafter35,920 
Total$105,701 

During the three months ended March 31, 2024, the Company’s market capitalization declined to below the book value of the Company’s equity, which management determined represented an indicator of impairment with respect to its long-lived assets. Applying the relevant accounting guidance, the Company first assessed the recoverability of its long-lived assets. Similar to its previous assessment in the fourth quarter of 2023, as described in the Company’s 2023 Form 10-K, management concluded it was appropriate to group its assets at the product level. After grouping the long-lived assets at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other assets and liabilities, the Company estimated the future net undiscounted cash flows expected to be generated from the use of the long-lived asset groups and their eventual disposition. The Company then compared the estimated undiscounted cash flows to the carrying amounts of the long-lived asset groups. Based on this test, the Company determined that the estimated undiscounted cash flows were in excess of the carrying amounts for all of the long-lived asset groups and, accordingly, that the long-lived asset groups are fully recoverable and no adjustment to their carrying values was required.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
OTHER LONG-TERM ASSETS
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
OTHER LONG-TERM ASSETS OTHER LONG-TERM ASSETS
 
The following table reflects other long-term assets as of March 31, 2024 and December 31, 2023 (in thousands): 

 March 31, 2024December 31, 2023
Operating lease right-of-use assets$1,234 $1,269 
Prepaid asset and deposits1,155 1,289 
Other 697 697 
Total other long-term assets$3,086 $3,255 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCRUED LIABILITIES
 3 Months Ended
Mar. 31, 2024
Accounts Payable and Accrued Liabilities, Current [Abstract]  
ACCRUED LIABILITIES ACCRUED LIABILITIES
 
The following table reflects accrued liabilities as of March 31, 2024 and December 31, 2023 (in thousands): 

 March 31, 2024December 31, 2023
Accrued compensation$1,452 $2,438 
Accrued restructuring costs (See Note 20)
3,368 4,378 
Other accrued liabilities9,123 9,492 
Interest payable217 867 
Accrued royalties1,241 1,038 
Total accrued liabilities$15,401 $18,213 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
 
The following table reflects the Company’s debt as of March 31, 2024 and December 31, 2023 (in thousands):

March 31, 2024December 31, 2023
6.5% Convertible Senior Secured Notes due 2027 principal amount
$40,000$40,000
Plus: derivative liability for embedded conversion feature308308
Less: unamortized debt issuance costs(1,687)(1,794)
Carrying value38,62138,514
Less: current portion of long-term debt——
Long-term debt, net$38,621$38,514


6.5% Convertible Senior Notes due 2027

On August 22, 2022, Assertio entered into a purchase agreement (the “Purchase Agreement”), with U.S. Bank Trust Company as the trustee (the “2027 Convertible Note Trustee”) of the initial purchasers (the “Initial Purchasers”) to issue $60.0 million in aggregate principal amount of 6.5% Convertible Senior Notes due 2027 (the “2027 Convertible Notes”). Under the Purchase Agreement, the Initial Purchasers were also granted an overallotment option to purchase up to an additional $10.0 million aggregate principal amount of the 2027 Convertible Notes solely to cover overallotment (the “Overallotment Option”) within a 13-day period from the date the initial 2027 Convertible Notes were issued. On August 24, 2022, the Initial Purchasers exercised the Overallotment Option in full for the $10.0 million aggregate principal of additional 2027 Convertible Notes. The 2027 Convertible Notes are senior unsecured obligations of the Company.

On February 27, 2023, the Company completed a privately negotiated exchange of $30.0 million principal amount of the 2027 Convertible Notes (the “Convertible Note Exchange”). As a result of the Convertible Note Exchange in the first quarter of 2023, the Company recorded an induced conversion expense of approximately $8.8 million and direct transaction costs of approximately $1.1 million, the total of which is reported in Debt-related expenses in the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2023. The induced conversion expense represents the fair value of the consideration transferred in the Convertible Note Exchange in excess of the fair value of common stock issuable under the original terms of the 2027 Convertible Notes.

The terms of the 2027 Convertible Notes are governed by an indenture dated August 25, 2022 (the “2027 Convertible Note Indenture”). The terms of the 2027 Convertible Notes allow for conversion into the Company’s common stock, cash, or a combination of cash and common stock, at the Company’s election only, at an initial conversion rate of 244.2003 shares of the Company’s common stock per $1,000 principal amount (equal to an initial conversion price of approximately $4.09 per share), subject to adjustments specified in the 2027 Convertible Note Indenture (the “Conversion Rate”). The 2027 Convertible Notes will mature on September 1, 2027, unless earlier repurchased or converted.

The 2027 Convertible Notes bear interest from August 25, 2022, at a rate of 6.5% per annum payable semiannually in arrears on March 1 and September 1 of each year, beginning on March 1, 2023.
Pursuant to the terms of the Indenture, the Company and its restricted subsidiaries must comply with certain covenants, including mergers, consolidations, and divestitures; guarantees of debt by subsidiaries; issuance of preferred and/or disqualified stock; and liens on the Company’s properties or assets. The Company was in compliance with its covenants with respect to the 2027 Convertible Notes as of March 31, 2024.

The following table reflects the carrying balance of the 2027 Convertible Notes as of March 31, 2024 and December 31, 2023 (in thousands):

March 31, 2024December 31, 2023
Principal balance$40,000 $40,000 
Derivative liability for embedded conversion feature308 308 
Unamortized debt issuance costs(1,687)(1,794)
Carrying balance$38,621 $38,514 

The debt issuance costs incurred related to the 2027 Convertible Notes are recognized as a debt discount and are being amortized as interest expense over the term of the 2027 Convertible Notes using the effective interest method, with an effective interest rate determined to be 7.8%. During each of the three months ended March 31, 2024 and 2023, the Company amortized $0.1 million of the debt discount on the 2027 Convertible Notes.

The Company determined that an embedded conversion feature included in the 2027 Convertible Notes required bifurcation from the host contract and to be recognized as a separate derivative liability carried at fair value. See Note 18, Fair Value, for further details around the estimated fair value of the derivative liability. All of the other embedded features of the 2027 Convertible Notes were clearly and closely related to the debt host and did not require bifurcation as a derivative liability, or the fair value of the bifurcated features was immaterial to the Company’s financial statements.
    
Interest Expense

The following table reflects debt-related interest included in Interest expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2024 and 2023 (in thousands):

Three Months Ended March 31,
20242023
Interest on 2027 Convertible Notes$650$975
Amortization of debt issuance costs107147
Total interest expense$757$1,122
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
OTHER LONG-TERM LIABILITIES
 3 Months Ended
Mar. 31, 2024
Other Liabilities Disclosure [Abstract]  
OTHER LONG-TERM LIABILITIES OTHER LONG-TERM LIABILITIES
The following table reflects other long-term liabilities as of March 31, 2024 and December 31, 2023 (in thousands):
 March 31, 2024December 31, 2023
ROLVEDON product royalties$9,224 $9,224 
Noncurrent operating lease liabilities1,350 1,470 
Liability for uncertain tax provisions4,620 4,553 
Deferred employee retention credits1,212 1,212 
Total other long-term liabilities$16,406 $16,459 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
    
The Company’s stock-based compensation generally includes time-based restricted stock units (“RSU”) and options, as well as performance-based RSUs and options.

For the three months ended March 31, 2024 and 2023, stock-based compensation of $1.2 million and $2.4 million, respectively, was recognized in Selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive Loss.

During the three months ended March 31, 2024, the Company granted 0.9 million RSUs at a weighted-average fair market value of $0.80 per share, and 3.0 million options at a weighted-average fair market value of $0.77 per share. During the three months ended March 31, 2023, the Company granted 0.5 million RSUs at a weighted-average fair market value of $5.15 per share, and 0.6 million options at a weighted-average fair market value of $4.39 per share.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
LEASES LEASES
As of March 31, 2024, the Company has a non-cancelable operating lease for its corporate office, which is located in Lake Forest, Illinois (the “Lake Forest Lease”). On May 1, 2023, the Company amended the Lake Forest Lease to reduce the size of leased premises and extend the term of the lease through December 31, 2030. Additionally, in connection with the Spectrum Merger, the Company assumed leases for two facilities and certain office equipment which Spectrum had previously been the lessee.

The following table reflects lease expense and income for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
Financial Statement Classification20242023
Operating lease costSelling, general and administrative expenses$66 $39 
The following table reflects supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Cash paid for amounts included in measurement of liabilities:
Operating cash flows from operating leases$282 $104 
The following table reflects supplemental balance sheet information related to leases as of March 31, 2024 and December 31, 2023 (in thousands):
Financial Statement ClassificationMarch 31, 2024December 31, 2023
Assets
Operating lease right-of-use assetsOther long-term assets$1,234 $1,269 
Liabilities
Current operating lease liabilitiesOther current liabilities$797 $928 
Noncurrent operating lease liabilitiesOther long-term liabilities1,350 1,470 
Total lease liabilities$2,147 $2,398 
LEASES LEASES
As of March 31, 2024, the Company has a non-cancelable operating lease for its corporate office, which is located in Lake Forest, Illinois (the “Lake Forest Lease”). On May 1, 2023, the Company amended the Lake Forest Lease to reduce the size of leased premises and extend the term of the lease through December 31, 2030. Additionally, in connection with the Spectrum Merger, the Company assumed leases for two facilities and certain office equipment which Spectrum had previously been the lessee.

The following table reflects lease expense and income for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
Financial Statement Classification20242023
Operating lease costSelling, general and administrative expenses$66 $39 
The following table reflects supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Cash paid for amounts included in measurement of liabilities:
Operating cash flows from operating leases$282 $104 
The following table reflects supplemental balance sheet information related to leases as of March 31, 2024 and December 31, 2023 (in thousands):
Financial Statement ClassificationMarch 31, 2024December 31, 2023
Assets
Operating lease right-of-use assetsOther long-term assets$1,234 $1,269 
Liabilities
Current operating lease liabilitiesOther current liabilities$797 $928 
Noncurrent operating lease liabilitiesOther long-term liabilities1,350 1,470 
Total lease liabilities$2,147 $2,398 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Jubilant HollisterStier Manufacturing and Supply Agreement

In connection with the Company’s merger with Zyla Life Sciences (“Zyla”) in May 2020 (the “Zyla Merger”), the Company assumed a Manufacturing and Supply Agreement (the “Jubilant HollisterStier Agreement”) with Jubilant HollisterStier LLC (“JHS”) pursuant to which the Company engaged JHS to provide certain services related to the manufacture and supply of SPRIX for the Company’s commercial use. Under the Jubilant HollisterStier Agreement, JHS is responsible for supplying a minimum of 75% of the Company’s annual requirements of SPRIX. The Company agreed to purchase a minimum number of batches of SPRIX per calendar year from JHS over the term of the Jubilant HollisterStier Agreement. Total annual commitments to JHS are approximately $1.5 million.

Antares Supply Agreement

In connection with the Otrexup acquisition, the Company entered into a supply agreement with Antares pursuant to which Antares will manufacture and supply the finished Otrexup products (the “Antares Supply Agreement”). Under the Antares Supply Agreement, the Company has agreed to annual minimum purchase obligations from Antares, which approximate $2.0 million annually. The Antares Supply Agreement has an initial term through December 2031 with renewal terms beyond.

Hanmi Supply Agreement

In connection with the Spectrum Merger, the Company assumed a Manufacturing and Supply Agreement (the “Hanmi Agreement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) pursuant to which the Company engaged Hanmi to provide certain services related to the manufacture and supply of ROLVEDON for the Company’s commercial use. The Company has agreed to purchase a minimum number of batches totaling approximately $19.1 million in 2024 and $3.8 million in 2025. The Company has purchased $8.4 million of inventory from Hanmi during the three months ended March 31, 2024.

General
The Company is currently involved in various lawsuits, claims, investigations and other legal proceedings that arise in the ordinary course of business. The Company recognizes a loss contingency provision in its financial statements when it concludes that a contingent liability is probable, and the amount thereof is estimable. Costs associated with the Company’s involvement in legal proceedings are expensed as incurred. Amounts accrued for legal contingencies are based on management’s best estimate of a loss based upon the status of the cases described below, assessments of the likelihood of damages, and the advice of counsel and often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. As of both March 31, 2024 and December 31, 2023, the Company had a legal contingency accrual of approximately $3.2 million. The Company continues to monitor each matter and adjust accruals as warranted based on new information and further developments in accordance with ASC 450-20-25. For matters discussed below for which a loss is not probable, or a probable loss cannot be reasonably estimated, no liability has been recorded. Provisions for loss contingencies are recorded in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss and the related accruals are recorded in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets.

Other than matters disclosed below, the Company may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of its business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims and other matters. The Company may also become party to further litigation in federal and state courts relating to opioid drugs. Although actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, other than the matters set forth below, the Company is not currently involved in any matters that the Company believes may have a material adverse effect on its business, results of operations, cash flows or financial condition. However, regardless of the outcome, litigation can have an adverse impact on the Company because of associated cost and diversion of management time.
Glumetza Antitrust Litigation
Antitrust class actions and related direct antitrust actions were filed in the U.S. District Court for the Northern District of California against the Company and several other defendants relating to its former drug Glumetza®. The plaintiffs sought to represent a putative class of direct purchasers of Glumetza. In addition, several retailers, including CVS Pharmacy, Inc., Rite Aid Corporation, Walgreen Co., the Kroger Co., the Albertsons Companies, Inc., H-E-B, L.P., and Hy-Vee, Inc. (the “Retailer Plaintiffs”), filed substantially similar direct purchaser antitrust claims in the same District Court.

On July 30, 2020, Humana Inc. (“Humana”) also filed a complaint against the Company and several other defendants in the U.S. District Court for the Northern District of California alleging similar claims related to Glumetza. The claims asserted by Humana in its federal case were ultimately withdrawn, and analogous claims were instead asserted by Humana in an action it filed in the Superior Court of the State of California for the County of Alameda on February 8, 2021, and subsequently amended in September 2021. Additionally, on April 5, 2022, Health Care Service Corporation (“HCSC”) filed a complaint against the Company and the same other defendants in the California Superior Court of Alameda alleging similar claims related to Glumetza.

These antitrust cases arise out of a Settlement and License Agreement (the “Settlement”) that the Company, Santarus, Inc. (“Santarus”) and Lupin Limited (“Lupin”) entered into in February 2012 that resolved patent infringement litigation filed by the Company against Lupin regarding Lupin’s Abbreviated New Drug Application for generic 500 mg and 1000 mg tablets of Glumetza. The antitrust plaintiffs allege, among other things, that the Settlement violated the antitrust laws because it allegedly included a “reverse payment” that caused Lupin to delay its entry in the market with a generic version of Glumetza. The alleged “reverse payment” is an alleged commitment on the part of the settling parties not to launch an authorized generic version of Glumetza for a certain period. The antitrust plaintiffs allege that the Company and its co-defendants, which include Lupin as well as Bausch Health (the alleged successor in interest to Santarus), are liable for damages under the antitrust laws for overcharges that the antitrust plaintiffs allege they paid when they purchased the branded version of Glumetza due to delayed generic entry. Plaintiffs seek treble damages for alleged past harm, attorneys’ fees and costs.

On September 14, 2021, the Retailer Plaintiffs voluntarily dismissed all claims against the Company pursuant to a settlement agreement with the Company in return for $3.15 million. On February 3, 2022, the District Court issued its final order approving a settlement of the direct purchaser class plaintiffs’ claims against the Company in return for $3.85 million.

With respect to the California state court lawsuits, on November 24, 2021, the state court granted in part and denied in part a demurrer by the defendants in the Humana action. That case was consolidated in November 2022 with the HCSC action for pre-trial and trial purposes. On July 5, 2023, the state court denied a motion for judgment on the pleadings filed by the defendants in the Humana action. These California state cases are now in the midst of discovery, and trial is scheduled for December 2024.

The Company intends to defend itself vigorously in the consolidated California state court lawsuits. A liability for this matter has been recorded in the financial statements.

Opioid-Related Request and Subpoenas

As a result of the greater public awareness of the public health issue of opioid abuse, there has been increased scrutiny of, and investigation into, the commercial practices of opioid manufacturers generally by federal, state, and local regulatory and governmental agencies. In March 2017, Assertio Therapeutics received a letter from then-Sen. Claire McCaskill (D-MO), the then-Ranking Member on the U.S. Senate Committee on Homeland Security and Governmental Affairs, requesting certain information regarding Assertio Therapeutics’ historical commercialization of opioid products. Assertio Therapeutics voluntarily furnished information responsive to Sen. McCaskill’s request. Since 2017, Assertio Therapeutics has received and responded to subpoenas from the U.S. Department of Justice (“DOJ”) seeking documents and information regarding its historical sales and marketing of opioid products. Assertio Therapeutics has also received and responded to subpoenas or civil investigative demands focused on its historical promotion and sales of Lazanda, NUCYNTA, and NUCYNTA ER from various state attorneys general seeking documents and information regarding Assertio Therapeutics’ historical sales and marketing of opioid products. In addition, Assertio Therapeutics received and responded to a subpoena from the State of California Department of Insurance (“CDI”) seeking information relating to its historical sales and marketing of Lazanda. The CDI subpoena also sought information on Gralise, a non-opioid product formerly in Assertio Therapeutics’ portfolio. In addition, Assertio Therapeutics received and responded to a subpoena from the New York Department of Financial Services seeking information relating to its historical sales and marketing of opioid products. The Company has also received a subpoena from the New York Attorney General in May 2023, pursuant to which the New York Attorney General is seeking information concerning the sales and marketing of opioid products (Lazanda, NUCYNTA, NUCYNTA ER, and OXAYDO) by Assertio Therapeutics and Zyla. The
Company also from time to time receives and responds to subpoenas from governmental authorities related to investigations primarily focused on third parties, including healthcare practitioners. The Company is cooperating with the foregoing governmental investigations and inquiries.

In July 2022, the Company became aware that the DOJ issued a press release stating that it had settled claims against a physician whom the DOJ alleged had received payments for paid speaking and consulting work from two pharmaceutical companies, including Depomed, Inc. (“Depomed,” now known as Assertio Therapeutics), in exchange for prescribing certain of the companies’ respective products. As part of the settlement, the physician did not admit liability for such claims and the press release stated that there has been no determination of any liability for such claims. The Company denies any wrongdoing and disputes the DOJ’s characterization of the payments from Depomed.

Multidistrict and Other Federal Opioid Litigation
A number of pharmaceutical manufacturers, distributors and other industry participants have been named in numerous lawsuits around the country brought by various groups of plaintiffs, including city and county governments, hospitals, individuals and others. In general, the lawsuits assert claims arising from defendants’ manufacturing, distributing, marketing and promoting of FDA-approved opioid drugs. The specific legal theories asserted vary from case to case, but the lawsuits generally include federal and/or state statutory claims, as well as claims arising under state common law. Plaintiffs seek various forms of damages, injunctive and other relief and attorneys’ fees and costs.
For such cases filed in or removed to federal court, the Judicial Panel on Multi-District Litigation issued an order in December 2017, establishing a Multi-District Litigation court (“MDL Court”) in the Northern District of Ohio (In re National Prescription Opiate Litigation, Case No. 1:17-MD-2804). Since that time, more than 2,000 such cases that were originally filed in U.S. District Courts, or removed to federal court from state court, have been filed in or transferred to the MDL Court. Assertio Therapeutics is currently involved in a subset of the lawsuits that have been filed in or transferred to the MDL Court. Assertio Holdings has also been named in six such cases. In April 2022, the Judicial Panel on Multi-District Litigation issued an order stating that it would no longer transfer new opioid cases to the MDL Court. Since that time, Assertio Therapeutics has been named in lawsuits pending in federal courts outside of the MDL Court (in Georgia and New York). Plaintiffs may file additional lawsuits in which the Company may be named, and plaintiffs may also seek leave to add the Company to lawsuits already on file in the MDL Court. Plaintiffs in the pending federal cases involving Assertio Therapeutics or Assertio Holdings include individuals; county, municipal and other governmental entities; employee benefit plans, health insurance providers and other payors; hospitals, health clinics and other health care providers; Native American tribes; and non-profit organizations who assert, for themselves and in some cases for a putative class, federal and state statutory claims and state common law claims, such as conspiracy, nuisance, fraud, negligence, gross negligence, negligent and intentional infliction of emotional distress, deceptive trade practices, and products liability claims (defective design/failure to warn). In these cases, plaintiffs seek a variety of forms of relief, including actual damages to compensate for alleged personal injuries and for alleged past and future costs such as to provide care and services to persons with opioid-related addiction or related conditions, injunctive relief, including to prohibit alleged deceptive marketing practices and abate an alleged nuisance, establishment of a compensation fund, establishment of medical monitoring programs, disgorgement of profits, punitive and statutory treble damages, and attorneys’ fees and costs. No trial date has been set for any of these lawsuits, which are at an early stage of proceedings. Assertio Therapeutics and Assertio Holdings intend to defend themselves vigorously in these matters.
State Opioid Litigation

Related to the federal cases noted above, there have been hundreds of similar lawsuits filed in state courts around the country, in which various groups of plaintiffs assert opioid-drug related claims against similar groups of defendants. Assertio Therapeutics is currently named in a subset of those cases, including cases in Delaware, Missouri, Pennsylvania, Texas and Utah. Assertio Holdings is named as a defendant in one of these cases in Pennsylvania. Plaintiffs may file additional lawsuits in which the Company may be named. In the pending cases involving Assertio Therapeutics or Assertio Holdings, plaintiffs are asserting state common law and statutory claims against the defendants, and the majority of those cases are similar in nature to the claims asserted in the MDL cases. Plaintiffs are seeking actual damages, disgorgement of profits, injunctive relief, punitive and statutory treble damages, and attorneys’ fees and costs. The state lawsuits in which Assertio Therapeutics or Assertio Holdings has been served are generally each at an early stage of proceedings. Assertio Therapeutics and Assertio Holdings intend to defend themselves vigorously in these matters.

Insurance Litigation

On January 15, 2019, Assertio Therapeutics was named as a defendant in a declaratory judgment action filed by Navigators Specialty Insurance Company (“Navigators”) in the U.S. District Court for the Northern District of California (Case No. 3:19-cv-255). Navigators was Assertio Therapeutics’ primary product liability insurer. Navigators was seeking declaratory
judgment that opioid litigation claims noticed by Assertio Therapeutics (as further described above under “Multidistrict and Other Federal Opioid Litigation” and “State Opioid Litigation”) are not covered by Assertio Therapeutics’ life sciences liability policies with Navigators. On February 3, 2021, Assertio Therapeutics entered into a Confidential Settlement Agreement and Mutual Release with Navigators to resolve the declaratory judgment action and Assertio Therapeutics’ counterclaims. Pursuant to the Settlement Agreement, the parties settled and the coverage action was dismissed without prejudice.

During the first quarter of 2021, Assertio Therapeutics received $5.0 million in insurance reimbursement for previous opioid-related spend, which was recognized within Selling, general and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the year ended December 31, 2021.

On July 16, 2021, Assertio Therapeutics filed a complaint for declaratory relief against one of its excess products liability insurers, Lloyd’s of London Newline Syndicate 1218 and related entities (“Newline”), in the Superior Court of the State of California for the County of Alameda. Newline removed the case to the U.S. District Court for the Northern District of California (Case No. 3:21-cv-06642). Assertio Therapeutics was seeking a declaratory judgment that Newline has a duty to defend Assertio Therapeutics or, alternatively, to reimburse Assertio Therapeutics’ attorneys’ fees and other defense costs for opioid litigation claims noticed by Assertio Therapeutics. On May 18, 2022, Assertio Therapeutics entered into a Confidential Settlement Agreement and Mutual Release with Newline to resolve Assertio Therapeutics’ declaratory judgment action. Pursuant to the Settlement Agreement, the parties settled and the coverage action was dismissed with prejudice.

During the second quarter of 2022, Assertio Therapeutics received $2.0 million in insurance reimbursement for previous opioid-related spend, which was recognized within Selling, general and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive (Loss) Income for the year ended December 31, 2022.

On April 1, 2022, Assertio Therapeutics filed a complaint against its former insurance broker, Woodruff-Sawyer & Co. (“Woodruff”), in the Superior Court of the State of California for the County of Alameda (Case No. 22CV009380). Assertio Therapeutics alleged claims for negligence and breach of fiduciary duty in connection with Woodruff’s negotiation and procurement of products liability insurance coverage for Assertio Therapeutics. On April 26, 2024, Assertio Therapeutics and Woodruff executed a binding settlement term sheet to resolve Assertio Therapeutics’ claims.

Stockholder Actions

Shapiro v. Assertio Holdings, Inc., et al., U.S. District Court, Northern District of Illinois, Case No. 1:24-cv-00169. On January 5, 2024, this putative securities class action lawsuit was filed by a purported shareholder, alleging that Assertio and certain of its current and former executive officers made false or misleading statements and failed to disclose material facts regarding the likely impact of INDOCIN sales and the Spectrum Merger on Assertio’s profitability in violation of Sections 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act of 1934, as amended (the “Exchange Act”). On April 11, 2024, the court appointed Continental General Insurance Company as the lead plaintiff. The Company intends to vigorously defend itself in this matter.

Edwards v. Assertio Holdings, Inc., et al., Court of Chancery of the State of Delaware, Case No. 2024-0151. On February 19, 2024, this putative securities class action lawsuit was filed by a purported shareholder, alleging that certain former officers and directors of Spectrum breached their fiduciary duties in connection the Spectrum Merger, and that Guggenheim Securities LLC and Assertio aided and abetted such fiduciary duty breaches. The Company intends to vigorously defend itself in this matter.

Jung v. Peisert, et al., U.S. District Court, Delaware, Case No. 1:24-cv-00383-UNA. On March 26, 2024, this putative stockholder derivative action was filed against the Company (as a nominal defendant) and certain of its current and former executive offers and directors. The stockholder derivative complaint alleges, inter alia, that certain of the Company’s current and former executive officers and directors are liable to the Company, pursuant to Section 10(b) and 21(d) of the Exchange Act for contribution and indemnification, relating to allegedly false or misleading statements and alleged failure to disclose material facts regarding the likely impact of INDOCIN sales and the Spectrum Merger on the Company’s profitability. The complaint further alleges that certain of the Company’s current and former officers and directors breached their fiduciary duties, and that certain of the Company’s directors negligently violated Section 14(a) of the Exchange Act, by allegedly causing such false or misleading statements to be issued and/or failing to disclose material facts about such matters. The allegations state that as a result of the violations, certain of the Company’s current and former executive officers and directors committed acts of gross mismanagement, abuse of control, or were unjustly enriched. The plaintiffs generally seek corporate reforms, damages, interest, costs, attorneys’ fees, and other unspecified equitable relief.
Luo v. Spectrum Pharmaceuticals, Inc., et al., U.S. District Court, District of Nevada, Case No. 2:21-cv-01612. On August 31, 2021, this putative securities class action lawsuit was filed by a purported shareholder, alleging that Spectrum and certain of its former executive officers and directors made false or misleading statements and failed to disclose material facts about Spectrum’s business and the prospects of approval for its Biologic License Application (“BLA”) to the FDA for eflapegrastim (ROLVEDON) in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act. On November 1, 2021, four individuals and one entity filed competing motions to be appointed lead plaintiff and for approval of counsel. On July 28, 2022, the Court appointed a lead plaintiff and counsel for the putative class. On September 26, 2022, an amended complaint was filed alleging, inter alia, false and misleading statements with respect to ROLVEDON manufacturing operations and controls and adding allegations that defendants misled investors about the efficacy of, clinical trial data and market need for poziotinib during a Class Period of March 7, 2018 to August 5, 2021. The amended complaint seeks damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the Court. On November 30, 2022, the defendants filed a motion to dismiss the amended complaint, which was fully briefed as of February 27, 2023. On February 6, 2024, the Court held a hearing on the motion to dismiss and issued an order dismissing the lawsuit without prejudice to the lead plaintiff’s ability to replead their claims. The lead plaintiff filed a further amended complaint on March 29, 2024. The Company intends to vigorously defend itself in this matter.

Christiansen v. Spectrum Pharmaceuticals, Inc. et al., Case No. 1:22-cv-10292 (filed December 5, 2022 in the U.S. District Court for the Southern District of New York) (the “New York Action”). Three additional related putative securities class action lawsuits were subsequently filed by Spectrum shareholders against Spectrum and certain of its former executive officers in the U.S. District Court for the Southern District of New York: Osorio-Franco v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10292 (filed December 5, 2022); Cummings v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10677 (filed December 19, 2022); and Carneiro v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:23-cv-00767 (filed January 30, 2023). These three New York lawsuits allege that Spectrum and certain of its former executive officers made false or misleading statements about, inter alia, the safety and efficacy of and clinical trial data for poziotinib in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act, and seek remedies including damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the Court. On February 15, 2023, the Court consolidated the three New York lawsuits. On March 21, 2023, the Court entered an order designating Steven Christiansen as the lead plaintiff. Lead plaintiff Christiansen filed an amended consolidated complaint in the New York Action under the caption Christiansen v. Spectrum Pharmaceuticals, Inc, et al., on May 30, 2023, alleging a Class Period between March 17, 2022 and September 2022. The defendants filed a motion to dismiss the consolidated New York Action on July 25, 2023, which was fully briefed as of October 19, 2023. On January 23, 2024, the Court granted the motion to dismiss in part as to five of the challenged statements but denied the motion to dismiss as to two specific statements. The Company filed its answer to the complaint on March 8, 2024. The Company intends to vigorously defend itself in this matter.

Csaba v. Turgeon, et. al (filed December 15, 2021 in the U.S. District Court District of Nevada); Shumacher v. Turgeon, et. al (filed March 15, 2022 in the U.S. District Court District of Nevada); Johnson v. Turgeon, et. al (filed March 29, 2022 in the U.S. District Court District of Nevada); Raul v. Turgeon, et. al (filed April 28, 2022 in the U.S. District Court District of Delaware); and Albayrak v. Turgeon, et. al (filed June 9, 2022 in the U.S. District Court District of Nevada). These putative stockholder derivative actions were filed against Spectrum (as a nominal defendant) and certain of Spectrum’s former executive officers and directors. The stockholder derivative complaints allege, inter alia, that certain of Spectrum’s former executive officers are liable to Spectrum, pursuant to Section 10(b) and 21(d) of the Exchange Act for contribution and indemnification, if they are deemed (in the Luo class action), to have made false or misleading statements and failed to disclose material facts about Spectrum’s business and the prospects of approval for its BLA to the FDA for eflapegrastim. The complaints generally but not uniformly further allege that certain of Spectrum’s former officers and directors breached their fiduciary duties, and certain of Spectrum’s former directors negligently violated Section 14(a) of the Exchange Act, by allegedly causing such false or misleading statements to be issued and/or failing to disclose material facts about Spectrum’s business and the prospects of approval for its BLA to the FDA for eflapegrastim. The allegations state that as a result of the violations, certain of Spectrum’s former executive officers and directors committed acts of gross mismanagement, abuse of control, or were unjustly enriched. The plaintiffs generally seek corporate reforms, damages, interest, costs, attorneys’ fees, and other unspecified equitable relief. The parties have agreed to stay these derivative actions until there is a decision in the Luo Nevada securities class action either denying a motion to dismiss in whole or in part, or dismissing that securities class action with prejudice.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHAREHOLDERS EQUITY
 3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
SHAREHOLDERS EQUITY SHAREHOLDERS EQUITY
Issuance of Common Stock in the Spectrum Merger

Pursuant to the Merger Agreement, shares of Spectrum common stock issued and outstanding immediately prior to the Effective Date, as well as Spectrum restricted stock units, certain stock appreciation rights, certain options to purchase Spectrum common stock, and warrants to purchase Spectrum common stock, which, in each case, were outstanding immediately prior to the Effective Date and were either vested or became vested as a result of the Spectrum Merger on the Effective Date, were converted into the right to receive fully paid and non-assessable shares of the Company’s common stock based on the exchange ratio as set forth in the Merger Agreement (see Note 2, Acquisitions) and the CVRs. Accordingly, on the Effective Date the Company issued approximately 38.0 million shares of its common stock to the previous holders of Spectrum common stock, net of a fractional share settlement.

Exchanged Convertible Notes

In connection with the Convertible Note Exchange (See Note 11, Debt) in the first quarter of 2023, the Company paid an aggregate of $10.5 million in cash and issued an aggregate of approximately 7.0 million shares of its common stock in partial settlement of the 2027 Convertible Notes (the “Exchanged Notes”). The Company did not receive any cash proceeds from the issuance of the shares of its common stock but recognized additional paid-in capital of $28.3 million during the three months ended March 31, 2023, related to the common stock share issuance, net of approximately $1.6 million of unamortized issuance costs related to the Exchanged Notes.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period.

Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, plus potentially dilutive common shares, consisting of stock-based awards and equivalents, and convertible debt. For the purposes of this calculation, stock-based awards and convertible debt are considered to be potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive. The Company uses the treasury-stock method to compute diluted earnings per share with respect to its stock-based awards and equivalents. The Company uses the if-converted method to compute diluted earnings per share with respect to its convertible debt. Under the if-converted method, the Company assumes any convertible debt outstanding was converted at the beginning of each period presented when the effect is dilutive. As a result, interest expense, net of tax, and any other income statement impact associated with the 2027 Convertible Notes, net of tax, is added back to net loss used in the diluted earnings per share calculation. Additionally, the diluted shares used in the diluted earnings per share calculation includes the potential dilution effect of the convertible debt if converted into the Company’s common stock. As the Company was in a loss position for the three months ended March 31, 2024 and March 31, 2023, the Company’s potentially dilutive stock-based awards and convertible debt were not included in the computation of diluted net loss per share, because to do so would be anti-dilutive.

The following table reflects the calculation of basic and diluted loss per common share for the three months ended March 31, 2024 and 2023 (in thousands, except for per share amounts):

 Three Months Ended March 31,
20242023
Basic and diluted net loss per share
Net loss$(4,510)$(3,484)
Weighted-average common shares outstanding94,980 51,005 
Basic and diluted net loss per share$(0.05)$(0.07)
 
The following table reflects outstanding potentially dilutive common shares that are not included in the computation of diluted net loss per share, because to do so would be anti-dilutive, for the three months ended March 31, 2024 and 2023 (in thousands):
 Three Months Ended March 31,
20242023
Convertible notes9,768 14,489 
Stock-based awards and equivalents8,422 8,271 
Total potentially dilutive common shares18,190 22,760 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE FAIR VALUE
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
 
•Level 1: Quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The following table reflects the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):

March 31, 2024Financial Statement ClassificationLevel 1Level 2Level 3Total
Assets:
U.S. TreasuriesCash and cash equivalents$— $36,518 $— $36,518 
U.S. Government agenciesCash and cash equivalents— 2,750 — 2,750 
Money market fundsCash and cash equivalents40,168 — — 40,168 
Total$40,168 $39,268 $— $79,436 
Liabilities:
Short-term contingent considerationContingent consideration, current portion$— $— $2,700 $2,700 
Derivative liabilityLong-term debt— — 308 308 
Total$— $— $3,008 $3,008 

December 31, 2023Financial Statement ClassificationLevel 1Level 2Level 3Total
Assets:
U.S. TreasuriesCash and cash equivalents$— $35,458 $— $35,458 
U.S. Government agenciesCash and cash equivalents— 3,294 — 3,294 
Money market fundsCash and cash equivalents32,534 — — 32,534 
Total$32,534 $38,752 $— $71,286 
Liabilities:
Short-term contingent considerationContingent consideration, current portion$— $— $2,700 $2,700 
Derivative liabilityLong-term debt— — 308 308 
Total$— $— $3,008 $3,008 
    
Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity date of purchase of three months or less to be cash equivalents. The Company invests its cash in money market funds and marketable securities including U.S. Treasury and government agency securities, commercial paper, and higher quality debt securities of financial and commercial institutions. The Company classified money market funds as Level 1, due to their short-term maturity, and measured the fair value based on quoted prices in active markets for identical assets. The Company classified commercial paper, U.S. Treasury and government agency securities as Level 2, as the inputs used to value these instruments are directly observable or can be corroborated by observable market data for substantially the full term of the assets.

Contingent Consideration Obligations

Spectrum Merger Contingent Variable Rights

In connection with the Spectrum Merger, the Company issued CVRs (See Note 2, Acquisitions) that represent a contingent consideration obligation which is measured at fair value.

As of both March 31, 2024 and December 31, 2023, the fair value of the Company’s CVR liability related to the Spectrum Merger was determined by the Company to be zero. Accordingly, the Company recognized no expense or benefit for the change in fair value of the CVR contingent consideration during the three months ended March 31, 2024. The fair value of the CVR contingent consideration is determined using a Monte Carlo simulation model under the income approach based on the probability of achievement of ROLVEDON net sales milestones using projections of 2024 and 2025 net sales and discounted to present value. The significant assumptions used in the calculation of the fair value as of March 31, 2024 included updated projections of future ROLVEDON product net sales, which resulted in no probability of achievement under the Monte Carlo simulation.
Zyla Merger Contingent Consideration Obligation

In connection with the Zyla Merger, the Company assumed a contingent consideration obligation which is measured at fair value. The Company has obligations to make contingent consideration payments for future royalties to an affiliate of CR Group L.P. based upon annual INDOCIN product net sales over $20.0 million at a 20% royalty through January 2029. The Company classified the acquisition-related contingent consideration liabilities to be settled in cash as Level 3, due to the lack of relevant observable inputs and market activity. As of both March 31, 2024 and December 31, 2023, the fair value of the INDOCIN product contingent consideration was determined to be $2.7 million and has been classified as current contingent consideration in the Company’s Condensed Consolidated Balance Sheets.

During the three months ended March 31, 2024 and 2023, the Company recognized an expense of zero and $9.2 million, respectively, for the change in fair value of contingent consideration, which was recognized in Change in fair value of contingent consideration in the Company’s Condensed Consolidated Statements of Comprehensive Loss. The fair value of the contingent consideration incurred in the Zyla Merger is determined using an option pricing model under the income approach based on estimated INDOCIN product revenues through January 2029 and discounted to present value. The significant assumptions used in the calculation of the fair value as of March 31, 2024 included revenue volatility of 15%, discount rate of 5.5%, credit spread of 9.2% and projections of future INDOCIN product revenues.

The following table summarizes changes in fair value of the Company’s contingent consideration obligations that are measured on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2024 and 2023 (in thousands):

 Three Months Ended March 31,
20242023
Fair value, beginning of the period$2,700 $48,500 
Change in fair value of contingent consideration recorded within costs and expenses— 9,167 
Cash payment related to contingent consideration— (6,609)
Fair value, end of the period$2,700 $51,058 

Derivative Liability
The Company determined that an embedded conversion feature included in the 2027 Convertible Notes required bifurcation from the host contract and to be recognized as a separate derivative liability carried at fair value. The estimated fair value of the derivative liability, which represents a Level 3 valuation, was $0.3 million as of both March 31, 2024 and December 31, 2023, and was determined using a binomial lattice model using certain assumptions and consideration of an increased conversion ratio on the underlying convertible notes that could result from the occurrence of certain events. The significant assumption used in the binomial lattice model is a credit spread of 8.8%.

There was no change in the fair value of the derivative liability for the three months ended March 31, 2024 or 2023.

Financial Instruments Not Required to be Remeasured at Fair Value

The Company’s other financial assets and liabilities are not remeasured to fair value, as the carrying cost of each approximates its fair value. As of March 31, 2024, the estimated fair value of the 2027 Convertible Notes, excluding the bifurcated embedded conversion option, was approximately $33.8 million, compared to a par value of $40.0 million. As of December 31, 2023, the estimated fair value of the 2027 Convertible Notes, excluding the bifurcated embedded conversion option, was approximately $35.7 million, compared to a par value of $40.0 million. The Company estimated the fair value of its 2027 Convertible Notes as of March 31, 2024 and December 31, 2023 based on a market approach which represents a Level 2 valuation.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
As of March 31, 2024, the Company has concluded that it is not more likely than not that it will realize the net deferred tax asset recorded as of March 31, 2024. As a result, the Company has recorded a full valuation allowance against the net deferred tax asset recorded as of March 31, 2024. The valuation allowance is determined in accordance with the provisions of ASC 740, Income Taxes, which require an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company primarily relied on its reversing taxable temporary differences to assess its valuation allowance, which resulted in recording a full valuation allowance against our net deferred tax assets during the quarter. If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made.

For the three months ended March 31, 2024, the Company recorded an income tax expense of $0.1 million. The difference between the income tax expense and the tax at the federal statutory rate of 21.0% on current year operations is principally due to the impact of the valuation allowance and state income taxes.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RESTRUCTURING CHARGES
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
RESTRUCTURING CHARGES RESTRUCTURING CHARGES
In August 2023, the Company implemented a reorganization plan of its workforce and other resources primarily designed to realize the synergies of the Spectrum Merger (the “Spectrum Reorganization Plan”). The Spectrum Reorganization Plan was primarily focused on the reduction of staff at the Company’s headquarters office and the exit of certain leased facilities and office equipment. The Company expects the recognition of any additional costs and all cash payments under the Spectrum Reorganization Plan to be completed by the end of 2024.

The staff reductions under the Spectrum Reorganization Plan were the result of a distinct severance plan approved by the Company’s Board of Directors and were not executed as part of established Company policies or plans. Total employee compensation costs recognized under the Spectrum Reorganization Plan through March 31, 2024, were approximately $3.3 million. In addition, the leased facilities and office equipment referenced above are not expected to be used for any business purpose, and the Company will not sublease the facilities and office equipment due to the short remaining lease terms. The facility exit costs represent the acceleration of the underlying right-of-use asset amortization to align with the cease use date for the abandoned facilities and office equipment. Total facility exit costs recognized under the Spectrum Reorganization Plan through March 31, 2024, were approximately $1.3 million. There were no remaining facility exit costs expected to be recognized by the Company under the Spectrum Reorganization Plan as of March 31, 2024.

Effective as of January 2, 2024, the Company separated from the service of its former President and Chief Executive Officer. Pursuant to his then existing Management Continuity Agreement with the Company, the former President and Chief Executive Officer was entitled to severance compensation and benefits of approximately $1.5 million, which was recognized as Restructuring charges within the Condensed Consolidated Statement of Comprehensive (Loss) Income for year ended December 31, 2023, the period in which the separation and related severance benefit was determined to be probable. The Company does not expect to recognize any additional restructuring charges related to the separation from the former President and Chief Executive Officer.

The Company recognized restructuring charges of $0.7 million for the three months ended March 31, 2024, all of which related to employee compensation costs. The Company recognized no restructuring charges for the three months ended March 31, 2023.

The following table summarizes the changes in the Company’s accrued restructuring liability for employee compensation costs, which is classified within Accrued liabilities in the Condensed Consolidated Balance Sheets (in thousands):
 Employee compensation costs
Balance as of December 31, 2023$4,378 
Restructuring charges720 
Cash paid(1,730)
Balance as of March 31, 2024$3,368 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation

The unaudited condensed consolidated financial statements of the Company and its subsidiaries and the related footnote information of the Company have been prepared pursuant to the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information that are normally required by United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of the Company’s management, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of the information for the periods presented. The results for the three months ended March 31, 2024, are not necessarily indicative of results to be expected for the entire year ending December 31, 2024 or future operating periods.

The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2023, included in Assertio Holdings, Inc.’s Annual Report on Form 10-K filed with the SEC on March 11, 2024 (the “2023 Form 10-K”). The Condensed Consolidated Balance Sheet as of December 31, 2023, has been derived from the audited financial statements at that date, as filed in the Company’s 2023 Form 10-K.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACQUISITIONS (Tables)
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Schedule of Consideration Transferred
The following table reflects the components of the consideration transferred in the Spectrum Merger (in thousands, except exchange ratio and per share data):

Assertio shares issued38,013 
Assertio closing price per share as of the Effective Date$5.69 
Fair value of Assertio shares issued$216,294 
Repayment of Spectrum's long-term debt (1)
32,647 
CVRs (2)
3,932 
Total fair value of consideration transferred$252,873 

(1)Represents settlement of Spectrum’s existing long-term debt in connection with the close of the transaction. The Company concluded it did not assume the debt, therefore the amount paid to settle the debt has been accounted for and disclosed as part of the consideration transferred.
(2)Represents the Effective Date fair value of 223,397 CVRs at $0.0176 per CVR issued to holders of Spectrum common stock, employee stock awards and warrants.
Schedule of Assets Acquired and Liabilities Assumed
The following table reflects the fair values of the assets acquired and liabilities assumed at the Effective Date (in thousands). The fair values were based on management’s estimates and assumptions. There were no changes for the three months ended March 31, 2024, to the estimated preliminary fair values of the assets acquired and liabilities assumed. The final determination was completed as of March 31, 2024.

Initial Preliminary Purchase Price Allocation to Fair Value
Adjustments to Purchase Price Allocation to Fair Value (2)
Final Purchase Price Allocation to Fair Value
Assets:
Cash and cash equivalents$34,600 $— $34,600 
Marketable securities2,194 — 2,194 
Accounts receivable50,975 — 50,975 
Inventories22,244 61 22,305 
Prepaid and other current assets1,287 698 1,985 
Property and equipment100 — 100 
Intangible assets234,000 (13,500)220,500 
Other long-term assets1,396 — 1,396 
Total$346,796 $(12,741)$334,055 
Liabilities:
Accounts payable$10,108 $— $10,108 
Accrued rebates, returns and discounts21,025 — 21,025 
Accrued liabilities36,509 (2,343)34,166 
Other current liabilities784 — 784 
Deferred taxes34,250 (30,254)3,996 
Other long-term liabilities11,103 — 11,103 
Total$113,779 $(32,597)$81,182 
Total Spectrum net assets acquired (1)
$233,017 $19,856 $252,873 
Goodwill$19,856 $(19,856)$— 

(1)Application of the acquisition method required the Company to adjust Spectrum assets and liabilities as of the Effective Date, including certain liabilities for variable consideration associated with ROLVEDON, to reflect conformity of Spectrum’s accounting policies to those of Assertio. Liabilities assumed include certain bonuses owed to former Spectrum executives under the terms of existing employment agreements triggered by the consummation of the Spectrum Merger.
(2)Adjustments made to the preliminary purchase price allocation to fair value primarily reflect completion of studies and other analysis necessary to determine the income tax effects of the net identifiable assets acquired and further refinement of the assumptions used in the valuation supporting the ROLVEDON product rights. These adjustments did not materially impact the Consolidated Statement of Comprehensive (Loss) Income.
Schedule of Pro Forma Financial Information
The following unaudited pro forma information represents the Company’s results of operations as if the Spectrum Merger had been completed as of January 1, 2023, (in thousands) and includes nonrecurring adjustments for additional costs of sales from the fair value step-up of inventories and transaction costs. The disclosure of pro forma net sales and net loss does not purport to indicate the results that would actually have been obtained had the Spectrum Merger been completed on the assumed date for the periods presented, or which may be realized in the future. The unaudited pro forma information does not reflect any operating efficiencies or cost savings that may be realized from the integration of the acquisition.

Three Months Ended
March 31, 2023
Total revenues$58,081 
Net loss(13,944)
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Net Revenue
The following table reflects total revenue, net for the three months ended March 31, 2024 and 2023 (in thousands): 
Three Months Ended March 31,
20242023
Product sales, net:
ROLVEDON$14,478 $— 
INDOCIN products8,682 30,346 
Sympazan2,617 2,502 
Otrexup2,882 2,822 
SPRIX1,437 1,889 
CAMBIA1,256 2,264 
Other products510 1,946 
Total product sales, net31,862 41,769 
Royalties and milestone revenue586 697 
Total revenues$32,448 $42,466 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES, NET (Tables)
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory, Net
The following table reflects the components of inventory, net as of March 31, 2024 and December 31, 2023 (in thousands): 
 March 31, 2024December 31, 2023
Raw materials$18,872 $10,537 
Work-in-process2,452 2,239 
Finished goods17,278 24,910 
Total inventories, net$38,602 $37,686 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PREPAID AND OTHER CURRENT ASSETS (Tables)
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid and Other Current Assets
The following table reflects prepaid and other current as of March 31, 2024 and December 31, 2023 (in thousands): 

March 31, 2024December 31, 2023
Prepaid assets and deposits$10,222 $11,973 
Other current assets297 299 
Total prepaid and other current assets$10,519 $12,272 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PROPERTY AND EQUIPMENT, NET (Tables)
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
The following table reflects property and equipment, net as of March 31, 2024 and December 31, 2023 (in thousands): 

March 31, 2024December 31, 2023
Furniture and office equipment$1,908 $1,908 
Laboratory equipment20 20 
Leasehold improvements3,473 2,945 
Construction in progress— 528 
5,401 5,401 
Less: Accumulated depreciation(4,697)(4,631)
Property and equipment, net$704 $770 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets and Goodwill
The following table reflects the gross carrying amounts and net book values of intangible assets as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands): 

 March 31, 2024December 31, 2023
Products rights:Remaining Useful Life
 (In years)		Gross Carrying AmountAccumulated AmortizationNet Book ValueGross Carrying AmountAccumulated AmortizationImpairmentNet Book Value
ROLVEDON9.3$63,405 $(6,787)$56,618 $220,500 $(5,270)$(157,095)$58,135 
INDOCIN1.865,606 (47,413)18,193 154,100 (44,814)(88,494)20,792 
Sympazan10.614,550 (1,718)12,832 14,550 (1,415)— 13,135 
Otrexup5.716,364 (10,364)6,000 44,086 (10,103)(27,723)6,260 
SPRIX3.132,673 (20,615)12,058 39,000 (19,663)(6,327)13,010 
Total intangible Assets $192,598 $(86,897)$105,701 $472,236 $(81,265)$(279,639)$111,332 
Schedule of the Future Amortization Expenses of Intangible Assets
The following table reflects future amortization expense the Company expects for its intangible assets (in thousands): 

Year Ending December 31,Estimated
Amortization Expense
2024 (remainder)16,894 
202522,526 
202612,130 
20279,909 
20288,322 
Thereafter35,920 
Total$105,701 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
OTHER LONG-TERM ASSETS (Tables)
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Long-Term Assets
The following table reflects other long-term assets as of March 31, 2024 and December 31, 2023 (in thousands): 

 March 31, 2024December 31, 2023
Operating lease right-of-use assets$1,234 $1,269 
Prepaid asset and deposits1,155 1,289 
Other 697 697 
Total other long-term assets$3,086 $3,255 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCRUED LIABILITIES (Tables)
 3 Months Ended
Mar. 31, 2024
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Schedule of Accrued Liabilities
The following table reflects accrued liabilities as of March 31, 2024 and December 31, 2023 (in thousands): 

 March 31, 2024December 31, 2023
Accrued compensation$1,452 $2,438 
Accrued restructuring costs (See Note 20)
3,368 4,378 
Other accrued liabilities9,123 9,492 
Interest payable217 867 
Accrued royalties1,241 1,038 
Total accrued liabilities$15,401 $18,213 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
The following table reflects the Company’s debt as of March 31, 2024 and December 31, 2023 (in thousands):

March 31, 2024December 31, 2023
6.5% Convertible Senior Secured Notes due 2027 principal amount
$40,000$40,000
Plus: derivative liability for embedded conversion feature308308
Less: unamortized debt issuance costs(1,687)(1,794)
Carrying value38,62138,514
Less: current portion of long-term debt——
Long-term debt, net$38,621$38,514
Schedule of Carrying Values Convertible Notes
The following table reflects the carrying balance of the 2027 Convertible Notes as of March 31, 2024 and December 31, 2023 (in thousands):

March 31, 2024December 31, 2023
Principal balance$40,000 $40,000 
Derivative liability for embedded conversion feature308 308 
Unamortized debt issuance costs(1,687)(1,794)
Carrying balance$38,621 $38,514 
Schedule of Debt Related Interest
The following table reflects debt-related interest included in Interest expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2024 and 2023 (in thousands):

Three Months Ended March 31,
20242023
Interest on 2027 Convertible Notes$650$975
Amortization of debt issuance costs107147
Total interest expense$757$1,122
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
OTHER LONG-TERM LIABILITIES (Tables)
 3 Months Ended
Mar. 31, 2024
Other Liabilities Disclosure [Abstract]  
Schedule of Other Long-term Liabilities
The following table reflects other long-term liabilities as of March 31, 2024 and December 31, 2023 (in thousands):
 March 31, 2024December 31, 2023
ROLVEDON product royalties$9,224 $9,224 
Noncurrent operating lease liabilities1,350 1,470 
Liability for uncertain tax provisions4,620 4,553 
Deferred employee retention credits1,212 1,212 
Total other long-term liabilities$16,406 $16,459 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Lease Expense
The following table reflects lease expense and income for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
Financial Statement Classification20242023
Operating lease costSelling, general and administrative expenses$66 $39 
The following table reflects supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Cash paid for amounts included in measurement of liabilities:
Operating cash flows from operating leases$282 $104 
Schedule of Supplemental Balance Sheet Information
The following table reflects supplemental balance sheet information related to leases as of March 31, 2024 and December 31, 2023 (in thousands):
Financial Statement ClassificationMarch 31, 2024December 31, 2023
Assets
Operating lease right-of-use assetsOther long-term assets$1,234 $1,269 
Liabilities
Current operating lease liabilitiesOther current liabilities$797 $928 
Noncurrent operating lease liabilitiesOther long-term liabilities1,350 1,470 
Total lease liabilities$2,147 $2,398 
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Calculation of Basic and Diluted Earnings Per Common Share
The following table reflects the calculation of basic and diluted loss per common share for the three months ended March 31, 2024 and 2023 (in thousands, except for per share amounts):

 Three Months Ended March 31,
20242023
Basic and diluted net loss per share
Net loss$(4,510)$(3,484)
Weighted-average common shares outstanding94,980 51,005 
Basic and diluted net loss per share$(0.05)$(0.07)
Schedule of Potentially Dilutive Common Shares
The following table reflects outstanding potentially dilutive common shares that are not included in the computation of diluted net loss per share, because to do so would be anti-dilutive, for the three months ended March 31, 2024 and 2023 (in thousands):
 Three Months Ended March 31,
20242023
Convertible notes9,768 14,489 
Stock-based awards and equivalents8,422 8,271 
Total potentially dilutive common shares18,190 22,760 
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following table reflects the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):

March 31, 2024Financial Statement ClassificationLevel 1Level 2Level 3Total
Assets:
U.S. TreasuriesCash and cash equivalents$— $36,518 $— $36,518 
U.S. Government agenciesCash and cash equivalents— 2,750 — 2,750 
Money market fundsCash and cash equivalents40,168 — — 40,168 
Total$40,168 $39,268 $— $79,436 
Liabilities:
Short-term contingent considerationContingent consideration, current portion$— $— $2,700 $2,700 
Derivative liabilityLong-term debt— — 308 308 
Total$— $— $3,008 $3,008 

December 31, 2023Financial Statement ClassificationLevel 1Level 2Level 3Total
Assets:
U.S. TreasuriesCash and cash equivalents$— $35,458 $— $35,458 
U.S. Government agenciesCash and cash equivalents— 3,294 — 3,294 
Money market fundsCash and cash equivalents32,534 — — 32,534 
Total$32,534 $38,752 $— $71,286 
Liabilities:
Short-term contingent considerationContingent consideration, current portion$— $— $2,700 $2,700 
Derivative liabilityLong-term debt— — 308 308 
Total$— $— $3,008 $3,008 
Schedule of Changes in Fair Value
The following table summarizes changes in fair value of the Company’s contingent consideration obligations that are measured on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2024 and 2023 (in thousands):

 Three Months Ended March 31,
20242023
Fair value, beginning of the period$2,700 $48,500 
Change in fair value of contingent consideration recorded within costs and expenses— 9,167 
Cash payment related to contingent consideration— (6,609)
Fair value, end of the period$2,700 $51,058 
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RESTRUCTURING CHARGES (Tables)
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Schedule of Accrued Restructuring and Severance Costs
The following table summarizes the changes in the Company’s accrued restructuring liability for employee compensation costs, which is classified within Accrued liabilities in the Condensed Consolidated Balance Sheets (in thousands):
 Employee compensation costs
Balance as of December 31, 2023$4,378 
Restructuring charges720 
Cash paid(1,730)
Balance as of March 31, 2024$3,368 
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACQUISITIONS - Narrative (Details) - Spectrum Pharmaceuticals, Inc.
$ / shares in Units, $ in Millions
 3 Months Ended
Jul. 31, 2023
USD ($)
$ / shares
Mar. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
Dec. 31, 2024
USD ($)
$ / shares
Business Acquisition [Line Items]        
Business acquisition, fixed exchange ratio 0.1783      
Business acquisition, contingent consideration, per share, maximum (in dollars per share) | $ / shares $ 0.20      
Acquired finite-lived intangible assets, useful life 10 years      
Acquisition costs related to the transaction   $ 0.0    
ROLVEDON        
Business Acquisition [Line Items]        
Business combination, contingent consideration arrangements, range of outcomes, value, high $ 44.7      
ROLVEDON | Forecast        
Business Acquisition [Line Items]        
Business acquisition, contingent consideration, per share, maximum (in dollars per share) | $ / shares     $ 0.10 $ 0.10
Business combination, contingent consideration arrangements, range of outcomes, value, high     $ 225.0 $ 175.0
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACQUISITIONS - Acquisition Date Fair Value of Consideration Transferred (Details) - Spectrum Pharmaceuticals, Inc. - USD ($)
$ / shares in Units, $ in Thousands
Jul. 31, 2023
Mar. 31, 2024
Dec. 31, 2023
Business Acquisition [Line Items]      
Assertio shares issued (in shares) 38,013,000    
Assertio closing price per share as of the Effective Date (in dollars per share) $ 5.69    
Fair value of Assertio shares issued $ 216,294    
Repayment of Spectrum's long-term debt 32,647    
CVRs 3,932 $ 0 $ 0
Total fair value of consideration transferred $ 252,873    
Business combination, contingent consideration liability, number of shares (in shares) 223,397    
Business acquisition, contingent consideration, per share (in dollars per share) $ 0.0176    
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACQUISITIONS - Fair Values of Assets Acquired and Liabilities Assumed (Details) - Spectrum Pharmaceuticals, Inc. - USD ($)
$ in Thousands
 5 Months Ended
Dec. 31, 2023
Jul. 31, 2023
Assets:    
Cash and cash equivalents $ 34,600 $ 34,600
Marketable securities 2,194 2,194
Accounts receivable 50,975 50,975
Inventories 22,305 22,244
Prepaid and other current assets 1,985 1,287
Property and equipment 100 100
Intangible assets 220,500 234,000
Other long-term assets 1,396 1,396
Total 334,055 346,796
Liabilities:    
Accounts payable 10,108 10,108
Accrued rebates, returns and discounts 21,025 21,025
Accrued liabilities 34,166 36,509
Other current liabilities 784 784
Deferred taxes 3,996 34,250
Other long-term liabilities 11,103 11,103
Total 81,182 113,779
Total Spectrum net assets acquired 252,873 233,017
Goodwill 0 $ 19,856
Adjustments to Purchase Price Allocation to Fair Value    
Inventories 61  
Prepaid and other current assets 698  
Intangible assets (13,500)  
Total (12,741)  
Accrued liabilities (2,343)  
Deferred taxes (30,254)  
Total (32,597)  
Total Spectrum net assets acquired 19,856  
Goodwill $ (19,856)  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACQUISITIONS - Unaudited Pro Forma Financial Information (Details) - Spectrum Pharmaceuticals, Inc.
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Business Acquisition [Line Items]  
Total revenues $ 58,081
Net loss $ (13,944)
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE - Schedule of Disaggregated Revenue from Contracts with Customers (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Total revenues $ 32,448 $ 42,466
Total product sales, net    
Disaggregation of Revenue [Line Items]    
Total revenues 31,862 41,769
ROLVEDON    
Disaggregation of Revenue [Line Items]    
Total revenues 14,478 0
INDOCIN products    
Disaggregation of Revenue [Line Items]    
Total revenues 8,682 30,346
Sympazan    
Disaggregation of Revenue [Line Items]    
Total revenues 2,617 2,502
Otrexup    
Disaggregation of Revenue [Line Items]    
Total revenues 2,882 2,822
SPRIX    
Disaggregation of Revenue [Line Items]    
Total revenues 1,437 1,889
CAMBIA    
Disaggregation of Revenue [Line Items]    
Total revenues 1,256 2,264
Other products    
Disaggregation of Revenue [Line Items]    
Total revenues 510 1,946
Royalties and milestone revenue    
Disaggregation of Revenue [Line Items]    
Total revenues $ 586 $ 697
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE - Narratives (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Royalties and milestone revenue    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Revenue recognized $ 0.0 $ 0.2
Canada | CAMBIA    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Revenue recognized $ 0.6 $ 0.5
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCOUNTS RECEIVABLES, NET (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Receivables [Abstract]    
Allowance for cash discounts for prompt payment $ 0.4 $ 0.9
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES, NET - Schedule of Inventories, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory    
Raw materials $ 18,872 $ 10,537
Work-in-process 2,452 2,239
Finished goods 17,278 24,910
Total inventories, net $ 38,602 $ 37,686
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES, NET - Narrative (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Inventory reserves $ 7.3 $ 6.8
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PREPAID AND OTHER CURRENT ASSETS (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid assets and deposits $ 10,222 $ 11,973
Other current assets 297 299
Total prepaid and other current assets $ 10,519 $ 12,272
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PREPAID AND OTHER CURRENT ASSETS - Narrative (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Credit loss allowance $ 3.5 $ 3.5
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 5,401 $ 5,401
Less: Accumulated depreciation (4,697) (4,631)
Property and equipment, net 704 770
Furniture and office equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,908 1,908
Laboratory equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 20 20
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3,473 2,945
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 0 $ 528
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PROPERTY AND EQUIPMENT, NET - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 0.1 $ 0.2
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Intangible assets    
Gross Carrying Amount $ 192,598 $ 472,236
Accumulated Amortization (86,897) (81,265)
Impairment   (279,639)
Total $ 105,701 111,332
ROLVEDON | Product Rights    
Intangible assets    
Remaining Useful Life (In years) 9 years 3 months 18 days  
Gross Carrying Amount $ 63,405 220,500
Accumulated Amortization (6,787) (5,270)
Impairment   (157,095)
Total $ 56,618 58,135
INDOCIN | Product Rights    
Intangible assets    
Remaining Useful Life (In years) 1 year 9 months 18 days  
Gross Carrying Amount $ 65,606 154,100
Accumulated Amortization (47,413) (44,814)
Impairment   (88,494)
Total $ 18,193 20,792
Sympazan | Product Rights    
Intangible assets    
Remaining Useful Life (In years) 10 years 7 months 6 days  
Gross Carrying Amount $ 14,550 14,550
Accumulated Amortization (1,718) (1,415)
Impairment   0
Total $ 12,832 13,135
Otrexup | Product Rights    
Intangible assets    
Remaining Useful Life (In years) 5 years 8 months 12 days  
Gross Carrying Amount $ 16,364 44,086
Accumulated Amortization (10,364) (10,103)
Impairment   (27,723)
Total $ 6,000 6,260
SPRIX | Product Rights    
Intangible assets    
Remaining Useful Life (In years) 3 years 1 month 6 days  
Gross Carrying Amount $ 32,673 39,000
Accumulated Amortization (20,615) (19,663)
Impairment   (6,327)
Total $ 12,058 $ 13,010
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization expense $ 5,631 $ 6,284
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INTANGIBLE ASSETS - Summary of Future Amortization Expense of Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
2024 (remainder) $ 16,894  
2025 22,526  
2026 12,130  
2027 9,909  
2028 8,322  
Thereafter 35,920  
Total $ 105,701 $ 111,332
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
OTHER LONG-TERM ASSETS (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Operating lease right-of-use assets $ 1,234 $ 1,269
Prepaid asset and deposits 1,155 1,289
Other 697 697
Total other long-term assets $ 3,086 $ 3,255
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCRUED LIABILITIES (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]    
Accrued compensation $ 1,452 $ 2,438
Accrued restructuring costs 3,368 4,378
Other accrued liabilities 9,123 9,492
Interest payable 217 867
Accrued royalties 1,241 1,038
Total accrued liabilities $ 15,401 $ 18,213
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Aug. 22, 2022
Debt Instrument [Line Items]        
Plus: derivative liability for embedded conversion feature $ 308 $ 308    
Less: unamortized debt issuance costs (1,687) (1,794)    
Carrying value 38,621 38,514    
Less: current portion of long-term debt 0 0    
Long-term debt, net $ 38,621 38,514    
Convertible Notes        
Debt Instrument [Line Items]        
Less: unamortized debt issuance costs     $ (1,600)  
Convertible Notes | 6.5% Convertible Senior Secured Notes due 2027 principal amount        
Debt Instrument [Line Items]        
Interest rate (as a percent) 6.50%     6.50%
Gross, long-term debt $ 40,000 40,000    
Plus: derivative liability for embedded conversion feature $ 308 $ 308    
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Narrative (Details)
 3 Months Ended
Feb. 27, 2023
USD ($)
Aug. 22, 2022
USD ($)
$ / shares
Rate
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Debt Instrument [Line Items]        
Direct transaction costs     $ 0 $ 9,918,000
Senior Notes        
Debt Instrument [Line Items]        
Amortization of debt issuance costs     $ 107,000 147,000
6.5% Convertible Senior Secured Notes due 2027 principal amount | Convertible Notes        
Debt Instrument [Line Items]        
Interest rate (as a percent)   6.50% 6.50%  
Aggregate principal amount $ 30,000,000 $ 60,000,000    
Additional purchase capacity   $ 10,000,000    
Number of days to cover over allotment (in days)   13 days    
Induced conversion of convertible debt expense 8,800,000      
Direct transaction costs $ 1,100,000      
Conversion ratio   0.2442003    
Conversion price (in dollars per share) | $ / shares   $ 4.09    
Effective interest rate (as a percent) | Rate   7.80%    
Amortization of debt issuance costs     $ 100,000 $ 100,000
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Schedule of Carrying Values Convertible Notes (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Derivative liability for embedded conversion feature $ 308 $ 308
6.5% Convertible Senior Secured Notes due 2027 principal amount | Convertible Notes    
Debt Instrument [Line Items]    
Principal balance 40,000 40,000
Derivative liability for embedded conversion feature 308 308
Unamortized debt issuance costs (1,687) (1,794)
Carrying balance $ 38,621 $ 38,514
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Schedule of Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Debt Instrument [Line Items]    
Total interest expense $ 757 $ 1,122
Senior Notes    
Debt Instrument [Line Items]    
Amortization of debt issuance costs 107 147
Senior Notes | Interest on 2027 Convertible Notes    
Debt Instrument [Line Items]    
Interest payable on notes $ 650 $ 975
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
OTHER LONG-TERM LIABILITIES (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Other Liabilities Disclosure [Abstract]    
ROLVEDON product royalties $ 9,224 $ 9,224
Noncurrent operating lease liabilities 1,350 1,470
Liability for uncertain tax provisions 4,620 4,553
Deferred employee retention credits 1,212 1,212
Other long-term liabilities $ 16,406 $ 16,459
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Restricted Stock Units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Awards granted (in shares) 0.9 0.5
Average fair market value (in dollars per share) $ 0.80 $ 5.15
Options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted (in shares) 3.0 0.6
Average market fair value (in dollars per share) $ 0.77 $ 4.39
Selling, General and Administrative Expenses    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 1.2 $ 2.4
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Lease Cost Components (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Selling, general and administrative expenses    
Lessee, Lease, Description [Line Items]    
Operating lease cost $ 66 $ 39
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Supplemental Cash Flow and Other Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash paid for amounts included in measurement of liabilities:    
Operating cash flows from operating leases $ 282 $ 104
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets    
Operating lease right-of-use assets $ 1,234 $ 1,269
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other long-term assets Other long-term assets
Liabilities    
Current operating lease liabilities $ 797 $ 928
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Other current liabilities Other current liabilities
Noncurrent operating lease liabilities $ 1,350 $ 1,470
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other long-term liabilities Other long-term liabilities
Total lease liabilities $ 2,147 $ 2,398
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES - Supply Agreements (Details) - Supply Agreement
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Supply Commitment [Line Items]  
Purchase obligation, percentage 75.00%
JHS  
Supply Commitment [Line Items]  
Annual purchase obligation $ 1.5
Antares  
Supply Commitment [Line Items]  
Annual purchase obligation 2.0
Hanmi  
Supply Commitment [Line Items]  
Purchase obligation in 2024 19.1
Purchase obligation in 2025 3.8
Purchase of inventory $ 8.4
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES - Legal Matters (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]    
Legal contingency accrual $ 3.2 $ 3.2
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES - Glumetza Antitrust Litigation (Details) - USD ($)
$ in Thousands
Feb. 03, 2022
Sep. 14, 2021
Glumetza Antitrust Litigation    
Loss Contingencies [Line Items]    
Settlement amount $ 3,850 $ 3,150
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES - Insurance Litigation (Details) - USD ($)
$ in Millions
 3 Months Ended
Jun. 30, 2022
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]    
Insurance reimbursement $ 2.0 $ 5.0
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHAREHOLDERS EQUITY (Details) - USD ($)
$ in Thousands, shares in Millions
 3 Months Ended
Jul. 31, 2023
Mar. 31, 2023
Mar. 31, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unamortized issuance costs     $ 1,687 $ 1,794
Spectrum Pharmaceuticals, Inc.        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Issuance of common stock (in shares) 38.0      
Additional Paid-In Capital        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Induced exchange of convertible notes, gross   $ 28,300    
Convertible Notes        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unamortized issuance costs   1,600    
6.5% Convertible Senior Secured Notes due 2027 principal amount | Convertible Notes        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Proceeds from the issuance of common stock   $ 10,500    
Induced exchange of convertible notes (in shares)   7.0    
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE - Schedule of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Net loss $ (4,510) $ (3,484)
Weighted-average common shares outstanding, basic (in shares) 94,980 51,005
Weighted-average common shares outstanding, diluted (in shares) 94,980 51,005
Basic net loss per share (in dollars per share) $ (0.05) $ (0.07)
Diluted net loss per share (in dollars per share) $ (0.05) $ (0.07)
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE - Schedule of Potentially Dilutive Common Shares (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive common shares (in shares) 18,190 22,760
Convertible notes    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive common shares (in shares) 9,768 14,489
Stock-based awards and equivalents    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive common shares (in shares) 8,422 8,271
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Liabilities:    
Short-term contingent consideration $ 2,700 $ 2,700
Derivative liability 308 308
Recurring    
ASSETS    
Total 79,436 71,286
Liabilities:    
Short-term contingent consideration 2,700 2,700
Derivative liability 308 308
Total 3,008 3,008
Recurring | U.S. Treasuries    
ASSETS    
Cash and cash equivalents 36,518 35,458
Recurring | U.S. Government agencies    
ASSETS    
Cash and cash equivalents 2,750 3,294
Recurring | Money market funds    
ASSETS    
Cash and cash equivalents 40,168 32,534
Recurring | Level 1    
ASSETS    
Total 40,168 32,534
Liabilities:    
Short-term contingent consideration 0 0
Derivative liability 0 0
Total 0 0
Recurring | Level 1 | U.S. Treasuries    
ASSETS    
Cash and cash equivalents 0 0
Recurring | Level 1 | U.S. Government agencies    
ASSETS    
Cash and cash equivalents 0 0
Recurring | Level 1 | Money market funds    
ASSETS    
Cash and cash equivalents 40,168 32,534
Recurring | Level 2    
ASSETS    
Total 39,268 38,752
Liabilities:    
Short-term contingent consideration 0 0
Derivative liability 0 0
Total 0 0
Recurring | Level 2 | U.S. Treasuries    
ASSETS    
Cash and cash equivalents 36,518 35,458
Recurring | Level 2 | U.S. Government agencies    
ASSETS    
Cash and cash equivalents 2,750 3,294
Recurring | Level 2 | Money market funds    
ASSETS    
Cash and cash equivalents 0 0
Recurring | Level 3    
ASSETS    
Total 0 0
Liabilities:    
Short-term contingent consideration 2,700 2,700
Derivative liability 308 308
Total 3,008 3,008
Recurring | Level 3 | U.S. Treasuries    
ASSETS    
Cash and cash equivalents 0 0
Recurring | Level 3 | U.S. Government agencies    
ASSETS    
Cash and cash equivalents 0 0
Recurring | Level 3 | Money market funds    
ASSETS    
Cash and cash equivalents $ 0 $ 0
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE - Narrative (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Rate
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jul. 31, 2023
USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]        
Change in fair value of contingent consideration $ 0 $ 9,167    
Derivative liability 308   $ 308  
Change in fair value of embedded derivative liability 0 $ 0    
Level 2        
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]        
Debt conversion option value 33,800   35,700  
Convertible notes, par value $ 40,000   40,000  
Revenue Volatility        
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]        
Contingent consideration, measurement input 0.15      
Discounted Cash Flow | Discount Rate        
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]        
Contingent consideration, measurement input 0.055      
Discounted Cash Flow | Credit Spread        
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]        
Contingent consideration, measurement input 0.092      
Option Pricing Model | Credit Spread        
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]        
Embedded derivative liability, measurement input 0.088      
INDOCIN        
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]        
Contingent consideration $ 2,700   2,700  
Contingent payment consideration, future royalties covenant, product net sales (over) $ 20,000      
Contingent consideration, royalty percentage | Rate 20.00%      
Spectrum Pharmaceuticals, Inc.        
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]        
Contingent consideration $ 0   $ 0 $ 3,932
Change in fair value of contingent consideration $ 0      
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE - Schedule of Changes in Fair Value (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Change in fair value of contingent consideration recorded within costs and expenses [Extensible Enumeration] Costs and Expenses Costs and Expenses
Level 3 | Contingent Consideration    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value, beginning of the period $ 2,700 $ 48,500
Change in fair value of contingent consideration recorded within costs and expenses 0 9,167
Cash payment related to contingent consideration 0 (6,609)
Fair value, end of the period $ 2,700 $ 51,058
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Income tax expense $ 132 $ (2,110)
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RESTRUCTURING CHARGES - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]      
Restructuring charges $ 720,000 $ 0  
Employee compensation costs      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges 720,000    
Employee compensation costs | Chief Executive Officer      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges     $ 1,500,000
Spectrum Reorganization Plan | Employee compensation costs      
Restructuring Cost and Reserve [Line Items]      
Cost incurred, cumulative $ 3,300,000    
Spectrum Reorganization Plan | Facility exit costs      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges     1,300,000
Restructuring and related cost, expected cost remaining     $ 0
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RESTRUCTURING CHARGES - Schedule of Accrued Restructuring Costs (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Accrued restructuring and severance costs rollforward    
Restructuring charges $ 720 $ 0
Employee compensation costs    
Accrued restructuring and severance costs rollforward    
Balance at beginning of period 4,378  
Restructuring charges 720  
Cash paid (1,730)  
Balance at end of period $ 3,368  
EXCEL 93 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 94 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 95 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 97 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 158 290 1 false 51 0 false 5 false false R1.htm 0000001 - Document - COVER PAGE Sheet http://www.assertiotx.com/role/COVERPAGE COVER PAGE Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.assertiotx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 0000008 - Disclosure - ACQUISITIONS Sheet http://www.assertiotx.com/role/ACQUISITIONS ACQUISITIONS Notes 8 false false R9.htm 0000009 - Disclosure - REVENUE Sheet http://www.assertiotx.com/role/REVENUE REVENUE Notes 9 false false R10.htm 0000010 - Disclosure - ACCOUNTS RECEIVABLES, NET Sheet http://www.assertiotx.com/role/ACCOUNTSRECEIVABLESNET ACCOUNTS RECEIVABLES, NET Notes 10 false false R11.htm 0000011 - Disclosure - INVENTORIES, NET Sheet http://www.assertiotx.com/role/INVENTORIESNET INVENTORIES, NET Notes 11 false false R12.htm 0000012 - Disclosure - PREPAID AND OTHER CURRENT ASSETS Sheet http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETS PREPAID AND OTHER CURRENT ASSETS Notes 12 false false R13.htm 0000013 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNET PROPERTY AND EQUIPMENT, NET Notes 13 false false R14.htm 0000014 - Disclosure - INTANGIBLE ASSETS Sheet http://www.assertiotx.com/role/INTANGIBLEASSETS INTANGIBLE ASSETS Notes 14 false false R15.htm 0000015 - Disclosure - OTHER LONG-TERM ASSETS Sheet http://www.assertiotx.com/role/OTHERLONGTERMASSETS OTHER LONG-TERM ASSETS Notes 15 false false R16.htm 0000016 - Disclosure - ACCRUED LIABILITIES Sheet http://www.assertiotx.com/role/ACCRUEDLIABILITIES ACCRUED LIABILITIES Notes 16 false false R17.htm 0000017 - Disclosure - DEBT Sheet http://www.assertiotx.com/role/DEBT DEBT Notes 17 false false R18.htm 0000018 - Disclosure - OTHER LONG-TERM LIABILITIES Sheet http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIES OTHER LONG-TERM LIABILITIES Notes 18 false false R19.htm 0000019 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.assertiotx.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 19 false false R20.htm 0000020 - Disclosure - LEASES Sheet http://www.assertiotx.com/role/LEASES LEASES Notes 20 false false R21.htm 0000021 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 21 false false R22.htm 0000022 - Disclosure - SHAREHOLDERS EQUITY Sheet http://www.assertiotx.com/role/SHAREHOLDERSEQUITY SHAREHOLDERS EQUITY Notes 22 false false R23.htm 0000023 - Disclosure - NET LOSS PER SHARE Sheet http://www.assertiotx.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 23 false false R24.htm 0000024 - Disclosure - FAIR VALUE Sheet http://www.assertiotx.com/role/FAIRVALUE FAIR VALUE Notes 24 false false R25.htm 0000025 - Disclosure - INCOME TAXES Sheet http://www.assertiotx.com/role/INCOMETAXES INCOME TAXES Notes 25 false false R26.htm 0000026 - Disclosure - RESTRUCTURING CHARGES Sheet http://www.assertiotx.com/role/RESTRUCTURINGCHARGES RESTRUCTURING CHARGES Notes 26 false false R27.htm 9954471 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.assertiotx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 27 false false R28.htm 9954472 - Disclosure - ACQUISITIONS (Tables) Sheet http://www.assertiotx.com/role/ACQUISITIONSTables ACQUISITIONS (Tables) Tables http://www.assertiotx.com/role/ACQUISITIONS 28 false false R29.htm 9954473 - Disclosure - REVENUE (Tables) Sheet http://www.assertiotx.com/role/REVENUETables REVENUE (Tables) Tables http://www.assertiotx.com/role/REVENUE 29 false false R30.htm 9954474 - Disclosure - INVENTORIES, NET (Tables) Sheet http://www.assertiotx.com/role/INVENTORIESNETTables INVENTORIES, NET (Tables) Tables http://www.assertiotx.com/role/INVENTORIESNET 30 false false R31.htm 9954475 - Disclosure - PREPAID AND OTHER CURRENT ASSETS (Tables) Sheet http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSTables PREPAID AND OTHER CURRENT ASSETS (Tables) Tables http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETS 31 false false R32.htm 9954476 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNET 32 false false R33.htm 9954477 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://www.assertiotx.com/role/INTANGIBLEASSETSTables INTANGIBLE ASSETS (Tables) Tables http://www.assertiotx.com/role/INTANGIBLEASSETS 33 false false R34.htm 9954478 - Disclosure - OTHER LONG-TERM ASSETS (Tables) Sheet http://www.assertiotx.com/role/OTHERLONGTERMASSETSTables OTHER LONG-TERM ASSETS (Tables) Tables http://www.assertiotx.com/role/OTHERLONGTERMASSETS 34 false false R35.htm 9954479 - Disclosure - ACCRUED LIABILITIES (Tables) Sheet http://www.assertiotx.com/role/ACCRUEDLIABILITIESTables ACCRUED LIABILITIES (Tables) Tables http://www.assertiotx.com/role/ACCRUEDLIABILITIES 35 false false R36.htm 9954480 - Disclosure - DEBT (Tables) Sheet http://www.assertiotx.com/role/DEBTTables DEBT (Tables) Tables http://www.assertiotx.com/role/DEBT 36 false false R37.htm 9954481 - Disclosure - OTHER LONG-TERM LIABILITIES (Tables) Sheet http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESTables OTHER LONG-TERM LIABILITIES (Tables) Tables http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIES 37 false false R38.htm 9954482 - Disclosure - LEASES (Tables) Sheet http://www.assertiotx.com/role/LEASESTables LEASES (Tables) Tables http://www.assertiotx.com/role/LEASES 38 false false R39.htm 9954483 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.assertiotx.com/role/NETLOSSPERSHARETables NET LOSS PER SHARE (Tables) Tables http://www.assertiotx.com/role/NETLOSSPERSHARE 39 false false R40.htm 9954484 - Disclosure - FAIR VALUE (Tables) Sheet http://www.assertiotx.com/role/FAIRVALUETables FAIR VALUE (Tables) Tables http://www.assertiotx.com/role/FAIRVALUE 40 false false R41.htm 9954485 - Disclosure - RESTRUCTURING CHARGES (Tables) Sheet http://www.assertiotx.com/role/RESTRUCTURINGCHARGESTables RESTRUCTURING CHARGES (Tables) Tables http://www.assertiotx.com/role/RESTRUCTURINGCHARGES 41 false false R42.htm 9954486 - Disclosure - ACQUISITIONS - Narrative (Details) Sheet http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails ACQUISITIONS - Narrative (Details) Details 42 false false R43.htm 9954487 - Disclosure - ACQUISITIONS - Acquisition Date Fair Value of Consideration Transferred (Details) Sheet http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails ACQUISITIONS - Acquisition Date Fair Value of Consideration Transferred (Details) Details 43 false false R44.htm 9954488 - Disclosure - ACQUISITIONS - Fair Values of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails ACQUISITIONS - Fair Values of Assets Acquired and Liabilities Assumed (Details) Details 44 false false R45.htm 9954489 - Disclosure - ACQUISITIONS - Unaudited Pro Forma Financial Information (Details) Sheet http://www.assertiotx.com/role/ACQUISITIONSUnauditedProFormaFinancialInformationDetails ACQUISITIONS - Unaudited Pro Forma Financial Information (Details) Details 45 false false R46.htm 9954490 - Disclosure - REVENUE - Schedule of Disaggregated Revenue from Contracts with Customers (Details) Sheet http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails REVENUE - Schedule of Disaggregated Revenue from Contracts with Customers (Details) Details 46 false false R47.htm 9954491 - Disclosure - REVENUE - Narratives (Details) Sheet http://www.assertiotx.com/role/REVENUENarrativesDetails REVENUE - Narratives (Details) Details 47 false false R48.htm 9954492 - Disclosure - ACCOUNTS RECEIVABLES, NET (Details) Sheet http://www.assertiotx.com/role/ACCOUNTSRECEIVABLESNETDetails ACCOUNTS RECEIVABLES, NET (Details) Details http://www.assertiotx.com/role/ACCOUNTSRECEIVABLESNET 48 false false R49.htm 9954493 - Disclosure - INVENTORIES, NET - Schedule of Inventories, Net (Details) Sheet http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails INVENTORIES, NET - Schedule of Inventories, Net (Details) Details 49 false false R50.htm 9954494 - Disclosure - INVENTORIES, NET - Narrative (Details) Sheet http://www.assertiotx.com/role/INVENTORIESNETNarrativeDetails INVENTORIES, NET - Narrative (Details) Details 50 false false R51.htm 9954495 - Disclosure - PREPAID AND OTHER CURRENT ASSETS (Details) Sheet http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSDetails PREPAID AND OTHER CURRENT ASSETS (Details) Details http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSTables 51 false false R52.htm 9954496 - Disclosure - PREPAID AND OTHER CURRENT ASSETS - Narrative (Details) Sheet http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSNarrativeDetails PREPAID AND OTHER CURRENT ASSETS - Narrative (Details) Details 52 false false R53.htm 9954497 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment (Details) Sheet http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment (Details) Details 53 false false R54.htm 9954498 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details) Sheet http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails PROPERTY AND EQUIPMENT, NET - Narrative (Details) Details 54 false false R55.htm 9954499 - Disclosure - INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) Sheet http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) Details 55 false false R56.htm 9954500 - Disclosure - INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.assertiotx.com/role/INTANGIBLEASSETSNarrativeDetails INTANGIBLE ASSETS - Narrative (Details) Details 56 false false R57.htm 9954501 - Disclosure - INTANGIBLE ASSETS - Summary of Future Amortization Expense of Intangible Assets (Details) Sheet http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails INTANGIBLE ASSETS - Summary of Future Amortization Expense of Intangible Assets (Details) Details 57 false false R58.htm 9954502 - Disclosure - OTHER LONG-TERM ASSETS (Details) Sheet http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails OTHER LONG-TERM ASSETS (Details) Details http://www.assertiotx.com/role/OTHERLONGTERMASSETSTables 58 false false R59.htm 9954503 - Disclosure - ACCRUED LIABILITIES (Details) Sheet http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails ACCRUED LIABILITIES (Details) Details http://www.assertiotx.com/role/ACCRUEDLIABILITIESTables 59 false false R60.htm 9954504 - Disclosure - DEBT - Schedule of Long-term Debt (Details) Sheet http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails DEBT - Schedule of Long-term Debt (Details) Details 60 false false R61.htm 9954505 - Disclosure - DEBT - Narrative (Details) Sheet http://www.assertiotx.com/role/DEBTNarrativeDetails DEBT - Narrative (Details) Details 61 false false R62.htm 9954506 - Disclosure - DEBT - Schedule of Carrying Values Convertible Notes (Details) Notes http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails DEBT - Schedule of Carrying Values Convertible Notes (Details) Details 62 false false R63.htm 9954507 - Disclosure - DEBT - Schedule of Interest Expense (Details) Sheet http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails DEBT - Schedule of Interest Expense (Details) Details 63 false false R64.htm 9954508 - Disclosure - OTHER LONG-TERM LIABILITIES (Details) Sheet http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails OTHER LONG-TERM LIABILITIES (Details) Details http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESTables 64 false false R65.htm 9954509 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails STOCK-BASED COMPENSATION (Details) Details http://www.assertiotx.com/role/STOCKBASEDCOMPENSATION 65 false false R66.htm 9954510 - Disclosure - LEASES - Lease Cost Components (Details) Sheet http://www.assertiotx.com/role/LEASESLeaseCostComponentsDetails LEASES - Lease Cost Components (Details) Details 66 false false R67.htm 9954511 - Disclosure - LEASES - Supplemental Cash Flow and Other Information (Details) Sheet http://www.assertiotx.com/role/LEASESSupplementalCashFlowandOtherInformationDetails LEASES - Supplemental Cash Flow and Other Information (Details) Details 67 false false R68.htm 9954512 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) Sheet http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails LEASES - Supplemental Balance Sheet Information (Details) Details 68 false false R69.htm 9954513 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supply Agreements (Details) Sheet http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails COMMITMENTS AND CONTINGENCIES - Supply Agreements (Details) Details 69 false false R70.htm 9954514 - Disclosure - COMMITMENTS AND CONTINGENCIES - Legal Matters (Details) Sheet http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESLegalMattersDetails COMMITMENTS AND CONTINGENCIES - Legal Matters (Details) Details 70 false false R71.htm 9954515 - Disclosure - COMMITMENTS AND CONTINGENCIES - Glumetza Antitrust Litigation (Details) Sheet http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESGlumetzaAntitrustLitigationDetails COMMITMENTS AND CONTINGENCIES - Glumetza Antitrust Litigation (Details) Details 71 false false R72.htm 9954516 - Disclosure - COMMITMENTS AND CONTINGENCIES - Insurance Litigation (Details) Sheet http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESInsuranceLitigationDetails COMMITMENTS AND CONTINGENCIES - Insurance Litigation (Details) Details 72 false false R73.htm 9954517 - Disclosure - SHAREHOLDERS EQUITY (Details) Sheet http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails SHAREHOLDERS EQUITY (Details) Details http://www.assertiotx.com/role/SHAREHOLDERSEQUITY 73 false false R74.htm 9954518 - Disclosure - NET LOSS PER SHARE - Schedule of Earnings Per Share (Details) Sheet http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofEarningsPerShareDetails NET LOSS PER SHARE - Schedule of Earnings Per Share (Details) Details 74 false false R75.htm 9954519 - Disclosure - NET LOSS PER SHARE - Schedule of Potentially Dilutive Common Shares (Details) Sheet http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails NET LOSS PER SHARE - Schedule of Potentially Dilutive Common Shares (Details) Details 75 false false R76.htm 9954520 - Disclosure - FAIR VALUE - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details) Sheet http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails FAIR VALUE - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details) Details 76 false false R77.htm 9954521 - Disclosure - FAIR VALUE - Narrative (Details) Sheet http://www.assertiotx.com/role/FAIRVALUENarrativeDetails FAIR VALUE - Narrative (Details) Details 77 false false R78.htm 9954522 - Disclosure - FAIR VALUE - Schedule of Changes in Fair Value (Details) Sheet http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails FAIR VALUE - Schedule of Changes in Fair Value (Details) Details 78 false false R79.htm 9954523 - Disclosure - INCOME TAXES (Details) Sheet http://www.assertiotx.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.assertiotx.com/role/INCOMETAXES 79 false false R80.htm 9954524 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details) Sheet http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails RESTRUCTURING CHARGES - Narrative (Details) Details 80 false false R81.htm 9954525 - Disclosure - RESTRUCTURING CHARGES - Schedule of Accrued Restructuring Costs (Details) Sheet http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails RESTRUCTURING CHARGES - Schedule of Accrued Restructuring Costs (Details) Details 81 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1 - asrt-20240331.htm 4 asrt-20240331.htm asrt-20240331.xsd asrt-20240331_cal.xml asrt-20240331_def.xml asrt-20240331_lab.xml asrt-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 100 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "asrt-20240331.htm": { "nsprefix": "asrt", "nsuri": "http://www.assertiotx.com/20240331", "dts": { "inline": { "local": [ "asrt-20240331.htm" ] }, "schema": { "local": [ "asrt-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "asrt-20240331_cal.xml" ] }, "definitionLink": { "local": [ "asrt-20240331_def.xml" ] }, "labelLink": { "local": [ "asrt-20240331_lab.xml" ] }, "presentationLink": { "local": [ "asrt-20240331_pre.xml" ] } }, "keyStandard": 259, "keyCustom": 31, "axisStandard": 24, "axisCustom": 0, "memberStandard": 31, "memberCustom": 19, "hidden": { "total": 14, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 9 }, "contextCount": 158, "entityCount": 1, "segmentCount": 51, "elementCount": 470, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 599, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://www.assertiotx.com/role/COVERPAGE", "longName": "0000001 - Document - COVER PAGE", "shortName": "COVER PAGE", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R5": { "role": "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R7": { "role": "http://www.assertiotx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.assertiotx.com/role/ACQUISITIONS", "longName": "0000008 - Disclosure - ACQUISITIONS", "shortName": "ACQUISITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.assertiotx.com/role/REVENUE", "longName": "0000009 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.assertiotx.com/role/ACCOUNTSRECEIVABLESNET", "longName": "0000010 - Disclosure - ACCOUNTS RECEIVABLES, NET", "shortName": "ACCOUNTS RECEIVABLES, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.assertiotx.com/role/INVENTORIESNET", "longName": "0000011 - Disclosure - INVENTORIES, NET", "shortName": "INVENTORIES, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETS", "longName": "0000012 - Disclosure - PREPAID AND OTHER CURRENT ASSETS", "shortName": "PREPAID AND OTHER CURRENT ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNET", "longName": "0000013 - Disclosure - PROPERTY AND EQUIPMENT, NET", "shortName": "PROPERTY AND EQUIPMENT, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.assertiotx.com/role/INTANGIBLEASSETS", "longName": "0000014 - Disclosure - INTANGIBLE ASSETS", "shortName": "INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.assertiotx.com/role/OTHERLONGTERMASSETS", "longName": "0000015 - Disclosure - OTHER LONG-TERM ASSETS", "shortName": "OTHER LONG-TERM ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.assertiotx.com/role/ACCRUEDLIABILITIES", "longName": "0000016 - Disclosure - ACCRUED LIABILITIES", "shortName": "ACCRUED LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.assertiotx.com/role/DEBT", "longName": "0000017 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIES", "longName": "0000018 - Disclosure - OTHER LONG-TERM LIABILITIES", "shortName": "OTHER LONG-TERM LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATION", "longName": "0000019 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.assertiotx.com/role/LEASES", "longName": "0000020 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000021 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.assertiotx.com/role/SHAREHOLDERSEQUITY", "longName": "0000022 - Disclosure - SHAREHOLDERS EQUITY", "shortName": "SHAREHOLDERS EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.assertiotx.com/role/NETLOSSPERSHARE", "longName": "0000023 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.assertiotx.com/role/FAIRVALUE", "longName": "0000024 - Disclosure - FAIR VALUE", "shortName": "FAIR VALUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.assertiotx.com/role/INCOMETAXES", "longName": "0000025 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.assertiotx.com/role/RESTRUCTURINGCHARGES", "longName": "0000026 - Disclosure - RESTRUCTURING CHARGES", "shortName": "RESTRUCTURING CHARGES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.assertiotx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.assertiotx.com/role/ACQUISITIONSTables", "longName": "9954472 - Disclosure - ACQUISITIONS (Tables)", "shortName": "ACQUISITIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.assertiotx.com/role/REVENUETables", "longName": "9954473 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.assertiotx.com/role/INVENTORIESNETTables", "longName": "9954474 - Disclosure - INVENTORIES, NET (Tables)", "shortName": "INVENTORIES, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSTables", "longName": "9954475 - Disclosure - PREPAID AND OTHER CURRENT ASSETS (Tables)", "shortName": "PREPAID AND OTHER CURRENT ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETTables", "longName": "9954476 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.assertiotx.com/role/INTANGIBLEASSETSTables", "longName": "9954477 - Disclosure - INTANGIBLE ASSETS (Tables)", "shortName": "INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.assertiotx.com/role/OTHERLONGTERMASSETSTables", "longName": "9954478 - Disclosure - OTHER LONG-TERM ASSETS (Tables)", "shortName": "OTHER LONG-TERM ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.assertiotx.com/role/ACCRUEDLIABILITIESTables", "longName": "9954479 - Disclosure - ACCRUED LIABILITIES (Tables)", "shortName": "ACCRUED LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.assertiotx.com/role/DEBTTables", "longName": "9954480 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESTables", "longName": "9954481 - Disclosure - OTHER LONG-TERM LIABILITIES (Tables)", "shortName": "OTHER LONG-TERM LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.assertiotx.com/role/LEASESTables", "longName": "9954482 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.assertiotx.com/role/NETLOSSPERSHARETables", "longName": "9954483 - Disclosure - NET LOSS PER SHARE (Tables)", "shortName": "NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.assertiotx.com/role/FAIRVALUETables", "longName": "9954484 - Disclosure - FAIR VALUE (Tables)", "shortName": "FAIR VALUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESTables", "longName": "9954485 - Disclosure - RESTRUCTURING CHARGES (Tables)", "shortName": "RESTRUCTURING CHARGES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails", "longName": "9954486 - Disclosure - ACQUISITIONS - Narrative (Details)", "shortName": "ACQUISITIONS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-30", "name": "asrt:BusinessAcquisitionFixedExchangeRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-30", "name": "asrt:BusinessAcquisitionFixedExchangeRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails", "longName": "9954487 - Disclosure - ACQUISITIONS - Acquisition Date Fair Value of Consideration Transferred (Details)", "shortName": "ACQUISITIONS - Acquisition Date Fair Value of Consideration Transferred (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-33", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-33", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954488 - Disclosure - ACQUISITIONS - Fair Values of Assets Acquired and Liabilities Assumed (Details)", "shortName": "ACQUISITIONS - Fair Values of Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-35", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-35", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.assertiotx.com/role/ACQUISITIONSUnauditedProFormaFinancialInformationDetails", "longName": "9954489 - Disclosure - ACQUISITIONS - Unaudited Pro Forma Financial Information (Details)", "shortName": "ACQUISITIONS - Unaudited Pro Forma Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-38", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-38", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails", "longName": "9954490 - Disclosure - REVENUE - Schedule of Disaggregated Revenue from Contracts with Customers (Details)", "shortName": "REVENUE - Schedule of Disaggregated Revenue from Contracts with Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-39", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R47": { "role": "http://www.assertiotx.com/role/REVENUENarrativesDetails", "longName": "9954491 - Disclosure - REVENUE - Narratives (Details)", "shortName": "REVENUE - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.assertiotx.com/role/ACCOUNTSRECEIVABLESNETDetails", "longName": "9954492 - Disclosure - ACCOUNTS RECEIVABLES, NET (Details)", "shortName": "ACCOUNTS RECEIVABLES, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "asrt:AccountsReceivableAllowanceForCashDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "asrt:AccountsReceivableAllowanceForCashDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails", "longName": "9954493 - Disclosure - INVENTORIES, NET - Schedule of Inventories, Net (Details)", "shortName": "INVENTORIES, NET - Schedule of Inventories, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.assertiotx.com/role/INVENTORIESNETNarrativeDetails", "longName": "9954494 - Disclosure - INVENTORIES, NET - Narrative (Details)", "shortName": "INVENTORIES, NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryValuationReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryValuationReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSDetails", "longName": "9954495 - Disclosure - PREPAID AND OTHER CURRENT ASSETS (Details)", "shortName": "PREPAID AND OTHER CURRENT ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "asrt:PrepaidExpenseAndDepositAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "asrt:PrepaidExpenseAndDepositAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSNarrativeDetails", "longName": "9954496 - Disclosure - PREPAID AND OTHER CURRENT ASSETS - Narrative (Details)", "shortName": "PREPAID AND OTHER CURRENT ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:FinancingReceivableAllowanceForCreditLosses", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:FinancingReceivableAllowanceForCreditLosses", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails", "longName": "9954497 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment (Details)", "shortName": "PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "longName": "9954498 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)", "shortName": "PROPERTY AND EQUIPMENT, NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails", "longName": "9954499 - Disclosure - INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.assertiotx.com/role/INTANGIBLEASSETSNarrativeDetails", "longName": "9954500 - Disclosure - INTANGIBLE ASSETS - Narrative (Details)", "shortName": "INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails", "longName": "9954501 - Disclosure - INTANGIBLE ASSETS - Summary of Future Amortization Expense of Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS - Summary of Future Amortization Expense of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails", "longName": "9954502 - Disclosure - OTHER LONG-TERM ASSETS (Details)", "shortName": "OTHER LONG-TERM ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "asrt:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "asrt:PrepaidExpenseAndDepositAssetsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R59": { "role": "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails", "longName": "9954503 - Disclosure - ACCRUED LIABILITIES (Details)", "shortName": "ACCRUED LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails", "longName": "9954504 - Disclosure - DEBT - Schedule of Long-term Debt (Details)", "shortName": "DEBT - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R61": { "role": "http://www.assertiotx.com/role/DEBTNarrativeDetails", "longName": "9954505 - Disclosure - DEBT - Narrative (Details)", "shortName": "DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-77", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R62": { "role": "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "longName": "9954506 - Disclosure - DEBT - Schedule of Carrying Values Convertible Notes (Details)", "shortName": "DEBT - Schedule of Carrying Values Convertible Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-73", "name": "us-gaap:ConvertibleDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R63": { "role": "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails", "longName": "9954507 - Disclosure - DEBT - Schedule of Interest Expense (Details)", "shortName": "DEBT - Schedule of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseOther", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "asrt:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-81", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "asrt:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R64": { "role": "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails", "longName": "9954508 - Disclosure - OTHER LONG-TERM LIABILITIES (Details)", "shortName": "OTHER LONG-TERM LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-3", "name": "asrt:ProductRoyaltyLiabilityNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "asrt:ProductRoyaltyLiabilityNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails", "longName": "9954509 - Disclosure - STOCK-BASED COMPENSATION (Details)", "shortName": "STOCK-BASED COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-87", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-87", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.assertiotx.com/role/LEASESLeaseCostComponentsDetails", "longName": "9954510 - Disclosure - LEASES - Lease Cost Components (Details)", "shortName": "LEASES - Lease Cost Components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-85", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.assertiotx.com/role/LEASESSupplementalCashFlowandOtherInformationDetails", "longName": "9954511 - Disclosure - LEASES - Supplemental Cash Flow and Other Information (Details)", "shortName": "LEASES - Supplemental Cash Flow and Other Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails", "longName": "9954512 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)", "shortName": "LEASES - Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "asrt:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "asrt:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R69": { "role": "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails", "longName": "9954513 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supply Agreements (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Supply Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-91", "name": "asrt:PurchaseObligationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-91", "name": "asrt:PurchaseObligationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESLegalMattersDetails", "longName": "9954514 - Disclosure - COMMITMENTS AND CONTINGENCIES - Legal Matters (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Legal Matters (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESGlumetzaAntitrustLitigationDetails", "longName": "9954515 - Disclosure - COMMITMENTS AND CONTINGENCIES - Glumetza Antitrust Litigation (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Glumetza Antitrust Litigation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESInsuranceLitigationDetails", "longName": "9954516 - Disclosure - COMMITMENTS AND CONTINGENCIES - Insurance Litigation (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Insurance Litigation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-99", "name": "us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails", "longName": "9954517 - Disclosure - SHAREHOLDERS EQUITY (Details)", "shortName": "SHAREHOLDERS EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-33", "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R74": { "role": "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofEarningsPerShareDetails", "longName": "9954518 - Disclosure - NET LOSS PER SHARE - Schedule of Earnings Per Share (Details)", "shortName": "NET LOSS PER SHARE - Schedule of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": null }, "R75": { "role": "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails", "longName": "9954519 - Disclosure - NET LOSS PER SHARE - Schedule of Potentially Dilutive Common Shares (Details)", "shortName": "NET LOSS PER SHARE - Schedule of Potentially Dilutive Common Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails", "longName": "9954520 - Disclosure - FAIR VALUE - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details)", "shortName": "FAIR VALUE - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-120", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R77": { "role": "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "longName": "9954521 - Disclosure - FAIR VALUE - Narrative (Details)", "shortName": "FAIR VALUE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R78": { "role": "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails", "longName": "9954522 - Disclosure - FAIR VALUE - Schedule of Changes in Fair Value (Details)", "shortName": "FAIR VALUE - Schedule of Changes in Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-143", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.assertiotx.com/role/INCOMETAXESDetails", "longName": "9954523 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": null }, "R80": { "role": "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails", "longName": "9954524 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details)", "shortName": "RESTRUCTURING CHARGES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-155", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } }, "R81": { "role": "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails", "longName": "9954525 - Disclosure - RESTRUCTURING CHARGES - Schedule of Accrued Restructuring Costs (Details)", "shortName": "RESTRUCTURING CHARGES - Schedule of Accrued Restructuring Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-156", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "asrt-20240331.htm", "unique": true } } }, "tag": { "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Liabilities, Current [Abstract]", "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/ACCRUEDLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "ACCRUED LIABILITIES", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20", "r569" ] }, "asrt_AccountsReceivableAllowanceForCashDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "AccountsReceivableAllowanceForCashDiscount", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/ACCOUNTSRECEIVABLESNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for cash discounts for prompt payment", "label": "Accounts Receivable, Allowance For Cash Discount", "documentation": "Accounts Receivable, Allowance For Cash Discount" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r228", "r229" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalties", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r81", "r131" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r51", "r152", "r442" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired finite-lived intangible assets, useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r111" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r85", "r569", "r645" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r358", "r359", "r360", "r463", "r606", "r607", "r608", "r631", "r646" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r58", "r59", "r325" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash from operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r354", "r361" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseOther", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r95", "r283", "r413", "r602" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/INTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "verboseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r45", "r49" ] }, "asrt_AmortizationOfRoyaltyRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "AmortizationOfRoyaltyRights", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs and Royalty Rights", "label": "Amortization Of Royalty Rights", "documentation": "Amortization Of Royalty Rights" } } }, "auth_ref": [] }, "asrt_AntaresMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "AntaresMember", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antares", "label": "Antares [Member]", "documentation": "Antares" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total potentially dilutive common shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r206" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r41" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r41" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r129", "r156", "r179", "r211", "r218", "r222", "r230", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r383", "r385", "r406", "r437", "r488", "r569", "r580", "r626", "r627", "r637" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "asrt_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Balance Sheet Information", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r148", "r162", "r179", "r230", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r383", "r385", "r406", "r569", "r626", "r627", "r637" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r70" ] }, "asrt_AssetsLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "AssetsLesseeAbstract", "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Lessee [Abstract]", "documentation": "Assets, Lessee" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.assertiotx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails", "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails", "http://www.assertiotx.com/role/ACQUISITIONSUnauditedProFormaFinancialInformationDetails", "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r377", "r565", "r566" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails", "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails", "http://www.assertiotx.com/role/ACQUISITIONSUnauditedProFormaFinancialInformationDetails", "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r61", "r62", "r377", "r565", "r566" ] }, "asrt_BusinessAcquisitionContingentConsiderationPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessAcquisitionContingentConsiderationPerShare", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, contingent consideration, per share (in dollars per share)", "label": "Business Acquisition, Contingent Consideration, Per Share", "documentation": "Business Acquisition, Contingent Consideration, Per Share" } } }, "auth_ref": [] }, "asrt_BusinessAcquisitionContingentConsiderationPerShareMaximum": { "xbrltype": "perShareItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessAcquisitionContingentConsiderationPerShareMaximum", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, contingent consideration, per share, maximum (in dollars per share)", "label": "Business Acquisition, Contingent Consideration, Per Share, Maximum", "documentation": "Business Acquisition, Contingent Consideration, Per Share, Maximum" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assertio shares issued (in shares)", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": [ "r127" ] }, "asrt_BusinessAcquisitionFixedExchangeRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessAcquisitionFixedExchangeRatio", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, fixed exchange ratio", "label": "Business Acquisition, Fixed Exchange Ratio", "documentation": "Business Acquisition, Fixed Exchange Ratio" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails", "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails", "http://www.assertiotx.com/role/ACQUISITIONSUnauditedProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r377" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pro Forma Financial Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r589", "r590" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "netLabel": "Assertio closing price per share as of the Effective Date (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSUnauditedProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r375", "r376" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSUnauditedProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r375", "r376" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition costs related to the transaction", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r60" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of consideration transferred", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r2", "r3", "r13" ] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of Assertio shares issued", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r2", "r3" ] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of Spectrum's long-term debt", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r2", "r3", "r66", "r379" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r381", "r601" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, contingent consideration arrangements, range of outcomes, value, high", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r68" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails", "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "CVRs", "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r4", "r67", "r380" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, current portion", "verboseLabel": "Short-term contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r67" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, measurement input", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r402" ] }, "asrt_BusinessCombinationContingentConsiderationLiabilityNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessCombinationContingentConsiderationLiabilityNumberOfShares", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, contingent consideration liability, number of shares (in shares)", "label": "Business Combination, Contingent Consideration Liability, Number of Shares", "documentation": "Business Combination, Contingent Consideration Liability, Number of Shares" } } }, "auth_ref": [] }, "asrt_BusinessCombinationContingentConsiderationRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessCombinationContingentConsiderationRoyaltyPercentage", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, royalty percentage", "label": "Business Combination, Contingent Consideration, Royalty Percentage", "documentation": "Business Combination, Contingent Consideration, Royalty Percentage" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONS" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUISITIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r125", "r378" ] }, "us-gaap_BusinessCombinationProvisionalInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProvisionalInformationAbstract", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to Purchase Price Allocation to Fair Value", "label": "Business Combination, Provisional Information [Abstract]" } } }, "auth_ref": [] }, "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Business Combination Provisional Information Initial Accounting Incomplete Adjustment, Accrued Liabilities", "documentation": "Business Combination Provisional Information Initial Accounting Incomplete Adjustment, Accrued Liabilities" } } }, "auth_ref": [] }, "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total Spectrum net assets acquired", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r65" ] }, "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "label": "Business Combination Provisional Information Initial Accounting Incomplete Adjustment Current Assets, Prepaid Expense and Other Assets", "documentation": "Business Combination Provisional Information Initial Accounting Incomplete Adjustment Current Assets, Prepaid Expense and Other Assets" } } }, "auth_ref": [] }, "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Business Combination Provisional Information Initial Accounting Incomplete Adjustment, Deferred Tax Liabilities", "documentation": "Business Combination Provisional Information Initial Accounting Incomplete Adjustment, Deferred Tax Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r65" ] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r65" ] }, "asrt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities" } } }, "auth_ref": [] }, "asrt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities", "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities", "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "asrt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedRebatesReturnsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedRebatesReturnsAndDiscounts", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued rebates, returns and discounts", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Rebates, Returns And Discounts", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Rebates, Returns And Discounts" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r63", "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r63", "r64" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Spectrum net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r64" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CA", "presentation": [ "http://www.assertiotx.com/role/REVENUENarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canada", "label": "CANADA" } } }, "auth_ref": [] }, "asrt_CAMBIAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "CAMBIAMember", "presentation": [ "http://www.assertiotx.com/role/REVENUENarrativesDetails", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CAMBIA", "label": "CAMBIA [Member]", "documentation": "Represents information pertaining to CAMBIA, a product of the entity." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r36", "r150", "r537" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r150" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of year", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r36", "r103", "r177" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r6", "r103" ] }, "asrt_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalCashFlowandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow, Lessee [Abstract]", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalCashFlowandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in measurement of liabilities:", "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r613" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.assertiotx.com/role/REVENUENarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r382" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 15)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r31", "r77", "r438", "r475" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r116", "r253", "r254", "r525", "r621" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common\u00a0Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r571", "r572", "r573", "r575", "r576", "r577", "r578", "r606", "r607", "r631", "r644", "r646" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r84", "r476" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "periodStartLabel": "Balances (in shares)", "periodEndLabel": "Balances (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r84", "r476", "r494", "r646", "r647" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.0001 par value, 200,000,000 shares authorized; 95,115,452 and 94,668,523 shares issued and outstanding as of March\u00a031, 2024 and December 31, 2023, respectively.", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r84", "r439", "r569" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r34", "r164", "r166", "r170", "r433", "r446" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "asrt_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ContingentConsiderationMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Consideration [Member]", "documentation": "Represents activity related to contingent consideration liabilities arising from business combinations." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/REVENUENarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r314" ] }, "asrt_ConversionOfStockAmountConvertedGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ConversionOfStockAmountConvertedGross", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Induced exchange of convertible notes, gross", "label": "Conversion Of Stock, Amount Converted, Gross", "documentation": "Conversion Of Stock, Amount Converted, Gross" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Induced exchange of convertible notes (in shares)", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r38", "r39", "r40" ] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails": { "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal balance", "label": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r18", "r132", "r642" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt conversion option value", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails", "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes", "netLabel": "Convertible notes", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r118", "r268", "r269", "r274", "r275", "r276", "r279", "r280", "r281", "r282", "r283", "r550", "r551", "r552", "r553", "r554" ] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Carrying balance", "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r18", "r132", "r642" ] }, "asrt_ConvertibleSeniorNotes65Member": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ConvertibleSeniorNotes65Member", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "6.5% Convertible Senior Secured Notes due 2027 principal amount", "verboseLabel": "Interest on 2027 Convertible Notes", "label": "Convertible Senior Notes, 6.5% [Member]", "documentation": "Convertible Senior Notes, 6.5% [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": [ "r592", "r593" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r96" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r181", "r182", "r271", "r292", "r425", "r542", "r544" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRefundLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued rebates, returns and discounts", "label": "Customer Refund Liability, Current", "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r18", "r80", "r81", "r130", "r132", "r183", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r414", "r550", "r551", "r552", "r553", "r554", "r603" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross, long-term debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r18", "r132", "r285" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r119", "r270" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion ratio", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r28", "r56", "r122", "r123", "r270" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r74", "r76", "r268", "r414", "r551", "r552" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r27", "r74", "r288", "r414" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r27", "r269" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r183", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r414", "r550", "r551", "r552", "r553", "r554", "r603" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r29", "r183", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r414", "r550", "r551", "r552", "r553", "r554", "r603" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r29", "r56", "r57", "r73", "r74", "r76", "r78", "r121", "r123", "r183", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r414", "r550", "r551", "r552", "r553", "r554", "r603" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: unamortized debt issuance costs", "verboseLabel": "Unamortized issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r75", "r274", "r286", "r551", "r552" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "asrt_DeferredEmployeeRetentionCreditsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "DeferredEmployeeRetentionCreditsNoncurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred employee retention credits", "label": "Deferred Employee Retention Credits, Noncurrent", "documentation": "Deferred Employee Retention Credits, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r105" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r50" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r11", "r214" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r313", "r555", "r556", "r557", "r558", "r559", "r560", "r561" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r313", "r555", "r556", "r557", "r558", "r559", "r560", "r561" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r323", "r327", "r355", "r356", "r357", "r567" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r584" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r585" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "netLabel": "Basic net loss per share (in dollars per share)", "verboseLabel": "Basic net loss per share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r171", "r189", "r190", "r191", "r192", "r193", "r199", "r201", "r203", "r204", "r205", "r209", "r395", "r396", "r434", "r447", "r546" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "netLabel": "Diluted net loss per share (in dollars per share)", "verboseLabel": "Diluted net loss per share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r171", "r189", "r190", "r191", "r192", "r193", "r201", "r203", "r204", "r205", "r209", "r395", "r396", "r434", "r447", "r546" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.assertiotx.com/role/NETLOSSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "NET LOSS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r198", "r206", "r207", "r208" ] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 }, "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 }, "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails": { "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails", "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plus: derivative liability for embedded conversion feature", "netLabel": "Derivative liability for embedded conversion feature", "verboseLabel": "Derivative liability", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": [ "r69" ] }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of embedded derivative liability", "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net", "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period." } } }, "auth_ref": [ "r630" ] }, "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeLiabilityMeasurementInput", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Embedded derivative liability, measurement input", "label": "Embedded Derivative Liability, Measurement Input", "documentation": "Value of input used to measure embedded derivative liability." } } }, "auth_ref": [ "r633" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails", "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee compensation costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r582" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r582" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r582" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r586" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r582" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r582" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Smaller Reporting Company", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r582" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r582" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r146", "r167", "r168", "r169", "r184", "r185", "r186", "r188", "r194", "r196", "r210", "r231", "r232", "r303", "r358", "r359", "r360", "r368", "r369", "r387", "r388", "r389", "r390", "r391", "r392", "r394", "r407", "r408", "r409", "r410", "r411", "r412", "r424", "r455", "r456", "r457", "r463", "r514" ] }, "us-gaap_FacilityClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FacilityClosingMember", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility exit costs", "label": "Facility Closing [Member]", "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r398", "r399", "r404" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r398", "r399", "r404" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r276", "r316", "r317", "r318", "r319", "r320", "r321", "r399", "r426", "r427", "r428", "r551", "r552", "r562", "r563", "r564" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r398", "r399", "r401", "r402", "r405" ] }, "asrt_FairValueDisclosureContingentConsiderationLiabilityFutureRoyaltiesMinimumProductNetSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "FairValueDisclosureContingentConsiderationLiabilityFutureRoyaltiesMinimumProductNetSales", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent payment consideration, future royalties covenant, product net sales (over)", "label": "Fair Value Disclosure, Contingent Consideration, Liability, Future Royalties, Minimum Product Net Sales", "documentation": "Fair Value Disclosure, Contingent Consideration, Liability, Future Royalties, Minimum Product Net Sales" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUE" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r397" ] }, "asrt_FairValueGainLossOfAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "FairValueGainLossOfAssetsAndLiabilities", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Recurring fair value measurements of assets and liabilities", "label": "Fair Value Gain (Loss) Of Assets And Liabilities", "documentation": "Fair Value Gain (Loss) Of Assets And Liabilities" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r276", "r316", "r321", "r399", "r426", "r562", "r563", "r564" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level\u00a02", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r276", "r316", "r321", "r399", "r427", "r551", "r552", "r562", "r563", "r564" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r276", "r316", "r317", "r318", "r319", "r320", "r321", "r399", "r428", "r551", "r552", "r562", "r563", "r564" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of all financial liabilities measured at fair value on a recurring basis", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r17", "r72" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Fair Value", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r17", "r72" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of contingent consideration recorded within costs and expenses", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r403" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payment related to contingent consideration", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r71" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value, beginning of the period", "periodEndLabel": "Fair value, end of the period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails", "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r276", "r316", "r317", "r318", "r319", "r320", "r321", "r426", "r427", "r428", "r551", "r552", "r562", "r563", "r564" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r397", "r405" ] }, "asrt_FairValueOfConvertibleNotesParValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "FairValueOfConvertibleNotesParValue", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, par value", "label": "Fair Value Of Convertible Notes, Par Value", "documentation": "Fair Value Of Convertible Notes, Par Value" } } }, "auth_ref": [] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofChangesinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of contingent consideration recorded within costs and expenses [Extensible Enumeration]", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth_ref": [ "r403" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit loss allowance", "label": "Financing Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement." } } }, "auth_ref": [ "r14", "r143", "r144", "r145", "r159", "r233", "r234", "r235", "r640" ] }, "asrt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Remaining Useful Life (In years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r154", "r241" ] }, "asrt_FiniteLivedIntangibleAssetsAccumulatedImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment", "label": "Finite-Lived Intangible Assets, Accumulated Impairment", "documentation": "Finite-Lived Intangible Assets, Accumulated Impairment" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r113" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r113" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r113" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r113" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r239", "r240", "r241", "r242", "r430", "r431" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r112", "r431" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r430" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r46", "r48" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofFutureAmortizationExpenseofIntangibleAssetsDetails", "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r112", "r430" ] }, "asrt_FurnitureAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "FurnitureAndOfficeEquipmentMember", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and office equipment", "label": "Furniture And Office Equipment [Member]", "documentation": "Represents information pertaining to equipment commonly used in offices and stores, which have no permanent connection to the structure of a building or utilities and tangible personal property used in an office setting." } } }, "auth_ref": [] }, "asrt_GlumetzaAntitrustLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "GlumetzaAntitrustLitigationMember", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESGlumetzaAntitrustLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Glumetza Antitrust Litigation", "label": "Glumetza Antitrust Litigation [Member]", "documentation": "Glumetza Antitrust Litigation" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r153", "r237", "r432", "r549", "r569", "r615", "r617" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Goodwill, Purchase Accounting Adjustments", "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r1", "r616" ] }, "asrt_HanmiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "HanmiMember", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hanmi", "label": "Hanmi [Member]", "documentation": "Hanmi" } } }, "auth_ref": [] }, "asrt_INDOCINProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "INDOCINProductsMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "INDOCIN products", "verboseLabel": "INDOCIN", "label": "INDOCIN Products [Member]", "documentation": "INDOCIN Products" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r93", "r135", "r211", "r217", "r221", "r223", "r435", "r444", "r548" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.assertiotx.com/role/LEASESLeaseCostComponentsDetails", "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r243", "r246", "r499" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.assertiotx.com/role/LEASESLeaseCostComponentsDetails", "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r246", "r499" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r180", "r363", "r365", "r366", "r367", "r370", "r372", "r373", "r374", "r462" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax (expense) benefit", "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r137", "r141", "r195", "r196", "r215", "r364", "r371", "r448" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r37" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and other accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "asrt_IncreaseDecreaseInAccruedRebatesReturnsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "IncreaseDecreaseInAccruedRebatesReturnsAndDiscounts", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued rebates, returns and discounts", "label": "Increase (Decrease) in Accrued Rebates, Returns and Discounts", "documentation": "The increase (decrease) during the reporting period related to rebates, returns and discounts incurred but not paid." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInsuranceSettlementsReceivable", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESInsuranceLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance reimbursement", "label": "Increase (Decrease) in Insurance Settlements Receivable", "documentation": "The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest payable", "label": "Increase (Decrease) in Interest Payable, Net", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_InducedConversionOfConvertibleDebtExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InducedConversionOfConvertibleDebtExpense", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Induced conversion of convertible debt expense", "label": "Induced Conversion of Convertible Debt Expense", "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms." } } }, "auth_ref": [ "r55" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r238" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r44", "r47" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 }, "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt-related expenses", "netLabel": "Debt-related expenses", "verboseLabel": "Direct transaction costs", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r99", "r281", "r289", "r553", "r554" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseOther", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest payable on notes", "label": "Interest Expense, Debt, Excluding Amortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r101", "r282", "r553", "r554" ] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseOther", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "totalLabel": "Total interest expense", "label": "Interest Expense, Other", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r173", "r175", "r176" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payable", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/INVENTORIESNET" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES, NET", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r236" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r110", "r539" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Total inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r160", "r538", "r569" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNetAbstract", "presentation": [ "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r110", "r541" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/INVENTORIESNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory reserves", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r43", "r596" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/INVENTORIESNETScheduleofInventoriesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r110", "r540" ] }, "asrt_JubilantHollisterStierLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "JubilantHollisterStierLLCMember", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "JHS", "label": "Jubilant HollisterStier LLC [Member]", "documentation": "Jubilant HollisterStier LLC" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Expense", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r635" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r115" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.assertiotx.com/role/LEASESLeaseCostComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r420" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.assertiotx.com/role/LEASESLeaseCostComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r420" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.assertiotx.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r415" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r23", "r179", "r230", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r384", "r385", "r386", "r406", "r474", "r547", "r580", "r626", "r637", "r638" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r89", "r134", "r441", "r569", "r604", "r614", "r634" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r149", "r179", "r230", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r384", "r385", "r386", "r406", "r569", "r626", "r637", "r638" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r70" ] }, "asrt_LiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "LiabilitiesLesseeAbstract", "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Lessee [Abstract]", "documentation": "Liabilities, Lessee [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for uncertain tax provisions", "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent." } } }, "auth_ref": [ "r30" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional purchase capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r22" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESGlumetzaAntitrustLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESGlumetzaAntitrustLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESGlumetzaAntitrustLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement amount", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/ACCOUNTSRECEIVABLESNET" ], "lang": { "en-us": { "role": { "terseLabel": "ACCOUNTS RECEIVABLES, NET", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": [ "r612" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Carrying value", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r18", "r132", "r275", "r287", "r551", "r552", "r642" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r157" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "terseLabel": "Long-term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r158" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.assertiotx.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r117" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails", "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r29" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails", "http://www.assertiotx.com/role/DEBTScheduleofLongtermDebtDetails", "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r29", "r54" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESGlumetzaAntitrustLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r255", "r256", "r257", "r258", "r622", "r623" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESGlumetzaAntitrustLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r255", "r256", "r257", "r258", "r622", "r623" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESLegalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal contingency accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r255", "r587" ] }, "us-gaap_MeasurementInputCreditSpreadMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputCreditSpreadMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Spread", "label": "Measurement Input, Credit Spread [Member]", "documentation": "Measurement input using amount above (below) yield between two debt instruments similar in maturity, but different in credit quality." } } }, "auth_ref": [ "r632" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r632" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r632" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r400" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r629" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r174" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r174" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r103", "r104", "r105" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Net (loss) income", "terseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r94", "r105", "r136", "r147", "r163", "r165", "r169", "r179", "r187", "r189", "r190", "r191", "r192", "r195", "r196", "r202", "r211", "r217", "r221", "r223", "r230", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r396", "r406", "r445", "r496", "r512", "r513", "r548", "r579", "r626" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r98" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "asrt_NumberOfDaysToCoverOverAllotment": { "xbrltype": "durationItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "NumberOfDaysToCoverOverAllotment", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days to cover over allotment (in days)", "label": "Number Of Days To Cover Over Allotment", "documentation": "Number Of Days To Cover Over Allotment" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpensesAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Operating Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r211", "r217", "r221", "r223", "r548" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/LEASESLeaseCostComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r421", "r568" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r417" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r417" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r418" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails", "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails" ], "lang": { "en-us": { "role": { "netLabel": "Noncurrent operating lease liabilities", "terseLabel": "Noncurrent operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r417" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r418" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalCashFlowandOtherInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r419", "r422" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails", "http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r416" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.assertiotx.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r418" ] }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessor, Operating Leases [Text Block]", "documentation": "The entire disclosure for lessor's operating leases." } } }, "auth_ref": [ "r423" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.assertiotx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r106", "r107", "r108", "r128" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r24" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r161", "r569" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/OTHERLONGTERMASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER LONG-TERM ASSETS", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Assets, Miscellaneous, Noncurrent", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "totalLabel": "Total other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r155" ] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "PREPAID AND OTHER CURRENT ASSETS", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r24", "r569" ] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER LONG-TERM LIABILITIES", "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r25" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 }, "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "totalLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r30" ] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Long-term Liabilities", "label": "Other Noncurrent Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other gain", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r100" ] }, "asrt_OtrexupAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "OtrexupAcquisitionMember", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Otrexup", "label": "Otrexup Acquisition [Member]", "documentation": "Otrexup Acquisition" } } }, "auth_ref": [] }, "asrt_OtrexupMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "OtrexupMember", "presentation": [ "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Otrexup", "label": "Otrexup [Member]", "documentation": "Otrexup" } } }, "auth_ref": [] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of direct transaction costs related to convertible debt inducement", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash paid", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r245", "r600" ] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments related to the vesting and settlement of equity awards, net", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r172" ] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of Sympazan", "label": "Payments to Acquire Other Productive Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r102" ] }, "us-gaap_PaymentsToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToSuppliers", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of inventory", "label": "Payments to Suppliers", "documentation": "Payments of cash to suppliers for goods and services during the current period." } } }, "auth_ref": [ "r598", "r599" ] }, "asrt_PrepaidExpenseAndDepositAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "PrepaidExpenseAndDepositAssetsCurrent", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid assets and deposits", "label": "Prepaid Expense And Deposit Assets, Current", "documentation": "Prepaid Expense And Deposit Assets, Current" } } }, "auth_ref": [] }, "asrt_PrepaidExpenseAndDepositAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "PrepaidExpenseAndDepositAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/OTHERLONGTERMASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid asset and deposits", "label": "Prepaid Expense And Deposit Assets, Noncurrent", "documentation": "Prepaid Expense And Deposit Assets, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "totalLabel": "Total prepaid and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r597" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product sales, net", "verboseLabel": "Total product sales, net", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r555" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails", "http://www.assertiotx.com/role/REVENUENarrativesDetails", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r224", "r429", "r449", "r450", "r451", "r452", "r453", "r454", "r535", "r555", "r570", "r591", "r624", "r625", "r628", "r643" ] }, "asrt_ProductOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ProductOtherMember", "presentation": [ "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other products", "label": "Product, Other [Member]", "documentation": "Product, Other" } } }, "auth_ref": [] }, "asrt_ProductRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ProductRightsMember", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Product Rights", "label": "Product Rights [Member]", "documentation": "Legal rights held to use a product." } } }, "auth_ref": [] }, "asrt_ProductRoyaltyLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ProductRoyaltyLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/OTHERLONGTERMLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROLVEDON product royalties", "label": "Product Royalty Liability, Noncurrent", "documentation": "Product Royalty Liability, Noncurrent" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails", "http://www.assertiotx.com/role/REVENUENarrativesDetails", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r224", "r429", "r449", "r450", "r451", "r452", "r453", "r454", "r535", "r555", "r570", "r591", "r624", "r625", "r628", "r643" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNET" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT, NET", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r114", "r138", "r139", "r140" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r115", "r151", "r443" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r436", "r443", "r569" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r115" ] }, "asrt_ProvisionForInventoryAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ProvisionForInventoryAndOtherAssets", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions for inventory and other assets", "label": "Provision For Inventory And Other Assets", "documentation": "Provision For Inventory And Other Assets" } } }, "auth_ref": [] }, "asrt_PurchaseObligationAnnualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "PurchaseObligationAnnualObligation", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual purchase obligation", "label": "Purchase Obligation, Annual Obligation", "documentation": "Purchase Obligation, Annual Obligation" } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation in 2024", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInSecondYear", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation in 2025", "label": "Purchase Obligation, to be Paid, Year Two", "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "asrt_PurchaseObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "PurchaseObligationPercentage", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation, percentage", "label": "Purchase Obligation, Percentage", "documentation": "Purchase Obligation, Percentage" } } }, "auth_ref": [] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Receivables [Abstract]", "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments in connection with 2027 Convertible Notes", "label": "Repayments of Convertible Debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r35" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r181", "r182", "r271", "r292", "r425", "r543", "r544" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r79", "r362", "r639" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r150" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost incurred, cumulative", "label": "Restructuring and Related Cost, Cost Incurred to Date", "documentation": "Amount of costs incurred to date for the specified restructuring cost." } } }, "auth_ref": [ "r244", "r247", "r250", "r252" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostExpectedCostRemaining1", "crdr": "debit", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related cost, expected cost remaining", "label": "Restructuring and Related Cost, Expected Cost Remaining", "documentation": "Amount of expected cost remaining for the specified restructuring cost." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails", "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "netLabel": "Restructuring charges", "terseLabel": "Restructuring charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r11", "r248", "r250", "r618" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails", "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r244", "r245", "r250", "r251" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails", "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r250", "r251", "r252" ] }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGES" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRUCTURING CHARGES", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r245", "r249" ] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveCurrent", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.assertiotx.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued restructuring costs", "label": "Restructuring Reserve, Current", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r595", "r619", "r620" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued restructuring and severance costs rollforward", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r86", "r124", "r440", "r458", "r459", "r461", "r477", "r569" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r146", "r184", "r185", "r186", "r188", "r194", "r196", "r231", "r232", "r358", "r359", "r360", "r368", "r369", "r387", "r389", "r390", "r392", "r394", "r455", "r457", "r463", "r646" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Product Sales and Royalties", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r212", "r213", "r216", "r219", "r220", "r224", "r225", "r227", "r312", "r313", "r429" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.assertiotx.com/role/REVENUE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r142", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r315" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "asrt_RolvedonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "RolvedonMember", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails", "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROLVEDON", "verboseLabel": "ROLVEDON", "label": "Rolvedon [Member]", "documentation": "Rolvedon" } } }, "auth_ref": [] }, "asrt_RoyaltiesAndMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "RoyaltiesAndMilestonesMember", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/REVENUENarrativesDetails", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties and milestones", "verboseLabel": "Royalties and milestone revenue", "label": "Royalties And Milestones [Member]", "documentation": "Royalties And Milestones [Member]" } } }, "auth_ref": [] }, "asrt_SPRIXNasalSprayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "SPRIXNasalSprayMember", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SPRIX", "verboseLabel": "SPRIX", "label": "SPRIX Nasal Spray [Member]", "documentation": "SPRIX Nasal Spray" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r322", "r609" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r197", "r322", "r587", "r609" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/ACCRUEDLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.assertiotx.com/role/NETLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potentially Dilutive Common Shares", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Consideration Transferred", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails", "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails", "http://www.assertiotx.com/role/ACQUISITIONSUnauditedProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r61", "r62", "r377" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Values Convertible Notes", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "asrt_ScheduleOfCashAndCashEquivalentsAndMarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ScheduleOfCashAndCashEquivalentsAndMarketableSecuritiesLineItems", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]", "label": "Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "asrt_ScheduleOfCashAndCashEquivalentsAndMarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ScheduleOfCashAndCashEquivalentsAndMarketableSecuritiesTable", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents and Marketable Securities [Table]", "label": "Schedule of Cash and Cash Equivalents and Marketable Securities [Table]", "documentation": "Schedule of cash and cash equivalent balances and investments in marketable securities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.assertiotx.com/role/REVENUENarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.assertiotx.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r29", "r56", "r57", "r73", "r74", "r76", "r78", "r121", "r123", "r551", "r553", "r605" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/NETLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Calculation of Basic and Diluted Earnings Per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r610" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://www.assertiotx.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Revenue", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r398", "r399" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r46", "r48", "r430" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets and Goodwill", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r46", "r48" ] }, "asrt_ScheduleOfInterestExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "ScheduleOfInterestExpenseTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt Related Interest", "label": "Schedule of Interest Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of interest expense." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/INVENTORIESNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Net", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r19", "r90", "r91", "r92" ] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": [ "http://www.assertiotx.com/role/OTHERLONGTERMASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Long-Term Assets", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": [ "r594" ] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/PREPAIDANDOTHERCURRENTASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid and Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.assertiotx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r126" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails", "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r250", "r251", "r252" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Restructuring and Severance Costs", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r52", "r53" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails", "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r324", "r326", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Future Amortization Expenses of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r48" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r581" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r583" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.assertiotx.com/role/REVENUENarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r225", "r226", "r465", "r466", "r467", "r519", "r520", "r521", "r522", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r556", "r573", "r628", "r643" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r97" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.assertiotx.com/role/LEASESLeaseCostComponentsDetails", "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses", "verboseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.assertiotx.com/role/DEBTNarrativeDetails", "http://www.assertiotx.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r342" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average fair market value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r342" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails", "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r324", "r326", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r335" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average market fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.assertiotx.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353" ] }, "asrt_SpectrumPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "SpectrumPharmaceuticalsIncMember", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSAcquisitionDateFairValueofConsiderationTransferredDetails", "http://www.assertiotx.com/role/ACQUISITIONSFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails", "http://www.assertiotx.com/role/ACQUISITIONSUnauditedProFormaFinancialInformationDetails", "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spectrum Pharmaceuticals, Inc.", "label": "Spectrum Pharmaceuticals, Inc. [Member]", "documentation": "Spectrum Pharmaceuticals, Inc." } } }, "auth_ref": [] }, "asrt_SpectrumReorganizationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "SpectrumReorganizationPlanMember", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spectrum Reorganization Plan", "label": "Spectrum Reorganization Plan [Member]", "documentation": "Spectrum Reorganization Plan" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r33", "r146", "r167", "r168", "r169", "r184", "r185", "r186", "r188", "r194", "r196", "r210", "r231", "r232", "r303", "r358", "r359", "r360", "r368", "r369", "r387", "r388", "r389", "r390", "r391", "r392", "r394", "r407", "r408", "r409", "r410", "r411", "r412", "r424", "r455", "r456", "r457", "r463", "r514" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.assertiotx.com/role/REVENUENarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r225", "r226", "r465", "r466", "r467", "r519", "r520", "r521", "r522", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r556", "r573", "r628", "r643" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r184", "r185", "r186", "r210", "r429", "r460", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r476", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r489", "r490", "r491", "r492", "r493", "r495", "r497", "r498", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r514", "r574" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.assertiotx.com/role/ACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r197", "r322", "r587", "r588", "r609" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r184", "r185", "r186", "r210", "r429", "r460", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r476", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r489", "r490", "r491", "r492", "r493", "r495", "r497", "r498", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r514", "r574" ] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveCommonSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based awards and equivalents", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r611" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.assertiotx.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r83", "r84", "r124" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Induced exchange of convertible notes (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r15", "r32", "r56", "r124", "r278" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issuance and other impacts of the vesting and settlement of equity awards (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r15", "r83", "r84", "r124" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Induced exchange of convertible notes", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r15", "r33", "r124" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issuance and other impacts of the vesting and settlement of equity awards", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r15", "r124" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r84", "r87", "r88", "r109", "r478", "r494", "r515", "r516", "r569", "r580", "r604", "r614", "r634", "r646" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.assertiotx.com/role/SHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r120", "r178", "r290", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r393", "r517", "r518", "r523" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosure of Cash Flow Information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentArrangementMember", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Commitment Arrangement [Domain]", "label": "Supply Commitment Arrangement [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r82", "r133" ] }, "us-gaap_SupplyCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentAxis", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Commitment [Axis]", "label": "Supply Commitment [Axis]", "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer." } } }, "auth_ref": [ "r82", "r133" ] }, "us-gaap_SupplyCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentLineItems", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Commitment [Line Items]", "label": "Supply Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentMember", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Agreement", "label": "Supply Commitment [Member]", "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments." } } }, "auth_ref": [ "r82", "r133" ] }, "us-gaap_SupplyCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentTable", "presentation": [ "http://www.assertiotx.com/role/COMMITMENTSANDCONTINGENCIESSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Commitment [Table]", "label": "Supply Commitment [Table]", "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has committed resources to supply goods or services to a customer. May include identification of the goods or services to be furnished, identity of the purchasing party, pricing, effects on pricing for failing to deliver the [minimum] quantities required to be furnished, cancellation rights, and termination provisions." } } }, "auth_ref": [ "r82", "r133" ] }, "asrt_SympazanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assertiotx.com/20240331", "localname": "SympazanMember", "presentation": [ "http://www.assertiotx.com/role/INTANGIBLEASSETSSummaryofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails", "http://www.assertiotx.com/role/REVENUEScheduleofDisaggregatedRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sympazan", "verboseLabel": "Sympazan", "label": "Sympazan [Member]", "documentation": "Sympazan" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r613", "r636" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.assertiotx.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESNarrativeDetails", "http://www.assertiotx.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r244", "r245", "r250", "r251" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government agencies", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r545", "r562", "r641" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUEScheduleofFairValueHierarchyforFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasuries", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r545", "r562", "r564", "r641" ] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails": { "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.assertiotx.com/role/DEBTScheduleofCarryingValuesConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discounted Cash Flow", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r632" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ValuationTechniqueOptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueOptionPricingModelMember", "presentation": [ "http://www.assertiotx.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Pricing Model", "label": "Valuation Technique, Option Pricing Model [Member]", "documentation": "Valuation technique calculating price of option." } } }, "auth_ref": [ "r632" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares used in computing diluted net loss per share (in shares)", "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r200", "r205" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.assertiotx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.assertiotx.com/role/NETLOSSPERSHAREScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "netLabel": "Shares used in computing basic net loss per share (in shares)", "verboseLabel": "Weighted-average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r199", "r205" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(1)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "40", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481194/470-20-40-16" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-4A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(c)", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-30/tableOfContent" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r587": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r588": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-10/tableOfContent" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815-15/tableOfContent" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 101 0001808665-24-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001808665-24-000023-xbrl.zip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end XML 103 asrt-20240331_htm.xml IDEA: XBRL DOCUMENT 0001808665 2024-01-01 2024-03-31 0001808665 2024-05-01 0001808665 2024-03-31 0001808665 2023-12-31 0001808665 us-gaap:ProductMember 2024-01-01 2024-03-31 0001808665 us-gaap:ProductMember 2023-01-01 2023-03-31 0001808665 asrt:RoyaltiesAndMilestonesMember 2024-01-01 2024-03-31 0001808665 asrt:RoyaltiesAndMilestonesMember 2023-01-01 2023-03-31 0001808665 2023-01-01 2023-03-31 0001808665 us-gaap:CommonStockMember 2023-12-31 0001808665 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001808665 us-gaap:RetainedEarningsMember 2023-12-31 0001808665 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001808665 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001808665 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001808665 us-gaap:CommonStockMember 2024-03-31 0001808665 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001808665 us-gaap:RetainedEarningsMember 2024-03-31 0001808665 us-gaap:CommonStockMember 2022-12-31 0001808665 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001808665 us-gaap:RetainedEarningsMember 2022-12-31 0001808665 2022-12-31 0001808665 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001808665 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001808665 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001808665 us-gaap:CommonStockMember 2023-03-31 0001808665 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001808665 us-gaap:RetainedEarningsMember 2023-03-31 0001808665 2023-03-31 0001808665 asrt:SpectrumPharmaceuticalsIncMember 2023-07-31 0001808665 asrt:RolvedonMember srt:ScenarioForecastMember asrt:SpectrumPharmaceuticalsIncMember 2024-12-31 0001808665 asrt:RolvedonMember srt:ScenarioForecastMember asrt:SpectrumPharmaceuticalsIncMember 2025-12-31 0001808665 asrt:SpectrumPharmaceuticalsIncMember 2023-07-31 2023-07-31 0001808665 asrt:RolvedonMember asrt:SpectrumPharmaceuticalsIncMember 2023-07-31 0001808665 asrt:SpectrumPharmaceuticalsIncMember 2023-12-31 0001808665 asrt:SpectrumPharmaceuticalsIncMember 2023-08-01 2023-12-31 0001808665 asrt:SpectrumPharmaceuticalsIncMember 2024-01-01 2024-03-31 0001808665 asrt:SpectrumPharmaceuticalsIncMember 2023-01-01 2023-03-31 0001808665 asrt:RolvedonMember 2024-01-01 2024-03-31 0001808665 asrt:RolvedonMember 2023-01-01 2023-03-31 0001808665 asrt:INDOCINProductsMember 2024-01-01 2024-03-31 0001808665 asrt:INDOCINProductsMember 2023-01-01 2023-03-31 0001808665 asrt:SympazanMember 2024-01-01 2024-03-31 0001808665 asrt:SympazanMember 2023-01-01 2023-03-31 0001808665 asrt:OtrexupMember 2024-01-01 2024-03-31 0001808665 asrt:OtrexupMember 2023-01-01 2023-03-31 0001808665 asrt:SPRIXNasalSprayMember 2024-01-01 2024-03-31 0001808665 asrt:SPRIXNasalSprayMember 2023-01-01 2023-03-31 0001808665 asrt:CAMBIAMember 2024-01-01 2024-03-31 0001808665 asrt:CAMBIAMember 2023-01-01 2023-03-31 0001808665 asrt:ProductOtherMember 2024-01-01 2024-03-31 0001808665 asrt:ProductOtherMember 2023-01-01 2023-03-31 0001808665 asrt:CAMBIAMember country:CA 2024-01-01 2024-03-31 0001808665 asrt:CAMBIAMember country:CA 2023-01-01 2023-03-31 0001808665 asrt:FurnitureAndOfficeEquipmentMember 2024-03-31 0001808665 asrt:FurnitureAndOfficeEquipmentMember 2023-12-31 0001808665 us-gaap:EquipmentMember 2024-03-31 0001808665 us-gaap:EquipmentMember 2023-12-31 0001808665 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001808665 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001808665 us-gaap:ConstructionInProgressMember 2024-03-31 0001808665 us-gaap:ConstructionInProgressMember 2023-12-31 0001808665 asrt:RolvedonMember asrt:ProductRightsMember 2024-03-31 0001808665 asrt:RolvedonMember asrt:ProductRightsMember 2023-12-31 0001808665 asrt:INDOCINProductsMember asrt:ProductRightsMember 2024-03-31 0001808665 asrt:INDOCINProductsMember asrt:ProductRightsMember 2023-12-31 0001808665 asrt:SympazanMember asrt:ProductRightsMember 2024-03-31 0001808665 asrt:SympazanMember asrt:ProductRightsMember 2023-12-31 0001808665 asrt:OtrexupAcquisitionMember asrt:ProductRightsMember 2024-03-31 0001808665 asrt:OtrexupAcquisitionMember asrt:ProductRightsMember 2023-12-31 0001808665 asrt:SPRIXNasalSprayMember asrt:ProductRightsMember 2024-03-31 0001808665 asrt:SPRIXNasalSprayMember asrt:ProductRightsMember 2023-12-31 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:ConvertibleDebtMember 2024-03-31 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:ConvertibleDebtMember 2023-12-31 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:ConvertibleDebtMember 2022-08-22 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:ConvertibleDebtMember 2022-08-22 2022-08-22 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:ConvertibleDebtMember 2023-02-27 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:ConvertibleDebtMember 2023-02-27 2023-02-27 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-03-31 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:SeniorNotesMember 2024-01-01 2024-03-31 0001808665 asrt:ConvertibleSeniorNotes65Member us-gaap:SeniorNotesMember 2023-01-01 2023-03-31 0001808665 us-gaap:SeniorNotesMember 2024-01-01 2024-03-31 0001808665 us-gaap:SeniorNotesMember 2023-01-01 2023-03-31 0001808665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-03-31 0001808665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001808665 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001808665 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001808665 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001808665 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001808665 us-gaap:SupplyCommitmentMember 2024-03-31 0001808665 asrt:JubilantHollisterStierLLCMember us-gaap:SupplyCommitmentMember 2024-03-31 0001808665 asrt:AntaresMember us-gaap:SupplyCommitmentMember 2024-03-31 0001808665 asrt:HanmiMember us-gaap:SupplyCommitmentMember 2024-03-31 0001808665 asrt:HanmiMember us-gaap:SupplyCommitmentMember 2024-01-01 2024-03-31 0001808665 asrt:GlumetzaAntitrustLitigationMember 2021-09-14 2021-09-14 0001808665 asrt:GlumetzaAntitrustLitigationMember 2022-02-03 2022-02-03 0001808665 2021-01-01 2021-03-31 0001808665 2022-04-01 2022-06-30 0001808665 us-gaap:ConvertibleDebtMember 2023-03-31 0001808665 us-gaap:ConvertibleDebtMember 2024-01-01 2024-03-31 0001808665 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0001808665 us-gaap:StockCompensationPlanMember 2024-01-01 2024-03-31 0001808665 us-gaap:StockCompensationPlanMember 2023-01-01 2023-03-31 0001808665 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001808665 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808665 asrt:SpectrumPharmaceuticalsIncMember 2024-03-31 0001808665 asrt:INDOCINProductsMember 2023-12-31 0001808665 asrt:INDOCINProductsMember 2024-03-31 0001808665 us-gaap:MeasurementInputPriceVolatilityMember 2024-03-31 0001808665 us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-03-31 0001808665 us-gaap:MeasurementInputCreditSpreadMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-03-31 0001808665 asrt:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001808665 asrt:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001808665 asrt:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-03-31 0001808665 asrt:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-03-31 0001808665 asrt:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2024-03-31 0001808665 asrt:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2023-03-31 0001808665 us-gaap:MeasurementInputCreditSpreadMember us-gaap:ValuationTechniqueOptionPricingModelMember 2024-03-31 0001808665 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001808665 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001808665 us-gaap:EmployeeSeveranceMember asrt:SpectrumReorganizationPlanMember 2024-03-31 0001808665 us-gaap:FacilityClosingMember asrt:SpectrumReorganizationPlanMember 2023-01-01 2023-12-31 0001808665 us-gaap:FacilityClosingMember asrt:SpectrumReorganizationPlanMember 2023-12-31 0001808665 srt:ChiefExecutiveOfficerMember us-gaap:EmployeeSeveranceMember 2023-01-01 2023-12-31 0001808665 us-gaap:EmployeeSeveranceMember 2023-12-31 0001808665 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-03-31 0001808665 us-gaap:EmployeeSeveranceMember 2024-03-31 shares iso4217:USD iso4217:USD shares pure utr:Rate 0001808665 false --12-31 2024 Q1 0.2442003 http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#CostsAndExpenses http://fasb.org/us-gaap/2023#CostsAndExpenses 10-Q true 2024-03-31 false 001-39294 ASSERTIO HOLDINGS, INC. DE 85-0598378 100 South Saunders Road Suite 300 Lake Forest IL 60045 224 419-7106 Common Stock, $0.0001 par value ASRT NASDAQ Yes Yes Accelerated Filer false false false 95124605 80743000 73441000 42610000 47663000 38602000 37686000 10519000 12272000 172474000 171062000 704000 770000 105701000 111332000 3086000 3255000 281965000 286419000 15650000 13439000 57870000 58137000 15401000 18213000 2700000 2700000 823000 954000 92444000 93443000 38621000 38514000 16406000 16459000 147471000 148416000 0.0001 0.0001 200000000 200000000 95115452 95115452 94668523 94668523 9000 9000 790538000 789537000 -656053000 -651543000 134494000 138003000 281965000 286419000 31862000 41769000 586000 697000 32448000 42466000 11177000 5467000 733000 0 18524000 16904000 0 9167000 5631000 6284000 720000 0 36785000 37822000 -4337000 4644000 0 9918000 757000 1122000 716000 802000 -41000 -10238000 -4378000 -5594000 132000 -2110000 -4510000 -3484000 -0.05 -0.05 -0.07 -0.07 94980000 94980000 51005000 51005000 94669000 9000 789537000 -651543000 138003000 446000 -206000 -206000 1207000 1207000 -4510000 -4510000 -4510000 -4510000 95115000 9000 790538000 -656053000 134494000 48320000 5000 545321000 -319601000 225725000 6990000 26699000 26699000 352000 -722000 -722000 2446000 2446000 -3484000 -3484000 -3484000 -3484000 55662000 5000 573744000 -323085000 250664000 -4510000 -3484000 5696000 6484000 107000 147000 0 -9167000 0 9918000 1428000 1072000 1207000 2446000 0 -1367000 -5054000 1109000 2344000 3602000 -1921000 -1824000 -134000 -290000 -267000 2887000 -650000 -1376000 7508000 22717000 0 105000 0 -105000 0 10500000 0 1119000 0 6609000 206000 722000 -206000 -18950000 7302000 3662000 73441000 64941000 80743000 68603000 11000 29000 1300000 2351000 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assertio Holdings, Inc., or the Company, is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients. The Company has built its product portfolio through the acquisition or licensing of approved products. The Company’s commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s primary marketed products include ROLVEDON</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elflapegrastim-xnst) injection for subcutaneous use, INDOCIN</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (indomethacin) Suppositories, INDOCIN</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (indomethacin) Oral Suspension, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sympazan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (clobazam) oral film, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methotrexate) injection for subcutaneous use, SPRIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ketorolac tromethamine) Nasal Spray, CAMBIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (diclofenac potassium for oral solution), and Zipsor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (diclofenac potassium) Liquid filled capsules. To date, substantially all of the Company’s revenues are related to product sales in the U.S. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless otherwise noted or required by context, use of “Assertio,” “Company,” “we,” “our” and “us” refer to Assertio Holdings and/or its applicable subsidiary or subsidiaries.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements of the Company and its subsidiaries and the related footnote information of the Company have been prepared pursuant to the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information that are normally required by United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of the Company’s management, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of the information for the periods presented. The results for the three months ended March 31, 2024, are not necessarily indicative of results to be expected for the entire year ending December 31, 2024 or future operating periods.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2023, included in Assertio Holdings, Inc.’s Annual Report on Form 10-K filed with the SEC on March 11, 2024 (the “2023 Form 10-K”). The Condensed Consolidated Balance Sheet as of December 31, 2023, has been derived from the audited financial statements at that date, as filed in the Company’s 2023 Form 10-K.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements of the Company and its subsidiaries and the related footnote information of the Company have been prepared pursuant to the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information that are normally required by United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of the Company’s management, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of the information for the periods presented. The results for the three months ended March 31, 2024, are not necessarily indicative of results to be expected for the entire year ending December 31, 2024 or future operating periods.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2023, included in Assertio Holdings, Inc.’s Annual Report on Form 10-K filed with the SEC on March 11, 2024 (the “2023 Form 10-K”). The Condensed Consolidated Balance Sheet as of December 31, 2023, has been derived from the audited financial statements at that date, as filed in the Company’s 2023 Form 10-K.</span></div> ACQUISITIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Spectrum Pharmaceuticals</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2023, (the “Effective Date”), the Company completed the acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”), a commercial stage biopharmaceutical company focused on novel and targeted oncology products (the “Spectrum Merger”). The Spectrum Merger was completed pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 24, 2023, through a merger of a wholly-owned subsidiary of the Company with and into Spectrum, with Spectrum surviving the Merger as a wholly-owned subsidiary of the Company. The Company accounted for the Spectrum Merger using the acquisition method of accounting under Accounting Standards Codification (“ASC”) 805 and is considered the accounting acquirer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, each issued and outstanding share of Spectrum common stock as of the Effective Date was converted into the right to receive (i) 0.1783 shares of the Company’s common stock and (ii) one contingent value right (“CVR”) representing a contractual right to receive future conditional payments worth up to an aggregate maximum amount of $0.20, settleable in cash, additional shares of Assertio common stock or a combination of cash and additional shares of Assertio common stock at the Company’s sole discretion, upon the achievement of certain sales milestones related to Spectrum’s product ROLVEDON. Subject to adjustments, each CVR represents the right to receive up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175 million during the calendar year ending December 31, 2024, and up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $225 million during the calendar year </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ending December 31, 2025. In addition, upon consummation of the Spectrum Merger, Spectrum’s outstanding employee stock awards and other warrants that were outstanding immediately as of the Effective Date automatically vested (if unvested) and/or cancelled, as applicable, which generally resulted in the issuance of shares of the Company’s common stock and/or CVRs to the holders of such stock awards or other warrants, in each case as dictated by the terms of the Merger Agreement. These shares and CVRs issued are considered part of the consideration transferred, and no compensation expense was recognized because the settlement was a condition of the Merger Agreement and other existing individual agreements, no future performance is required by the holders, and the fair value of the shares and CVRs is equivalent to the fair value of the existing employee stock awards and other warrants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of the consideration transferred in the Spectrum Merger (in thousands, except exchange ratio and per share data):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assertio shares issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assertio closing price per share as of the Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Assertio shares issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of Spectrum's long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CVRs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Represents settlement of Spectrum’s existing long-term debt in connection with the close of the transaction. The Company concluded it did not assume the debt, therefore the amount paid to settle the debt has been accounted for and disclosed as part of the consideration transferred.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Represents the Effective Date fair value of 223,397 CVRs at $0.0176 per CVR issued to holders of Spectrum common stock, employee stock awards and warrants.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CVRs represent a contingent consideration obligation measured at fair value and classified as liabilities on the Company’s Condensed Consolidated Balance Sheets. The fair value of the CVR contingent consideration is determined using a Monte Carlo simulation model under the income approach and is based on Level 3 inputs. Refer to </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic63ad6565a9d4801a11244c733cb38e2_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 18</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Fair Value, for additional information. Fair value is based on the probability of achievement of 2024 and 2025 annual ROLVEDON net sales milestones. Significant assumptions include the discount rate and the probability assigned to the achievement of the net sales milestones. Achievement of both the 2024 and 2025 annual ROLVEDON net sales milestones would obligate the Company to transfer a maximum of approximately $44.7 million of additional consideration. No additional consideration would be paid by the Company if neither the 2024 nor 2025 annual ROLVEDON net sales milestones are achieved.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the fair values of the assets acquired and liabilities assumed at the Effective Date (in thousands). The fair values were based on management’s estimates and assumptions. There were no changes for the three months ended March 31, 2024, to the estimated preliminary fair values of the assets acquired and liabilities assumed. The final determination was completed as of March 31, 2024. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.348%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Preliminary Purchase Price Allocation to Fair Value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Purchase Price Allocation to Fair Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Final Purchase Price Allocation to Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,779 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,597)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,182 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Spectrum net assets acquired </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,856)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Application of the acquisition method required the Company to adjust Spectrum assets and liabilities as of the Effective Date, including certain liabilities for variable consideration associated with ROLVEDON, to reflect conformity of Spectrum’s accounting policies to those of Assertio. Liabilities assumed include certain bonuses owed to former Spectrum executives under the terms of existing employment agreements triggered by the consummation of the Spectrum Merger. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Adjustments made to the preliminary purchase price allocation to fair value primarily reflect completion of studies and other analysis necessary to determine the income tax effects of the net identifiable assets acquired and further refinement of the assumptions used in the valuation supporting the ROLVEDON product rights. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">These adjustments did not materially impact the Consolidated Statement of Comprehensive (Loss) Income. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income approach was primarily used to value the acquired intangible assets, representing rights to Spectrum’s product ROLVEDON. Significant assumptions include the amount and timing of projected future cash flows; the discount rate selected to measure the inherent risk of future cash flows; and the assessment of the product’s life cycle and the competitive trends impacting the product. The ROLVEDON product rights will be amortized on a straight-line basis over its estimated useful life of 10 years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no acquisition costs related to the Spectrum Merger recognized for the three months ended March 31, 2024. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information represents the Company’s results of operations as if the Spectrum Merger had been completed as of January 1, 2023, (in thousands) and includes nonrecurring adjustments for additional costs of sales from</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the fair value step-up of inventories and transaction costs. The disclosure of pro forma net sales and net loss do</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es not purport to indicate the results that would actually have been obtained had the Spectrum Merger been completed on the assumed date for the periods presented, or which may be realized in the future. The unaudited pro forma information does not reflect any operating efficiencies or cost savings that may be realized from the integration of the acquisition. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.340%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,944)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.1783 0.20 0.10 175000000 0.10 225000000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of the consideration transferred in the Spectrum Merger (in thousands, except exchange ratio and per share data):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assertio shares issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assertio closing price per share as of the Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Assertio shares issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of Spectrum's long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CVRs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Represents settlement of Spectrum’s existing long-term debt in connection with the close of the transaction. The Company concluded it did not assume the debt, therefore the amount paid to settle the debt has been accounted for and disclosed as part of the consideration transferred.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Represents the Effective Date fair value of 223,397 CVRs at $0.0176 per CVR issued to holders of Spectrum common stock, employee stock awards and warrants.</span></div> 38013000 5.69 216294000 32647000 3932000 252873000 223397 0.0176 44700000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the fair values of the assets acquired and liabilities assumed at the Effective Date (in thousands). The fair values were based on management’s estimates and assumptions. There were no changes for the three months ended March 31, 2024, to the estimated preliminary fair values of the assets acquired and liabilities assumed. The final determination was completed as of March 31, 2024. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.348%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Preliminary Purchase Price Allocation to Fair Value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Purchase Price Allocation to Fair Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Final Purchase Price Allocation to Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,779 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,597)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,182 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Spectrum net assets acquired </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,856)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Application of the acquisition method required the Company to adjust Spectrum assets and liabilities as of the Effective Date, including certain liabilities for variable consideration associated with ROLVEDON, to reflect conformity of Spectrum’s accounting policies to those of Assertio. Liabilities assumed include certain bonuses owed to former Spectrum executives under the terms of existing employment agreements triggered by the consummation of the Spectrum Merger. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Adjustments made to the preliminary purchase price allocation to fair value primarily reflect completion of studies and other analysis necessary to determine the income tax effects of the net identifiable assets acquired and further refinement of the assumptions used in the valuation supporting the ROLVEDON product rights. </span>These adjustments did not materially impact the Consolidated Statement of Comprehensive (Loss) Income. 34600000 34600000 2194000 2194000 50975000 50975000 22244000 61000 22305000 1287000 698000 1985000 100000 100000 234000000 -13500000 220500000 1396000 1396000 346796000 -12741000 334055000 10108000 10108000 21025000 21025000 36509000 -2343000 34166000 784000 784000 34250000 -30254000 3996000 11103000 11103000 113779000 -32597000 81182000 233017000 -19856000 252873000 19856000 -19856000 0 P10Y 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information represents the Company’s results of operations as if the Spectrum Merger had been completed as of January 1, 2023, (in thousands) and includes nonrecurring adjustments for additional costs of sales from</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the fair value step-up of inventories and transaction costs. The disclosure of pro forma net sales and net loss do</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es not purport to indicate the results that would actually have been obtained had the Spectrum Merger been completed on the assumed date for the periods presented, or which may be realized in the future. The unaudited pro forma information does not reflect any operating efficiencies or cost savings that may be realized from the integration of the acquisition. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.340%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,944)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 58081000 -13944000 REVENUE <div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregated Revenue</span></div><div style="text-indent:99pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects total revenue, net for the three months ended March 31, 2024 and 2023 (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product sales, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROLVEDON</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INDOCIN products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sympazan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otrexup</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPRIX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAMBIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,862 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,769 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and milestone revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,448 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,466 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, net</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Spectrum Merger, the Company began recognizing ROLVEDON sales in August 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other net product sales for the three months ended March 31, 2023 include product sales for OXAYDO and Zipsor. The Company ceased OXAYDO product sales beginning in September</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties and Milestone Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2010, the Company entered into a license agreement granting Miravo the rights to commercially market CAMBIA in Canada. Miravo independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. The Company recognized royalties revenue related to the CAMBIA licensing agreement of $0.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.5 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no milestone revenue associated with the completion of certain service milestones for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.2 million for t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he three months ended March 31, 2023.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects total revenue, net for the three months ended March 31, 2024 and 2023 (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product sales, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROLVEDON</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INDOCIN products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sympazan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otrexup</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPRIX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAMBIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,862 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,769 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and milestone revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,448 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,466 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 14478000 0 8682000 30346000 2617000 2502000 2882000 2822000 1437000 1889000 1256000 2264000 510000 1946000 31862000 41769000 586000 697000 32448000 42466000 600000 500000 0 200000 ACCOUNTS RECEIVABLES, NET <div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, accounts receivable, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted entirely of receivables related to product sales, net of allowances for cash discounts for prompt payment o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f $0.4 million and </span>$0.9 million, respectively. 400000 900000 INVENTORIES, NET <div style="text-indent:81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of inventory, net as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,602 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,686 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company writes down the value of inventory for potential excess or obsolete inventories based on an analysis of inventory on hand and projected demand. As of March 31, 2024 and December 31, 2023, inventory reserves were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.3 million an</span>d $6.8 million, respectively. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of inventory, net as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,602 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,686 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 18872000 10537000 2452000 2239000 17278000 24910000 38602000 37686000 7300000 6800000 PREPAID AND OTHER CURRENT ASSETS<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects prepaid and other current as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets and deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,973 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,272 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into a Convertible Secured Note Purchase Agreement (the “Note Agreement”) with NES Therapeutic, Inc. (“NES”), pursuant to which it purchased a Convertible Secured Promissory Note (the “NES Note”). The Company’s investment in the NES Note, which is included in other current assets, is accounted for as a loan receivable and is valued at amortized cost. As of both March 31, 2024 and December 31, 2023, the Company has assessed an estimated $3.5 million expected credit loss reserve on its investment based on its evaluation of probability of default that exists. The expected credit loss reserve recognized in each period represents the entire aggregate principal amount and outstanding interest incurred on the NES Note as of both March 31, 2024 and December 31, 2023.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects prepaid and other current as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets and deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,973 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,272 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10222000 11973000 297000 299000 10519000 12272000 3500000 3500000 PROPERTY AND EQUIPMENT, NET<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects property and equipment, net as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $0.1 million and $0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for </span>the three months ended March 31, 2024 and 2023, respectively. Depreciation expense is recognized in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects property and equipment, net as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1908000 1908000 20000 20000 3473000 2945000 0 528000 5401000 5401000 4697000 4631000 704000 770000 100000 200000 INTANGIBLE ASSETS<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the gross carrying amounts and net book values of intangible assets as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Products rights:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Remaining Useful Life<br/> (In years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ROLVEDON</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">63,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">56,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">220,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(157,095)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">58,135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">INDOCIN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">65,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(47,413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">18,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">154,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(44,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">20,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Sympazan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1,718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Otrexup</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">16,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">44,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(27,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">SPRIX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">32,673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(20,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(19,663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6,327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total intangible Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">192,598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(86,897)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">105,701 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">472,236 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(81,265)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(279,639)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">111,332 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $5.6 million and $6.3 million for the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects future amortization expense the Company expects for its intangible assets (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,701 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company’s market capitalization declined to below the book value of the Company’s equity, which management determined represented an indicator of impairment with respect to its long-lived assets. Applying the relevant accounting guidance, the Company first assessed the recoverability of its long-lived assets. Similar to its previous assessment in the fourth quarter of 2023, as described in the Company’s 2023 Form 10-K, management concluded it was appropriate to group its assets at the product level. After grouping the long-lived assets at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other assets and liabilities, the Company estimated the future net undiscounted cash flows expected to be generated from the use of the long-lived asset groups and their eventual disposition. The Company then compared the estimated undiscounted cash flows to the carrying amounts of the long-lived asset groups. Based on this test, the Company determined that the estimated undiscounted cash flows were in excess of the carrying amounts for all of the long-lived asset groups and, accordingly, that the long-lived asset groups are fully recoverable and no adjustment to their carrying values was required.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the gross carrying amounts and net book values of intangible assets as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Products rights:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Remaining Useful Life<br/> (In years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ROLVEDON</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">63,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">56,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">220,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(157,095)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">58,135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">INDOCIN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">65,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(47,413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">18,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">154,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(44,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">20,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Sympazan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1,718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Otrexup</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">16,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">44,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(27,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">SPRIX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">32,673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(20,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(19,663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6,327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total intangible Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">192,598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(86,897)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">105,701 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">472,236 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(81,265)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(279,639)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">111,332 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> P9Y3M18D 63405000 6787000 56618000 220500000 5270000 157095000 58135000 P1Y9M18D 65606000 47413000 18193000 154100000 44814000 88494000 20792000 P10Y7M6D 14550000 1718000 12832000 14550000 1415000 0 13135000 P5Y8M12D 16364000 10364000 6000000 44086000 10103000 27723000 6260000 P3Y1M6D 32673000 20615000 12058000 39000000 19663000 6327000 13010000 192598000 86897000 105701000 472236000 81265000 279639000 111332000 5600000 6300000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects future amortization expense the Company expects for its intangible assets (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,701 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 16894000 22526000 12130000 9909000 8322000 35920000 105701000 OTHER LONG-TERM ASSETS<div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects other long-term assets as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid asset and deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,255 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects other long-term assets as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid asset and deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,255 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1234000 1269000 1155000 1289000 697000 697000 3086000 3255000 ACCRUED LIABILITIES <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects accrued liabilities as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued restructuring costs (See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#ic63ad6565a9d4801a11244c733cb38e2_94" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Note 20</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,213 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects accrued liabilities as of March 31, 2024 and December 31, 2023 (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued restructuring costs (See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#ic63ad6565a9d4801a11244c733cb38e2_94" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Note 20</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,213 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1452000 2438000 3368000 4378000 9123000 9492000 217000 867000 1241000 1038000 15401000 18213000 DEBT <div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s debt as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5% Convertible Senior Secured Notes due 2027 principal amount</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: derivative liability for embedded conversion feature</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,687)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,794)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,621</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,514</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,621</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,514</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6.5% Convertible Senior Notes due 2027</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2022, Assertio entered into a purchase agreement (the “Purchase Agreement”), with U.S. Bank Trust Company as the trustee (the “2027 Convertible Note Trustee”) of the initial purchasers (the “Initial Purchasers”) to issue $60.0 million in aggregate principal amount of 6.5% Convertible Senior Notes due 2027 (the “2027 Convertible Notes”). Under the Purchase Agreement, the Initial Purchasers were also granted an overallotment option to purchase up to an additional $10.0 million aggregate principal amount of the 2027 Convertible Notes solely to cover overallotment (the “Overallotment Option”) within a 13-day period from the date the initial 2027 Convertible Notes were issued. On August 24, 2022, the Initial Purchasers exercised the Overallotment Option in full for the $10.0 million aggregate principal of additional 2027 Convertible Notes. The 2027 Convertible Notes are senior unsecured obligations of the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, the Company completed a privately negotiated exchange of $30.0 million principal amount of the 2027 Convertible Notes (the “Convertible Note Exchange”). As a result of the Convertible Note Exchange in the first quarter of 2023, the Company recorded an induced conversion expense of approximately $8.8 million and direct transaction costs of approximately $1.1 million, the total of which is reporte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d in Debt-related expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Company’s Condensed Consolidated Statements of Comprehensive Loss </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The induced conversion expense represents the fair value of the consideration transferred in the Convertible Note Exchange in excess of the fair value of common stock issuable under the original terms of the 2027 Convertible Notes. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2027 Convertible Notes are governed by an indenture dated August 25, 2022 (the “2027 Convertible Note Indenture”). The terms of the 2027 Convertible Notes allow for conversion into the Company’s common stock, cash, or a combination of cash and common stock, at the Company’s election only, at an initial conversion rate of 244.2003 shares of the Company’s common stock per $1,000 principal amount (equal to an initial conversion price of approximately $4.09 per share), subject to adjustments specified in the 2027 Convertible Note Indenture (the “Conversion Rate”). The 2027 Convertible Notes will mature on September 1, 2027, unless earlier repurchased or converted. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes bear interest from August 25, 2022, at a rate of 6.5% per annum payable semiannually in arrears on March 1 and September 1 of each year, beginning on March 1, 2023.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Indenture, the Company and its restricted subsidiaries must comply with certain covenants, including mergers, consolidations, and divestitures; guarantees of debt by subsidiaries; issuance of preferred and/or disqualified stock; and liens on the Company’s properties or assets. The Company was in compliance with its covenants with respect to the 2027 Convertible Notes as of March 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the carrying balance of the 2027 Convertible Notes as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for embedded conversion feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,514 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt issuance costs incurred related to the 2027 Convertible Notes are recognized as a debt discount and are being amortized as interest expense over the term of the 2027 Convertible Notes using the effective interest method, with an effective interest rate determined </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be 7.8%. During each of the three months ended March 31, 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company amortized $0.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the debt discount on the 2027 Convertible Notes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that an embedded conversion feature included in the 2027 Convertible Notes required bifurcation from the host contract and to be recognized as a separate derivative liability carried at fair value. See </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic63ad6565a9d4801a11244c733cb38e2_88" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 18</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Fair Value, for further details around the estimated fair value of the derivative liability. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ll of the other embedded features of the 2027 Convertible Notes were clearly and closely related to the debt host and did not require bifurcation as a derivative liability, or the fair value of the bifurcated features was immaterial to the Company’s financial statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects debt-related interest included in Interest expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on 2027 Convertible Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s debt as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5% Convertible Senior Secured Notes due 2027 principal amount</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: derivative liability for embedded conversion feature</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,687)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,794)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,621</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,514</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,621</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,514</span></td></tr></table></div> 0.065 40000000 40000000 308000 308000 1687000 1794000 38621000 38514000 0 0 38621000 38514000 0.065 60000000 0.065 10000000 P13D 10000000 30000000 8800000 1100000 4.09 0.065 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the carrying balance of the 2027 Convertible Notes as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for embedded conversion feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,514 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 40000000 40000000 308000 308000 1687000 1794000 38621000 38514000 0.078 100000 100000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects debt-related interest included in Interest expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on 2027 Convertible Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 650000 975000 107000 147000 757000 1122000 OTHER LONG-TERM LIABILITIES <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects other long-term liabilities as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROLVEDON product royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for uncertain tax provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred employee retention credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,406 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,459 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects other long-term liabilities as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROLVEDON product royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for uncertain tax provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred employee retention credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,406 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,459 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 9224000 9224000 1350000 1470000 4620000 4553000 1212000 1212000 16406000 16459000 STOCK-BASED COMPENSATION <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s stock-based compensation generally includes time-based restricted stock units (“RSU”) and options, as well as performance-based RSUs and options.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2024 and 2023, stock-based compensati</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on of $1.2 million and $2.4 million, resp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ectively, was recognized in Selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive Loss.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2024, the Company granted 0.9 million RSUs at a weighted-average fair market value of $0.80 per share, and 3.0 million options at a weighted-average fair market value of $0.77 per share. During the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2023, the Company granted </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.5 million RSUs at a weighted-average fair market value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$5.15 per share, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.6 million options at a weighted-average fair market value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$4.39 per share.</span></div> 1200000 2400000 900000 0.80 3000000 0.77 500000 5.15 600000 4.39 LEASES<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company has a non-cancelable operating lease for its corporate office, which is located in Lake Forest, Illinois (the “Lake Forest Lease”). On May 1, 2023, the Company am</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended the Lake Forest Lease to reduce the size of leased premises and extend the term of the lease through December 31, 2030.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Additionally, in connection with the Spectrum Merger, the Company assumed leases for two facilities and certain office equipment which Spectrum had previously been the lessee. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects lease expense and income for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects supplemental balance sheet information related to leases as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-525"><span style="-sec-ix-hidden:f-526">Other long-term assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-529"><span style="-sec-ix-hidden:f-530">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-533"><span style="-sec-ix-hidden:f-534">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> LEASES<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company has a non-cancelable operating lease for its corporate office, which is located in Lake Forest, Illinois (the “Lake Forest Lease”). On May 1, 2023, the Company am</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended the Lake Forest Lease to reduce the size of leased premises and extend the term of the lease through December 31, 2030.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Additionally, in connection with the Spectrum Merger, the Company assumed leases for two facilities and certain office equipment which Spectrum had previously been the lessee. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects lease expense and income for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects supplemental balance sheet information related to leases as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-525"><span style="-sec-ix-hidden:f-526">Other long-term assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-529"><span style="-sec-ix-hidden:f-530">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-533"><span style="-sec-ix-hidden:f-534">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects lease expense and income for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 66000 39000 282000 104000 <div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects supplemental balance sheet information related to leases as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-525"><span style="-sec-ix-hidden:f-526">Other long-term assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-529"><span style="-sec-ix-hidden:f-530">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-533"><span style="-sec-ix-hidden:f-534">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 1234000 1269000 797000 928000 1350000 1470000 2147000 2398000 COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jubilant HollisterStier Manufacturing and Supply Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company’s merger with Zyla Life Sciences (“Zyla”) in May 2020 (the “Zyla Merger”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company assumed a Manufacturing and Supply Agreement (the “Jubilant HollisterStier Agreement”) with Jubilant HollisterStier LLC (“JHS”) pursuant to which the Company engaged JHS to provide certain services related to the manufacture and supply of SPRIX for the Company’s commercial use. Under the Jubilant HollisterStier Agreement, JHS is responsible for supplying a minimum of 75% of the C</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ompany’s annual requirements of SPRIX. The Company agreed to purchase a minimum number of batches of SPRIX per calendar year from JHS over the term of the Jubilant HollisterStier Agreement. Total annual commitments to JHS are approximately $1.5 million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antares Supply Agreement</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Otrexup acquisition, the Company entered into a supply agreement with Antares pursuant to which Antares will manufacture and supply the finished Otrexup products (the “Antares Supply Agreement”). Under the Antares Supply Agreement, the Company has agreed to annual minimum purchase obligations from Antares, which approximat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e $2.0 million an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nually. The Antares Supply Agreement has an initial term through December 2031 with renewal terms beyond.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hanmi Supply Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spectrum Merger, the Company assumed a Manufacturing and Supply Agreement (the “Hanmi Agreement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) pursuant to which the Company engaged Hanmi to provide certain services related to the manufacture and supply of ROLVEDON for the Company’s commercial use. The Company has agreed to purchase a minimum number of batches totaling approximatel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y $19.1 million in 2024 and $3.8 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025. The Company has purchased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.4 million of inventory from Hanmi during the three months ended March 31, 2024.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently involved in various lawsuits, claims, investigations and other legal proceedings that arise in the ordinary course of business. The Company recognizes a loss contingency provision in its financial statements when it concludes that a contingent liability is probable, and the amount thereof is estimable. Costs associated with the Company’s involvement in legal proceedings are expensed as incurred. Amounts accrued for legal contingencies are based on management’s best estimate of a loss based upon the status of the cases described below, assessments of the likelihood of damages, and the advice of counsel and often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March 31, 2024 and December 31, 2023, the Company had a legal contingency accrual of approximately $3.2 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor each matter and adjust accruals as warranted based on new information and further developments in accordance with ASC 450-20-25. For matters discussed below for which a loss is not probable, or a probable loss cannot be reasonably estimated, no liability has been recorded. Provisions for loss contingencies are recorded in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Comprehensive Loss and the related accruals are recorded in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than matters disclosed below, the Company may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of its business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims and other matters. The Company may also become party to further litigation in federal and state courts relating to opioid drugs. Although actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, other than the matters set forth below, the Company is not currently involved in any matters that the Company believes may have a material adverse effect on its business, results of operations, cash flows or financial condition. However, regardless of the outcome, litigation can have an adverse impact on the Company because of associated cost and diversion of management time.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glumetza Antitrust Litigation </span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antitrust class actions and related direct antitrust actions were filed in the U.S. District Court for the Northern District of California against the Company and several other defendants relating to its former drug Glumetza®. The plaintiffs sought to represent a putative class of direct purchasers of Glumetza. In addition, several retailers, including CVS Pharmacy, Inc., Rite Aid Corporation, Walgreen Co., the Kroger Co., the Albertsons Companies, Inc., H-E-B, L.P., and Hy-Vee, Inc. (the “Retailer Plaintiffs”), filed substantially similar direct purchaser antitrust claims in the same District Court. </span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, Humana Inc. (“Humana”) also filed a complaint against the Company and several other defendants in the U.S. District Court for the Northern District of California alleging similar claims related to Glumetza. The claims asserted by Humana in its federal case were ultimately withdrawn, and analogous claims were instead asserted by Humana in an action it filed in the Superior Court of the State of California for the County of Alameda on February 8, 2021, and subsequently amended in September 2021. Additionally, on April 5, 2022, Health Care Service Corporation (“HCSC”) filed a complaint against the Company and the same other defendants in the California Superior Court of Alameda alleging similar claims related to Glumetza.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These antitrust cases arise out of a Settlement and License Agreement (the “Settlement”) that the Company, Santarus, Inc. (“Santarus”) and Lupin Limited (“Lupin”) entered into in February 2012 that resolved patent infringement litigation filed by the Company against Lupin regarding Lupin’s Abbreviated New Drug Application for generic 500 mg and 1000 mg tablets of Glumetza. The antitrust plaintiffs allege, among other things, that the Settlement violated the antitrust laws because it allegedly included a “reverse payment” that caused Lupin to delay its entry in the market with a generic version of Glumetza. The alleged “reverse payment” is an alleged commitment on the part of the settling parties not to launch an authorized generic version of Glumetza for a certain period. The antitrust plaintiffs allege that the Company and its co-defendants, which include Lupin as well as Bausch Health (the alleged successor in interest to Santarus), are liable for damages under the antitrust laws for overcharges that the antitrust plaintiffs allege they paid when they purchased the branded version of Glumetza due to delayed generic entry. Plaintiffs seek treble damages for alleged past harm, attorneys’ fees and costs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2021, the Retailer Plaintiffs voluntarily dismissed all claims against the Company pursuant to a settlement agreement with the Company in return for $3.15 million. On February 3, 2022, the District Court issued its final order approving a settlement of the direct purchaser class plaintiffs’ claims against the Company in return for $3.85 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the California state court lawsuits, on November 24, 2021, the state court granted in part and denied in part a demurrer by the defendants in the Humana action. That case was consolidated in November 2022 with the HCSC action for pre-trial and trial purposes. On July 5, 2023, the state court denied a motion for judgment on the pleadings filed by the defendants in the Humana action. These California state cases are now in the midst of discovery, and trial is scheduled for December 2024. </span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend itself vigorously in the consolidated California state court lawsuits. A liability for this matter has been recorded in the financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opioid-Related Request and Subpoenas</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the greater public awareness of the public health issue of opioid abuse, there has been increased scrutiny of, and investigation into, the commercial practices of opioid manufacturers generally by federal, state, and local regulatory and governmental agencies. In March 2017, Assertio Therapeutics received a letter from then-Sen. Claire McCaskill (D-MO), the then-Ranking Member on the U.S. Senate Committee on Homeland Security and Governmental Affairs, requesting certain information regarding Assertio Therapeutics’ historical commercialization of opioid products. Assertio Therapeutics voluntarily furnished information responsive to Sen. McCaskill’s request. Since 2017, Assertio Therapeutics has received and responded to subpoenas from the U.S. Department of Justice (“DOJ”) seeking documents and information regarding its historical sales and marketing of opioid products. Assertio Therapeutics has also received and responded to subpoenas or civil investigative demands focused on its historical promotion and sales of Lazanda, NUCYNTA, and NUCYNTA ER from various state attorneys general seeking documents and information regarding Assertio Therapeutics’ historical sales and marketing of opioid products. In addition, Assertio Therapeutics received and responded to a subpoena from the State of California Department of Insurance (“CDI”) seeking information relating to its historical sales and marketing of Lazanda. The CDI subpoena also sought information on Gralise, a non-opioid product formerly in Assertio Therapeutics’ portfolio. In addition, Assertio Therapeutics received and responded to a subpoena from the New York Department of Financial Services seeking information relating to its historical sales and marketing of opioid products. The Company has also received a subpoena from the New York Attorney General in May 2023, pursuant to which the New York Attorney General is seeking information concerning the sales and marketing of opioid products (Lazanda, NUCYNTA, NUCYNTA ER, and OXAYDO) by Assertio Therapeutics and Zyla. The </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company also from time to time receives and responds to subpoenas from governmental authorities related to investigations primarily focused on third parties, including healthcare practitioners. The Company is cooperating with the foregoing governmental investigations and inquiries.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company became aware that the DOJ issued a press release stating that it had settled claims against a physician whom the DOJ alleged had received payments for paid speaking and consulting work from two pharmaceutical companies, including Depomed, Inc. (“Depomed,” now known as Assertio Therapeutics), in exchange for prescribing certain of the companies’ respective products. As part of the settlement, the physician did not admit liability for such claims and the press release stated that there has been no determination of any liability for such claims. The Company denies any wrongdoing and disputes the DOJ’s characterization of the payments from Depomed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multidistrict and Other Federal Opioid Litigation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of pharmaceutical manufacturers, distributors and other industry participants have been named in numerous lawsuits around the country brought by various groups of plaintiffs, including city and county governments, hospitals, individuals and others. In general, the lawsuits assert claims arising from defendants’ manufacturing, distributing, marketing and promoting of FDA-approved opioid drugs. The specific legal theories asserted vary from case to case, but the lawsuits generally include federal and/or state statutory claims, as well as claims arising under state common law. Plaintiffs seek various forms of damages, injunctive and other relief and attorneys’ fees and costs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For such cases filed in or removed to federal court, the Judicial Panel on Multi-District Litigation issued an order in December 2017, establishing a Multi-District Litigation court (“MDL Court”) in the Northern District of Ohio (In re National Prescription Opiate Litigation, Case No. 1:17-MD-2804). Since that time, more than 2,000 such cases that were originally filed in U.S. District Courts, or removed to federal court from state court, have been filed in or transferred to the MDL Court. Assertio Therapeutics is currently involved in a subset of the lawsuits that have been filed in or transferred to the MDL Court. Assertio Holdings has also been named in six such cases. In April 2022, the Judicial Panel on Multi-District Litigation issued an order stating that it would no longer transfer new opioid cases to the MDL Court. Since that time, Assertio Therapeutics has been named in lawsuits pending in federal courts outside of the MDL Court (in Georgia and New York). Plaintiffs may file additional lawsuits in which the Company may be named, and plaintiffs may also seek leave to add the Company to lawsuits already on file in the MDL Court. Plaintiffs in the pending federal cases involving Assertio Therapeutics or Assertio Holdings include individuals; county, municipal and other governmental entities; employee benefit plans, health insurance providers and other payors; hospitals, health clinics and other health care providers; Native American tribes; and non-profit organizations who assert, for themselves and in some cases for a putative class, federal and state statutory claims and state common law claims, such as conspiracy, nuisance, fraud, negligence, gross negligence, negligent and intentional infliction of emotional distress, deceptive trade practices, and products liability claims (defective design/failure to warn). In these cases, plaintiffs seek a variety of forms of relief, including actual damages to compensate for alleged personal injuries and for alleged past and future costs such as to provide care and services to persons with opioid-related addiction or related conditions, injunctive relief, including to prohibit alleged deceptive marketing practices and abate an alleged nuisance, establishment of a compensation fund, establishment of medical monitoring programs, disgorgement of profits, punitive and statutory treble damages, and attorneys’ fees and costs. No trial date has been set for any of these lawsuits, which are at an early stage of proceedings. Assertio Therapeutics and Assertio Holdings intend to defend themselves vigorously in these matters.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State Opioid Litigation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to the federal cases noted above, there have been hundreds of similar lawsuits filed in state courts around the country, in which various groups of plaintiffs assert opioid-drug related claims against similar groups of defendants. Assertio Therapeutics is currently named in a subset of those cases, including cases in Delaware, Missouri, Pennsylvania, Texas and Utah. Assertio Holdings is named as a defendant in one of these cases in Pennsylvania. Plaintiffs may file additional lawsuits in which the Company may be named. In the pending cases involving Assertio Therapeutics or Assertio Holdings, plaintiffs are asserting state common law and statutory claims against the defendants, and the majority of those cases are similar in nature to the claims asserted in the MDL cases. Plaintiffs are seeking actual damages, disgorgement of profits, injunctive relief, punitive and statutory treble damages, and attorneys’ fees and costs. The state lawsuits in which Assertio Therapeutics or Assertio Holdings has been served are generally each at an early stage of proceedings. Assertio Therapeutics and Assertio Holdings intend to defend themselves vigorously in these matters.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 15, 2019, Assertio Therapeutics was named as a defendant in a declaratory judgment action filed by Navigators Specialty Insurance Company (“Navigators”) in the U.S. District Court for the Northern District of California (Case No. 3:19-cv-255). Navigators was Assertio Therapeutics’ primary product liability insurer. Navigators was seeking declaratory </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment that opioid litigation claims noticed by Assertio Therapeutics (as further described above under “Multidistrict and Other Federal Opioid Litigation” and “State Opioid Litigation”) are not covered by Assertio Therapeutics’ life sciences liability policies with Navigators. On February 3, 2021, Assertio Therapeutics entered into a Confidential Settlement Agreement and Mutual Release with Navigators to resolve the declaratory judgment action and Assertio Therapeutics’ counterclaims. Pursuant to the Settlement Agreement, the parties settled and the coverage action was dismissed without prejudice.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, Assertio Therapeutics received $5.0 million in insurance reimbursement for previous opioid-related spend, which was recognized within Selling, general and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the year ended December 31, 2021.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2021, Assertio Therapeutics filed a complaint for declaratory relief against one of its excess products liability insurers, Lloyd’s of London Newline Syndicate 1218 and related entities (“Newline”), in the Superior Court of the State of California for the County of Alameda. Newline removed the case to the U.S. District Court for the Northern District of California (Case No. 3:21-cv-06642). Assertio Therapeutics was seeking a declaratory judgment that Newline has a duty to defend Assertio Therapeutics or, alternatively, to reimburse Assertio Therapeutics’ attorneys’ fees and other defense costs for opioid litigation claims noticed by Assertio Therapeutics. On May 18, 2022, Assertio Therapeutics entered into a Confidential Settlement Agreement and Mutual Release with Newline to resolve Assertio Therapeutics’ declaratory judgment action. Pursuant to the Settlement Agreement, the parties settled and the coverage action was dismissed with prejudice.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, Assertio Therapeutics received $2.0 million in insurance reimbursement for previous opioid-related spend, which was recognized within Selling, general and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive (Loss) Income for the year ended December 31, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, Assertio Therapeutics filed a complaint against its former insurance broker, Woodruff-Sawyer &amp; Co. (“Woodruff”), in the Superior Court of the State of California for the County of Alameda (Case No. 22CV009380). Assertio Therapeutics alleged claims for negligence and breach of fiduciary duty in connection with Woodruff’s negotiation and procurement of products liability insurance coverage for Assertio Therapeutics. On April 26, 2024, Assertio Therapeutics and Woodruff executed a binding settlement term sheet to resolve Assertio Therapeutics’ claims.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Actions</span></div><div><span><br/></span></div><div style="text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Shapiro v. Assertio Holdings, Inc., et al., U.S. District Court, Northern District of Illinois, Case No. 1:24-cv-00169. On January 5, 2024, this putative securities class action lawsuit was filed by a purported shareholder, alleging that Assertio and certain of its current and former executive officers made false or misleading statements and failed to disclose material facts regarding the likely impact of INDOCIN sales and the Spectrum Merger on Assertio’s profitability in violation of Sections 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act of 1934, as amended (the “Exchange Act”). On April 11, 2024, the court appointed Continental General Insurance Company as the lead plaintiff. The Company intends to vigorously defend itself in this matter.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Edwards v. Assertio Holdings, Inc., et al., Court of Chancery of the State of Delaware, Case No. 2024-0151. On February 19, 2024, this putative securities class action lawsuit was filed by a purported shareholder, alleging that certain former officers and directors of Spectrum breached their fiduciary duties in connection the Spectrum Merger, and that Guggenheim Securities LLC and Assertio aided and abetted such fiduciary duty breaches. The Company intends to vigorously defend itself in this matter.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jung v. Peisert, et al., U.S. District Court, Delaware, Case No. 1:24-cv-00383-UNA. On March 26, 2024, this putative stockholder derivative action was filed against the Company (as a nominal defendant) and certain of its current and former executive offers and directors. The stockholder derivative complaint alleges, inter alia, that certain of the Company’s current and former executive officers and directors are liable to the Company, pursuant to Section 10(b) and 21(d) of the Exchange Act for contribution and indemnification, relating to allegedly false or misleading statements and alleged failure to disclose material facts regarding the likely impact of INDOCIN sales and the Spectrum Merger on the Company’s profitability. The complaint further alleges that certain of the Company’s current and former officers and directors breached their fiduciary duties, and that certain of the Company’s directors negligently violated Section 14(a) of the Exchange Act, by allegedly causing such false or misleading statements to be issued and/or failing to disclose material facts about such matters. The allegations state that as a result of the violations, certain of the Company’s current and former executive officers and directors committed acts of gross mismanagement, abuse of control, or were unjustly enriched. The plaintiffs generally seek corporate reforms, damages, interest, costs, attorneys’ fees, and other unspecified equitable relief.</span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Luo v. Spectrum Pharmaceuticals, Inc., et al., U.S. District Court, District of Nevada, Case No. 2:21-cv-01612. On August 31, 2021, this putative securities class action lawsuit was filed by a purported shareholder, alleging that Spectrum and certain of its former executive officers and directors made false or misleading statements and failed to disclose material facts about Spectrum’s business and the prospects of approval for its Biologic License Application (“BLA”) to the FDA for eflapegrastim (ROLVEDON) in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act. On November 1, 2021, four individuals and one entity filed competing motions to be appointed lead plaintiff and for approval of counsel. On July 28, 2022, the Court appointed a lead plaintiff and counsel for the putative class. On September 26, 2022, an amended complaint was filed alleging, inter alia, false and misleading statements with respect to ROLVEDON manufacturing operations and controls and adding allegations that defendants misled investors about the efficacy of, clinical trial data and market need for poziotinib during a Class Period of March 7, 2018 to August 5, 2021. The amended complaint seeks damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the Court. On November 30, 2022, the defendants filed a motion to dismiss the amended complaint, which was fully briefed as of February 27, 2023. On February 6, 2024, the Court held a hearing on the motion to dismiss and issued an order dismissing the lawsuit without prejudice to the lead plaintiff’s ability to replead their claims. The lead plaintiff filed a further amended complaint on March 29, 2024. The Company intends to vigorously defend itself in this matter.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christiansen v. Spectrum Pharmaceuticals, Inc. et al., Case No. 1:22-cv-10292 (filed December 5, 2022 in the U.S. District Court for the Southern District of New York) (the “New York Action”). Three additional related putative securities class action lawsuits were subsequently filed by Spectrum shareholders against Spectrum and certain of its former executive officers in the U.S. District Court for the Southern District of New York: Osorio-Franco v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10292 (filed December 5, 2022); Cummings v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10677 (filed December 19, 2022); and Carneiro v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:23-cv-00767 (filed January 30, 2023). These three New York lawsuits allege that Spectrum and certain of its former executive officers made false or misleading statements about, inter alia, the safety and efficacy of and clinical trial data for poziotinib in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act, and seek remedies including damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the Court. On February 15, 2023, the Court consolidated the three New York lawsuits. On March 21, 2023, the Court entered an order designating Steven Christiansen as the lead plaintiff. Lead plaintiff Christiansen filed an amended consolidated complaint in the New York Action under the caption Christiansen v. Spectrum Pharmaceuticals, Inc, et al., on May 30, 2023, alleging a Class Period between March 17, 2022 and September 2022. The defendants filed a motion to dismiss the consolidated New York Action on July 25, 2023, which was fully briefed as of October 19, 2023. On January 23, 2024, the Court granted the motion to dismiss in part as to five of the challenged statements but denied the motion to dismiss as to two specific statements. The Company filed its answer to the complaint on </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 8, 2024. The Company intends to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vigorously defend itself in this matter.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Csaba v. Turgeon, et. al (filed December 15, 2021 in the U.S. District Court District of Nevada); Shumacher v. Turgeon, et. al (filed March 15, 2022 in the U.S. District Court District of Nevada); Johnson v. Turgeon, et. al (filed March 29, 2022 in the U.S. District Court District of Nevada); Raul v. Turgeon, et. al (filed April 28, 2022 in the U.S. District Court District of Delaware); and Albayrak v. Turgeon, et. al (filed June 9, 2022 in the U.S. District Court District of Nevada). These putative stockholder derivative actions were filed against Spectrum (as a nominal defendant) and certain of Spectrum’s former executive officers and directors. The stockholder derivative complaints allege, inter alia, that certain of Spectrum’s former executive officers are liable to Spectrum, pursuant to Section 10(b) and 21(d) of the Exchange Act for contribution and indemnification, if they are deemed (in the Luo class action), to have made false or misleading statements and failed to disclose material facts about Spectrum’s business and the prospects of approval for its BLA to the FDA for eflapegrastim. The complaints generally but not uniformly further allege that certain of Spectrum’s former officers and directors breached their fiduciary duties, and certain of Spectrum’s former directors negligently violated Section 14(a) of the Exchange Act, by allegedly causing such false or misleading statements to be issued and/or failing to disclose material facts about Spectrum’s business and the prospects of approval for its BLA to the FDA for eflapegrastim. The allegations state that as a result of the violations, certain of Spectrum’s former executive officers and directors committed acts of gross mismanagement, abuse of control, or were unjustly enriched. The plaintiffs generally seek corporate reforms, damages, interest, costs, attorneys’ fees, and other unspecified equitable relief. The parties have agreed to stay these derivative actions until there is a decision in the Luo Nevada securities class action either denying a motion to dismiss in whole or in part, or dismissing that securities class action with prejudice.</span></div> 0.75 1500000 2000000 19100000 3800000 8400000 3200000 3200000 3150000 3850000 5000000 2000000 SHAREHOLDERS EQUITY<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock in the Spectrum Merger</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, shares of Spectrum common stock issued and outstanding immediately prior to the Effective Date, as well as Spectrum restricted stock units, certain stock appreciation rights, certain options to purchase Spectrum common stock, and warrants to purchase Spectrum common stock, which, in each case, were outstanding immediately prior to the Effective Date and were either vested or became vested as a result of the Spectrum Merger on the Effective Date, were converted into the right to receive fully paid and non-assessable shares of the Company’s common stock based on the exchange ratio as set forth in the Merger Agreement (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic63ad6565a9d4801a11244c733cb38e2_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Acquisitions) and the CVRs. Accordingly, on the Effective Date the Company issued approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.0 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of its common stock to the previous holders of Spectrum common stock, net of a fractional share settlement.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchanged Convertible Notes</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Convertible Note Exchange (See </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic63ad6565a9d4801a11244c733cb38e2_67" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 11,</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Debt) in the first quarter of 2023, the Company paid an aggregate of $10.5 million in cash and issued an aggregate of approximately 7.0 million shares of its common stock in partial settlement of the 2027 Convertible Notes (the “Exchanged Notes”). The Company did not receive any cash proceed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s from the issuance of the shares of its common stock but recognized additional paid-in capital of $28.3 million during the three months ended March 31, 2023, related to the common stock share issuance, net of approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.6 million of unamortized issuance costs related to the Exchanged Notes.</span></div> 38000000 10500000 7000000 28300000 1600000 NET LOSS PER SHARE<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, plus potentially dilutive common shares, consisting of stock-based awards and equivalents, and convertible debt. For the purposes of this calculation, stock-based awards and convertible debt are considered to be potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive. The Company uses the treasury-stock method to compute diluted earnings per share with respect to its stock-based awards and equivalents. The Company uses the if-converted method to compute diluted earnings per share with respect to its convertible debt. Under the if-converted method, the Company assumes any convertible debt outstanding was converted at the beginning of each period presented when the effect is dilutive. As a result, interest expense, net of tax, and any other income statement impact associated with the 2027 Convertible Notes, net of tax, is added back to net loss used in the diluted earnings per share calculation. Additionally, the diluted shares used in the diluted earnings per share calculation includes the potential dilution effect of the convertible debt if converted into the Company’s common stock. As the Company was in a loss p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">osition for the three months ended March 31, 2024 and March 31, 2023, the Company’s potentially dilutive stock-based awards and convertible debt were not included in the computation of diluted net loss per share, because to do so would be anti-dilutive.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the calculation of basic and diluted loss per common share for the three months ended March 31, 2024 and 2023 (in thousands, except for per share amounts):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,484)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects outstanding potentially dilutive common shares that are not included in the computation of diluted net loss per share, because to do so would be anti-dilutive, for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based awards and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,760 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the calculation of basic and diluted loss per common share for the three months ended March 31, 2024 and 2023 (in thousands, except for per share amounts):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,484)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -4510000 -3484000 94980000 94980000 51005000 51005000 -0.05 -0.05 -0.07 -0.07 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects outstanding potentially dilutive common shares that are not included in the computation of diluted net loss per share, because to do so would be anti-dilutive, for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based awards and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,760 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 9768000 14489000 8422000 8271000 18190000 22760000 FAIR VALUE<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,168 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,436 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:26.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,534 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,752 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,286 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity date of purchase of three months or less to be cash equivalents. The Company invests its cash in money market funds and marketable securities including U.S. Treasury and government agency securities, commercial paper, and higher quality debt securities of financial and commercial institutions. The Company classified money market funds as Level 1, due to their short-term maturity, and measured the fair value based on quoted prices in active markets for identical assets. The Company classified commercial paper, U.S. Treasury and government agency securities as Level 2, as the inputs used to value these instruments are directly observable or can be corroborated by observable market data for substantially the full term of the assets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spectrum Merger Contingent Variable Rights </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spectrum Merger, the Company issued CVRs (See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic63ad6565a9d4801a11244c733cb38e2_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Acquisitions) that represent a contingent consideration obligation which is measured at fair value. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March 31, 2024 and December 31, 2023, the fair value of the Company’s CVR liability related to the Spectrum Merger was determined by the Company t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o be zero. Accordingly, the Company recognized no expense or benefit for the change in fair value of the CVR contingent consideration during the three months ended March 31, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CVR contingent consideration is determined using a Monte Carlo simulation model under the income approach based on the probability of achievement of ROLVEDON net sales milestones using projections of 2024 and 2025 net sales and discounted to present value. The significant assumptions used in the calculation of the fair value as of March 31, 2024 included updated projections of future ROLVEDON product net sales, which resulted in no probability of achievement under the Monte Carlo simulation. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zyla Merger Contingent Consideration Obligation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Zyla Merger, the Company assumed a contingent consideration obligation which is measured at fair value. The Company has obligations to make contingent consideration payments for future royalties to an affiliate of CR Group L.P. based upon annual INDOCIN product net sales over $20.0 million at a 20% royalty through January 2029. The Company classified the acquisition-related contingent consideration liabilities to be settled in cash as Level 3, due to the lack of relevant observable inputs and market activity. As of both March 31, 2024 and December 31, 2023, the fair value of the INDOCIN product contingent consideration was determined to be $2.7 million and has been classified as current contingent consideration in the Company’s Condensed Consolidated Balance Sheets. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, the Company recognized an expense of zero and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, for the change in fair value of contingent consideration, whi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ch was recognized in Change in fair value of contingent consideration in the Company’s Condensed Consolidated Statements of Comprehensive Loss. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration incurred in the Zyla Merger is determined using an option pricing model under the income approach based on estimated INDOCIN product revenues through January 2029 and discounted to present value. The significant assumptions used in the calculation of the fair value as of March 31, 2024 included revenue volatility of 15%, discount rate of 5.5%, credit spread of 9.2% and projections of future INDOCIN product revenues. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes in fair value of the Company’s contingent consideration obligations that are measured on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-650"><span style="-sec-ix-hidden:f-651">Change in fair value of contingent consideration recorded within costs and expenses</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment related to contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Derivative Liability</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that an embedded conversion feature included in the 2027 Convertible Notes required bifurcation from the host contract and to be recognized as a separate derivative liability carried at fair value. The estimated fair value of the derivative liability, which represents a Level 3 valuation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of both March 31, 2024 and December 31, 2023, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was determined using a binomial lattice model using certain assumptions and consideration of an increased conversion ratio on the underlying convertible notes that could result from the occurrence of certain events. The significant assumption used in the binomial lattice model i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s a credit spread of 8.8%. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There was no change in the fair value of the derivative liability for the three months ended March 31, 2024 or 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments Not Required to be Remeasured at Fair Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s other financial assets and liabilities are not remeasured to fair value, as the carrying cost of each approximates its fair value. As of March 31, 2024, the estimated fair value of the 2027 Convertible Notes, excluding the bifurcated embedded conversion option, was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">approximately $33.8 million, co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mpared to a par </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">value of $40.0 million. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s of December 31, 2023, the estimated fair value of the 2027 Convertible Notes, excluding the bifurcated embedded conversion option, was approximately $35.7 million, compared to a par value o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$40.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Company estimated the fair value of its 2027 Convertible Notes as of March 31, 2024 and December 31, 2023 based on a market approach which represents a Level 2 valuation.</span></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,168 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,436 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:26.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Statement Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,534 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,752 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,286 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 36518000 0 36518000 0 2750000 0 2750000 40168000 0 0 40168000 40168000 39268000 0 79436000 0 0 2700000 2700000 0 0 308000 308000 0 0 3008000 3008000 0 35458000 0 35458000 0 3294000 0 3294000 32534000 0 0 32534000 32534000 38752000 0 71286000 0 0 2700000 2700000 0 0 308000 308000 0 0 3008000 3008000 0 0 0 20000000 0.20 2700000 2700000 0 9200000 0.15 0.055 0.092 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes in fair value of the Company’s contingent consideration obligations that are measured on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-650"><span style="-sec-ix-hidden:f-651">Change in fair value of contingent consideration recorded within costs and expenses</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment related to contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2700000 48500000 0 9167000 0 6609000 2700000 51058000 300000 300000 0.088 0 0 33800000 40000000 35700000 40000000 INCOME TAXES<div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2024, the Company has concluded that it is not more likely than not that it will realize the net deferred tax asset recorded as of March 31, 2024. As a result, the Company has recorded a full valuation allowance against the net deferred tax asset recorded as of March 31, 2024. The valuation allowance is determined in accordance with the provisions of ASC 740, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which require an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company primarily relied on its reversing taxable temporary differences to assess its valuation allowance, which resulted in recording a full valuation allowance against our net deferred tax assets during the quarter. If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2024, the Company recorded an income tax expense of $0.1 million. The difference between the income tax expense and the tax at the federal statutory rate of 21.0% on current year operations is principally due to the impact of the valuation allowance and state income taxes.</span></div> 100000 RESTRUCTURING CHARGES<div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2023, the Company implemented a reorganization plan of its workforce and other resources primarily designed to realize the synergies of the Spectrum Merger (the “Spectrum Reorganization Plan”). The Spectrum Reorganization Plan was primarily focused on the reduction of staff at the Company’s headquarters office and the exit of certain leased facilities and office equipment. The Company expects the recognition of any additional costs and all cash payments under the Spectrum Reorganization Plan to be completed by the end of 2024.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The staff reductions under the Spectrum Reorganization Plan were the result of a distinct severance plan approved by the Company’s Board of Directors and were not executed as part of established Company policies or plans. Total employee compensation costs recognized under the Spectrum Reorganization Plan through March 31, 2024, were approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$3.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> addition, the leased facilities and office equipment referenced above are not expected to be used for any business purpose, and the Company will not sublease the facilities and office equipment due to the short remaining lease terms. The facility exit costs represent the acceleration of the underlying right-of-use asset amortization to align with the cease use date for the abandoned facilities and office equipment. Total facility exit costs recognized under the Spectrum Reorganization Plan through March 31, 2024, were approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$1.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. There were no remaining facility exit costs expected to be recognized by the Company under the Spectrum Reorganization Plan as of March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective as of January 2, 2024, the Company separated from the service of its former President and Chief Executive Officer. Pursuant to his then existing Management Continuity Agreement with the Company, the former President and Chief Executive Officer was entitled to severance compensation and benefits of approximately $1.5 million, which was recognized as Restructuring charges within the Condensed Consolidated Statement of Comprehensive (Loss) Income for year ended December 31, 2023, the period in which the separation and related severance benefit was determined to be probable. The Company does not expect to recognize any additional restructuring charges related to the separation from the former President and Chief Executive Officer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized restructuring charges of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024, all of which related to employee compensation costs. The Company recognized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> restructuring charges for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the Company’s accrued restructuring liability for employee compensation costs, which is classified within Accrued liabilities in the Condensed Consolidated Balance Sheets (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.193%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee compensation costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,368 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 3300000 1300000 0 1500000 700000 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the Company’s accrued restructuring liability for employee compensation costs, which is classified within Accrued liabilities in the Condensed Consolidated Balance Sheets (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.193%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee compensation costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,368 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 4378000 720000 1730000 3368000